var title_f10_41_10896="DIP joint palpation";
var content_f10_41_10896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the distal interphalangeal (DIP) joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The examiner places two fingers of one hand on the lateral joint lines and two fingers from the opposite hand at the base of the finger. Pressure is applied from the sides while simultaneously feeling for the distensibility of synovial thickening, excessive joint fluid, or both. The synovial lining of the small joints extends 5 to 6 mm above and below the joint line. An excessive amount of fluid causes the characteristic fusiform shape.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10896=[""].join("\n");
var outline_f10_41_10896=null;
var title_f10_41_10897="FAST perisplenic fluid";
var content_f10_41_10897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Perisplenic view with free fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image, obtained during a FAST examination, shows free fluid surrounding the spleen and obscuring the interface between the spleen and kidney.",
"    <div class=\"footnotes\">",
"     F: fluid; K: kidney; S: spleen",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10897=[""].join("\n");
var outline_f10_41_10897=null;
var title_f10_41_10898="Metaphyseal variants";
var content_f10_41_10898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Normal metaphyseal variants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Step-off. Note acute angulation (arrow) of the distal femur. (B) Beak. A dense medial projection (arrow) is noted arising from proximal humerus. (C) Proximal tibial cortical irregularity. A slightly raised area with indistinct cortical margins (open arrow) is noted along medial aspect of the proximal tibia. (D) Spur. A discrete longitudinal projection of bone (arrow) that is continuous with the cortex and extends beyond the metaphyseal margin of the base of the fifth metatarsal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kleinman, PK, Belanger, PL, Karellas, A, Spevak, MR. Normal metaphyseal radiologic variants not to be confused with findings of infant abuse. AJR Am J Roentgenol 1991; 156:781.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10898=[""].join("\n");
var outline_f10_41_10898=null;
var title_f10_41_10899="Peritonsillar abscess needle aspiration";
var content_f10_41_10899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Needle aspiration of peritonsillar abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10899=[""].join("\n");
var outline_f10_41_10899=null;
var title_f10_41_10900="Ustekinumab: Patient drug information";
var content_f10_41_10900=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ustekinumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     see \"Ustekinumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9419532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stelara&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6867209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Stelara&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ustekinumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-term use may raise your chance of cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need a TB (tuberculosis) test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12204 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10900=[""].join("\n");
var outline_f10_41_10900=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9419532\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6867209\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028899\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028901\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028900\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028905\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028906\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028908\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028903\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028904\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028910\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=related_link\">",
"      Ustekinumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_41_10901="Neostigmine: Drug information";
var content_f10_41_10901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neostigmine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/38/28260?source=see_link\">",
"    see \"Neostigmine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/38/44644?source=see_link\">",
"    see \"Neostigmine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prostigmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prostigmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acetylcholinesterase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myasthenia gravis, diagnosis:",
"     </b>",
"     I.M.: 0.02 mg/kg as a single dose;",
"     <b>",
"      Note:",
"     </b>",
"     In the diagnosis of myasthenia gravis, all anticholinesterase medications should be discontinued for at least 8 hours before administering neostigmine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myasthenia gravis, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     15 mg/dose every 3-4 hours up to 375 mg/day maximum; interval between doses must be individualized to maximal response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V., SubQ:",
"     </i>",
"     0.5-2.5 mg every 1-3 hours up to 10 mg/24 hours maximum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reversal of nondepolarizing neuromuscular blockade after surgery in conjunction with atropine:",
"     </b>",
"     I.V.: 0.5-2.5 mg; total dose not to exceed 5 mg; must administer atropine several minutes prior to neostigmine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder atony:",
"     </b>",
"     I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prevention:",
"     </i>",
"     0.25 mg every 4-6 hours for 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     0.5-1 mg every 3 hours for 5 doses after bladder has emptied",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/38/44644?source=see_link\">",
"      see \"Neostigmine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myasthenia gravis, diagnosis:",
"     </b>",
"     I.M.: Children: 0.04 mg/kg as a single dose;",
"     <b>",
"      Note:",
"     </b>",
"     In the diagnosis of myasthenia gravis, all anticholinesterase medications should be discontinued for at least 8 hours before administering neostigmine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myasthenia gravis, treatment:",
"     </b>",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     2 mg/kg/day divided every 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V., SubQ:",
"     </i>",
"     0.01-0.04 mg/kg every 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reversal of nondepolarizing neuromuscular blockade after surgery in conjunction with atropine",
"     </b>",
"     (must administer atropine several minutes prior to neostigmine): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0.025-0.1 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.025-0.08 mg/kg/dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F200748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 25% of normal dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as methylsulfate: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as bromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prostigmin&reg;: 15 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered undiluted by slow I.V. injection over several minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: In the diagnosis of myasthenia gravis, all anticholinesterase medications should be discontinued for at least 8 hours before administering neostigmine.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F200787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, palonosetron, potassium chloride, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Glycopyrrolate, heparin, ondansetron, pentobarbital, thiopental.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversal of the effects of nondepolarizing neuromuscular-blocking agents; treatment of myasthenia gravis; prevention and treatment of postoperative bladder distention and urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Prostigmin&reg; may be confused with physostigmine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (especially bradycardia), AV block, cardiac arrest,  flushing, hypotension, nodal rhythm, nonspecific ECG changes, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Convulsions, dizziness, drowsiness, dysarthria, dysphonia, headache, loss of consciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin rash, thrombophlebitis (I.V.), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dysphagia, flatulence, hyperperistalsis, nausea, salivation, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgias, fasciculations, muscle cramps, spasms, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, small pupils",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchiolar constriction, bronchospasm, dyspnea, increased bronchial secretions, laryngospasm, respiratory arrest, respiratory depression, respiratory muscle paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, diaphoresis increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neostigmine, bromides, or any component of the formulation; GI or GU obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinesterase insensitivity: For brief or prolonged periods, anticholinesterase insensitivity can develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholinergic effects: Discontinue if symptoms of excess cholinergic activity (eg, salivation, sweating, urinary incontinence); overdosage may result in cholinergic crisis, which must be distinguished from myasthenic crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Have atropine and epinephrine ready to treat hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with bradycardia and cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI disease: Use with caution in patients with GI disease, including peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vagotonia: Not generally recommended for use in patients with vagotonia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Muscle relaxants: Does",
"     <b>",
"      not",
"     </b>",
"     antagonize and may prolong the Phase I block of depolarizing muscle relaxants (eg, succinylcholine).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13855370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; anticholinesterases have caused uterine irritability and induced premature labor with I.V. use in near-term pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neostigmine Methylsulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/mL (10 mL): $8.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (10 mL): $9.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prostigmin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/mL (1 mL): $4.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Prostigmin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $254.71",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fadastigmina (AR);",
"     </li>",
"     <li>",
"      Intrastigmina (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, PT, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Metastigmin[inj.] (FI);",
"     </li>",
"     <li>",
"      Neostigmin (HR, SE);",
"     </li>",
"     <li>",
"      Neostigmina Braun (ES);",
"     </li>",
"     <li>",
"      Normastigmin (AT);",
"     </li>",
"     <li>",
"      Polstigminum (PL);",
"     </li>",
"     <li>",
"      Prostig (PH);",
"     </li>",
"     <li>",
"      Prostigmin (AE, AT, BB, BF, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, DE, EC, EG, ET, GH, GM, GN, GY, ID, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, PK, PR, PY, QA, SA, SC, SD, SG, SL, SN, SR, SY, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Prostigmin INJ (AU);",
"     </li>",
"     <li>",
"      Prostigmina (IT);",
"     </li>",
"     <li>",
"      Prostigmine (BE, BR, CN, CO, ES, FR, GR, LU, MX, PE, PT, UY);",
"     </li>",
"     <li>",
"      Prostigmin[inj.] (GB, HR, IE);",
"     </li>",
"     <li>",
"      Setisin (MY, SG);",
"     </li>",
"     <li>",
"      Stigmin (KP);",
"     </li>",
"     <li>",
"      Stigmosan (HU);",
"     </li>",
"     <li>",
"      Syntostigmin (BG);",
"     </li>",
"     <li>",
"      Tilstigmin (IN);",
"     </li>",
"     <li>",
"      Vagostin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across myoneural junction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 20-30 minutes; I.V.: 1-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: 2.5-4 hours; I.V.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poor, &lt;2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 0.5-2.1 hours; End-stage renal disease: Prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Fisher DM, Cronnelly R, Miller RD, et al, &ldquo;The Neuromuscular Pharmacology of Neostigmine in Infants and Children,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1983, 59(3):220-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/41/10901/abstract-text/6309036/pubmed\" id=\"6309036\" target=\"_blank\">",
"        6309036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Payne JP, Hughes R, and Al Azawi S, &ldquo;Neuromuscular Blockade by Neostigmine in Anaesthetized Man,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1980, 52(1):69-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/41/10901/abstract-text/7378232/pubmed\" id=\"7378232\" target=\"_blank\">",
"        7378232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ponec RJ, Saunders MD, and Kimmey MB, \"Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(3):137-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/41/10901/abstract-text/10403850/pubmed\" id=\"10403850\" target=\"_blank\">",
"        10403850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP, et al, \"Neostigmine Resolves Critical Illness-Related Colonic Ileus in Intensive Care Patients With Multiple Organ Failure--A Prospective, Double-Blind, Placebo-Controlled Trial,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2001, 27(5):822-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/41/10901/abstract-text/11430537/pubmed\" id=\"11430537\" target=\"_blank\">",
"        11430537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9693 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10901=[""].join("\n");
var outline_f10_41_10901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200742\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200743\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200781\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200746\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200763\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200747\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200748\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200722\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200710\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200725\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200787\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200724\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200789\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200779\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200728\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200714\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299756\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200718\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200719\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13855370\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200750\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323488\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200731\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200713\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200727\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9693|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/38/28260?source=related_link\">",
"      Neostigmine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/38/44644?source=related_link\">",
"      Neostigmine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_41_10902="Herpes esophagitis Light";
var content_f10_41_10902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAb8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC3rmuad4fsVmv5AskmRDCn35SPT0A9a8z1v4l6s8EM9ktrYxseI1BZzz1Jq78WNPn1PVbPWLSGZrAQG2d/LJ8l0JJyBzg+teTT43yykSBHwQ6cqPrVxcbHHhcJHkU2rtnU+IPEEvjO8gl1GKMXMcRCFF2s2P55qCLU7nTLmO+hkdlZgiFW2tFg9R/Kuf0uKZ7oSxjdHH8xkzgL3zXceANO8M634htzresvFP5gaG0WA+XM+eAXJ4z9KpaP3TrqqMKTc1oe76I8sunW8t2CJJVEm0+hHBP86tMXQHKvtHfsa5r4o6zd+H/ClzfQSxW180ywpHgZx/sj2Ary/TPizrNvrtpPq9xBeWj7UmjUYGzvx2NZ2b2PFWFlUTmtj32B2YcHA4+b19quJ8x2gBSPxGKz7SW3uIYbi0cPazL5sR7EHpVzKLliQoUZZicAD3NJp7M47a6FhVYkg4AHOB1xT1xkkckgfh/jUdvi4jkks54btQPmaGQPt/KpFwsZUbieDux0pSiikmiDUtOhv7WKKYyAxypOhRsYZDkfX8avkkh2PLH+tRKd+BkHHJwOTTndUjld3jQIMkk9BWaj1RW+g5V5xklO/qDS4DKvA9/cVyl746s4rj7Pp0IuyoBNzM/lxr7AdSaiHirULkSGOOwtlVR0Jds5xx71UadtTpWHqPWxQ+MWhyXtpZatC5WOFWguSByEPQn1GcfSvHrzTZ0YeU3m3AfynWIZGcjGD3zX0jpcM7pKdQPnKyBTG8fyEHqT6g0qaHplrJNNp1hb21w6FQ6rkLnuB6jtTUmjtpYxUqfspFzTIZbfR9MgmR0lSBVkVzkg4q6CcfKcLt429ahijMVvbxO7TPGoUyScs5x1NSrgR7gcHpjFVe55ctx2C23afQ/Q0rBizZ7ckYpoPzfMCBnDf405W+cAqCOzevtRZbghy7gcbeMYznp6Zp4OWAYHpyM0wEOjBnCpnpjJpWO5SSQW7DqR9aVhjojt3Fc7ifrgUqN8pDMQCSMgcn1qMkLgqFyvGcdadkgMOnU4A6U0BJ8oGM9Mc45JoIxkqAcnucGkKjCgsB25HaniMZ3YGQMDaOKrVK1gSVxyA5w2GAGMehpwxzx8xO0Z6miNS7iM/ff5QD0+ua4jxN8R7LRdTlsILeO4jgm8qe5Zj8zD7wXHpVrQ2o4apXbVNXsd0JY4wgkdU3j5S+BmsPx3NquneEtQvNGmS3ubYCRpZG/hHUr7+grE+NMyjwJaCyAIv5ozG+SCsZBJwR36Vh6v9s1T4ExyzSN5tjNG7guf3iKcYbPXiq5rp9LHbhsD8E3s3Y8u1Rn8SapHqeqWSxXc8YWU242eYf75/wBroag1GKS10CWMyNdz5ykkq5JA7A/SuQ1XWb9NXmmFy9vDFKVRByoHrj3/AEr0zSZZZYsx2vmi7tgzbuBC5GB17H1qpKysfSUpU7uKXlf8Cz8AviGbG5bRdZlL6dcZEUjdYW+vpXuGraDHctIJIUlj5mEeAcnHBX09eK+N9Rhk0PX5EMZWFzzkYCt3Ar6p+CHiOTXvAUVxqMu+axkeB5Dwdg4GT64qbXXmjxsVTdCalHe9n/XZnnvhrSrjWNS1Sa2vY43sJPmeY/MTz09BxXqnw7DnwhbyyxlTNM8gbPDrnGR7V4n4f0S71rxtqltpckyxyXLLvViMxk/xevGa950ue3WdtJ0q1m+yWEflGdvlUMOoAPWojqkaZrK8FFf16mySSMLjb1xnkVLjDEqeFA6Goh6oPlHbHf0p2Q2AzDkdhTtqfPEN9a215ZzWmo28dxZzABonXOB6j3r5v+IvhRvB3jCNIFmudKu0zGsvImUjr/vKePpivpkNlSwwB378VU1izt9TspLS9gSWMqdjMgJjz3QnoaV3F8yOvC4hUvdl8L/B9zxH4Q6RJqvimJyr/Y9NUySzrnAkPCoPwr3R95JSNdxLYJJwR71WsLKy0yAW2m2y2sKgZSI/fI6sfU1LfXDwRvLHF5kg+6oOMe5NJaaMrF4l4utzehxbeN7SDU7uzKQyQx7jHKhPmMwyMYz04NReHfiEur3V5amzMBs03+bjcJE9D6NXkF6bxvErJHaglZZFM7HGRnP5jNa0E8en3t5f2N0Ylto1WddnE4Y/xD1960R2zwMPZuaPoBJg8KyAnkcccilZsyKCBnbnp+tU7JEgsYRECInhDozkljkVYT7qkg7ev4VDbT2PFnFJ6BubaW5UdPY0jBvNyce5pSfmBY554U96ZwSD368DOB9KcfIhoVjuUkDAHof0pGbZgowx15GcfSnOcZLqNo7DkmoZDgcL07AVpt6kWuNdj5w3KAgG4NnPzemPSmsxIGVzn+KnOoWThvlPOMfpUG0AsFAUg5IFVtuKw9yQu48Y/lTS2AcEdewzxTJkWSMJKuUY8fNg8fSnEYYOdq44CkU0kHQjZspkDax7Hp9ahfIAGDu7nPapyo46H1BGah3lmYBdxPGMdKfKI8q1XxlHoV+sax+eo4YZ6+vFeX6lqUUQvbewWOXSdSn82SFowHLE5AA9ievpXW/E7w7qDn+0dKhMsYGZEUZwO/HWvN7a/s7tWSdDHIRtDZww9cVxxs9T6nBUKLppxer/ADKHiw2lrdvZ6OJUsl/vtkyNjk5HGKxLJnW8gaMlXEilSOoOa6fxRpss1iuoxyiaFD5bMcKQfTb/AFrd+D3gePxBqh1LU5EGm6e6vLDnDSnqqj+tCDFP2d3I774peBb/AF6xjntrx5bq3hjkMUrdcrljntXgM1rOLtbQ27C53BAijlj/AFr6116+nhtZZLa2mea4fyQsXBiBGA30FY3grw1NpkQuNegsb3VoZC1vdeWC0SfX1P6VlzPVnm0sWoU7S+Rt+FbCTR/CWiaZcODcQWymUHqpPO0/SvOfjl4n1m1km0PT45INPZVLui8zEjk59PavVwxdzvG5yeW9abc29rexCHULWG7hB5WVcj0/kalzadzloThGpzTR8s/D7UL608S2f2K+mtpN+W/ebVYDqD619bQSRyW0bQsRHIof65/+vXlq/B7QP+EogvYJ5004N5j2jNzxzgN1xXpqBUhVYsLFGoWNR0VfT3rSc3KJpip05NchaRvl4Xac8MDx9KrXWnWWoJm8tklxkBtxH409SCPvAnHSpVYpt6fn69jWLbaOePuO6KGj6BpulQtHBapcNIcs0y5Ax0xV3+z7MahHdpAiOVw0aqNrnsSPUVOHIbOPvf3TSszNH0IwQSxPWku6LdWberJzIQzKzEEjgdqfGSJCf3ZOcEdgarbiTwBx054/CnoeCCQHPLY71TfVkJFpxnnjgc/Sm7wxzldo7n+I1GSXBDgjHqcZprsCB0I7DPSmpaisSgnB4G3GMZpVckD7oAHFViwBXueMex71IjgAHOD2z6UKbHylhHbHAwpHPFKjMR8oGQePcVArZOM5GCMDuacm4kryGPOP61SbewNEhcMBtyecEdhTxIchccno3Tn3qBA3G0EAZ+lOUgg7SCM9zxn2pqTE0iwrYzlQHzjk/rTvk27ucAcgNUG7glCQfQ+lZPiTSm1rRWsWup7WQkSRXMDlWhkByre/09Pzqua2g0rtHRpPDAsk9y6xW8EZeSUnhB618739lp+pXLXVvfq0N1cO5tG4dDuzz7Hg/jW/4n8Wa23hW88OX9u3/CRJKjSeUPlvYAeXj/Lle35gQeHvA93bStf3dqv22RQQCfuA/wBcU21LRnvZZU+ppzb3LHi7XDrFvZ215Iyw2iBfLX/ZHAH5VTGpnVPh89myS29tDeqCj5/eE9N3tW5rGjWmlwyXmrXaRIR+7QD52+lcX4o8SWOraWps7V7SO3wjzs21rhh0XHce9aRb1v1PQ9tCryqktEeUaxbSnUru1yZd0/yMOmM17XoVxLc20NlcXMcNsIUh3seVVRnB/HpXCaLaS3E4mIURljJjqVPb6/StvUrmSztI4bc7C53TODnAAzyfetOc6aWFWshvj/SXu7c36SCZjkuCuRx3HvXZeA9YsNK+EF3Y5ltNUumGxX+UybjjI9hivNdH1cST3MiXNxPDzgOcg/hWrZ2p1C3e51CRnUDZDEWICL1yKi7TaY62FhX5ZRf9I9u8D2umaBpM2oanfaZBMwVWlM65RQOvXqc1NonjvTdd1WWy0ZZZ4YQR9oVT5Z/3T3r5/v7FAcCzSeLbn5Rgso6/jjvXs3wmukOhpHabGtyuUO3BUenHehS6I8XMcF7K9Sb1PRVmTeSPwwCKbNdxW8LzzsiQxqXdnO1QoGSWz071wXif4i6V4c16z0zUpH3yqWldF3C35wu4deeemcccc1nK118Sb7DGW38HQyckZRtSdT+YjBH4/X7sqbZ4/sWtZaI6vwh4nm8SXF9dW1m8ehxkR213IxVrogncVTH3c4wf/rgdUZgRhiwDdMnpWfbiOGCKKJFiiijCIqjAQdBgdhUgkLMqsGCrn3xRzNbmMrN6LQsiYEZJUEHjPc0Flc7GU85yM9c1W3lhkjKnp60McAcfN1qlInqfO3xNstRs9ZltViKxsw27eNi+vv65qO3KPd6dpcp2efPBHLIXz5iBskH69K9q8XaXFqUH2pmZGt0+fam9nXPAX86xT8N9JutQ02+kvLqIwYl+zEAKT1H0OetNTsrM9pYyEqbct2j0O6ZTMyxqoiChUXPQAYAFRmXJywDFVwcnAqJioyo6bRw3QfSggMgADAk5qU9LHjzd3ckLgKFYgBsHninM4CtyM9BjrUTOwbB69MfSlJHqPVh/hVJ6GQryEHHABBGSe39KacqCE+7nAxzUcwwCz4GeTntQGwMjBAGQwrRS7it2JOAqbjkZ+b0zUTks2eQg9uR75709sBQV5PT2NMKqAcsqqo3MWPAA7mq+QrDexJ25PTtn3pXOXHBbHSuB1f4j2UWuLYaXh4o2DSXrjKuO4UenvXaadfw6lp8N3aHdBMSVPc1UYtI0qUZQipSQ8YzgncOpGenrTM5UhWGM8EA8ipRkD5iRjheOaheMuxDE4Iyad+5gcxbyvBKJAeR1+np9K8t8XfDKaTV5Lrw+izJdOZTDKwURueePQV6moAYFsEY4PrT2RW9cgA56V53mjrw+Jnh5XjqcJoPw40f+zbdte064GoYzcJ9q3xuR/EAOldPoGhw6RealJAY/KunVkRV2+UgUAL71rABO/B7/AOFPU5PTDEdhnFD0FVxFSs25MkVirEnk4wTjtSbAMEKSc529M0+OMhvnTPp/OpAN6nbgg8e5qLXMbkJxtOV+buCMCnqg2YOdvUkU5l2t8x2luPr7UySIKA25ju4xSfmOyEUKWy/GOASe9Spkj5guB0APWoQqo+QQT6HtT0LKAu3gcc/0qGaLclXkZ247571MOH2sQT6/1pin1TJ7A/zqZB1OMnn6UrAwXoNxO4fLgDrUkSkxncwGBk5FNXc2QSAR39qkIA5/DJ6img2EViNjKQAD+ApQGL9jzx7Upwo3dAeMD+tOQZcZ4wc9OKOXpcq6GgkkbgPcnrThuXrghu4xxQc8nduPuOlSdx6HgY/lRayuFxh4VScDnv3pFJOWc47E4zn2qTG5sA5I656ClKEZK9uM0Wb1C6ABsg4UDtg9KVHO7qMY9s0oDdcY9sd6ad5AC/N6kcY9qpNoWjHMQE+UknPApmQCegHUjvQeA4AwuOM/qKa2VYjbgkYNNvQaQ7cQDszjq2eaY7ZyAQA3btSKduABjGfeqcd3bSyCJJ0Lkn5c9OO9LV7FxjcyfHGl2OraU819O1nJZA3EN8nyvbsBncD6ccjv9cGvG4vi3r0mr6W93On2K2ZVnSJMfaF6Mze+DkAYGccV7xfWkN7ZzW97Ck8Ei7ZI3GQfwry7xP8AB+zud8vh+4+yS9fImJaM+wP3h+tXF31fU6qMqaXLM0fipZ299PaaxqGpyHSUhDQW0RBaVyvAAHOOhz6VwQ0tYdMTUNcQ3Nzfqo0+3gbHk57lfUelJNbXUGzTvFTzQ/2fEYEaP5lcDJT5unfH0ArUsPE9rPa3EMum3dzLcW/kp5igG3Kj5Sh9PeuiKdrnqUrxiorX5FSVbm2u4be2sQm2FCyLwd3vg9TUVxbMolW+nEMf3WROpz1FULi8vLa0SdzsmwCTG2Sx9SfWqcGtWupW5jeWVnBJwf8AWDsc/nRKL3PWo1ZQSg9LnT+GfC1veSXNlBNHa5haazLSDPAzlj6VRFzcWulmOeBRdRchFcEN759KivYbdY0s48hIUDTSEkE/Tvj2qK2EFyIksF3s7bQn8Wfb2qGdFFSjK7asZVt4ku0niknSMW7fK5j/AIM8d67HwTr7+FdYmuUlZ9GuYt00Y6oP70foRXmmpRNYapLFdK6JLnhl4B/u1o+H9SspbRtL1EsNufKP/wBerS6o5qv7+LpVXr0v3/yY57fVvGGvXNxaQTXUsr5LHGFHRdzdAcAV9A/CDTNR0jwjFb6hdLOpkYrB0NsM8qc+/PTuetec+F7mxfw9FB9ju7nVLWZgr2/y+THnjcO/Q1qrrcUmtWF3qIkfSi2JkhJDEjozDuc1PIeLXouScT2wMVjKMBkDHPegsQxwQG9qp219a3y+ZaSCVFwuR1H1FWQw25J+X0HUUnfqeI42diVBlyGJB7nGKUcHc7deBxTSdwyvCdhjOaArAbjyc9B/hT3WpFtRy8YIypznmh8KhdzwPmOOT/8ArpiSK8pUHcVPI64HaktPOJnFztKrIRE6cbh349qVtbDs7XY8DLAEnDHvTiDtOCMZySKflmQBlyc4Ixj9aM4kB2gduearbcnfYaAUYrtyCOp/SmAsR/CSfYcVI3KgJxzxxnn2qMDGMEkE7cYpgJJgKc4Ixggd6ZgAnYR/hT3bbI2445IwRUUQJBxnGfzqm0tCUupIBkBPvEHv2qLVYBcaTd2uC5kjKYHGfb9KsL9/JH1B/pSktkEN8oORj61cWkCdmn2PlbUGltdce2aJpLXzjGkpjIyR0GPY19A/D61ntfB+n/bY3Sdi0jIy7WwTxkdq35bG2a7a4ktYHmY5LsgP6VKVPmFmLFz/AHu9aNuWljpr4mM42RCQWwQp+pNQtvOShx69zVkg5bPHPJ9KiKsWk59sZ7UlucTscspOcE9BnJGcVMvK5ODt9e1Mwfm3Y2n04xQxLMN2Bk4Bzz+Nee7IrVkgG1QMjK5IH9akGSMkcjt3HtUY4XKkFh1J709SrbcdM8gcZqVYdh6EbzvHYYDGpU+Yg4Ax375qLo7FjuOcdfyqVjgBSMNjIJ6VN7DtcMZU8gEce4qJVRU5BIyec0jHYp+cgk8nFU9T1LT9Mt1l1O+trNW+4Jnwz/QUNN7IaVy7nYV2nAHJzTwR3G0cDryKo3XmyS2yRqjwysjl85G3qCMdQaubvmLDgk5Oe1QzS1iZCwcEcYycE9amiOGUttOeAT/EfSoFb5ycgkjIJ7VNGwJyQoOec9c+3pQmLcnQfKDuA5Ofen7gMYHXHUcZpqdwuG/z0pQ3LKpAUgZz2PpTXkK4DaSScZzzxgA06NeSd27njJ4o3cduPwqS3VHaNCeHOCfSnaw07iE/NtGMdyppUXJG0A9q4bTPHl1L4nn0e60aAok5hBikbeOwZuMflXfmLZIQzYAPGDVL3tjWtQnQa51YZwCqtuKk43D+VKBtY/3RzzQnG7cxxjgA8fhSmT7owcdB6/jTimtTG9xoIbKj7vX/AOtSKMMyj7pPUnFK23dgZJzjjvSb8gDGD3WlbUdxrBdw28DHQDmg/MMZBcfp+NLjcBlcenPWk4wcnrwBnkU1rsUU9WZv7LvGUhdse4EV5Jdaq0su2VDwRzyOP8K9a1ZC2jamGAEYtWPDYPFeDxztJGJXZ5XcfKRk5GPSqaPpchpQqKSkeqeDNUkvrcx3CFsbmhctkj1X3rqI03SomPl3c85rwTTtXu9C1Wxns7khY5g20jIHquO+a+gLWVZLiF0XZHKAwXOSARVcrtdM8/McOqFdqx4Z4p8bp/wk1xDqWy6ihmMZUoAsCg4UjHXrkj2rmdj2d08U83mNIxeOXP3ge/tVTxRBdxeIdbuLe1aS3gv3SdMbsBulOuXi3qY3VYkwvlnk/n2rVfDdHsYRKFkzA1NZbq5Lx3EqsrY2D7uarW4kmclQBdJJiTHG5a6STSJbi1u7uzVWt4WCyNuxtJ5HH9aqW1qlo7Esd8vJZjjFNS6HXPC6uT27myk8l3oZuxA3niXy5ZwxIZccDHqKoWtrMkmYtxdjviaL72RyKu+HtZ027u7jSVeU28m4owO0KfYVqS+GzBKJFuxHDEN2QcZHrnP6VTuicPKNTfW2hS17y9bjt729KzJMuLhlXaUlHHI9feuFvNGure+dwGKAl43HI29q7+SGK4iK28eLYMFaTJHmEnhfrW5beBLk2KS29+GmBIMLDgL7ZqVfdF4j2Nowqvbqc54Y1aSyvRetFKscsTW9wq/xgj731BrqoUsp/AFlcWfl/upPJdnYl1YMSd31FZ954V1C2jeSDcSvO1iMYxzjHesVfKMJWOV4TIcvGT8rMO5Hr70XVrESoRrS56ctevmdLpHjj/hEfEUMFzumtLgqZYF4cZGA+a9lsdQt7pY5rO6klhlJ+6Nx4+8M+nNfO0DyG1mup41lS3TPmuuSuOihu/0r1f4Ya+s9lb6aZbZElj+0Rxo4yhJ5HrVPVeh42ZYRRbmlv0PRUchGMSq/OMZwQD61Hfxzz2csVncC3nfiOfH3fU0EYYgYHOSR/WiWWNNolljiZ22pvbG72FZ3ueGrplbRrGSwtZluZVlmfgKM4AHcn1J5rTjTy4IgyopC8hemazdW1CPT4UmnlVV3bSrNg9Ogq7byNLBHLvY+YoZc+hpa311KneS5mWsggjLcdT3pY1CqcnHPbrmo45AoBIJGOeeuafnAG1Sceh61o9PUwsOA4I4z2OMZqMsVYgLjJ6f0+tSdFzuXDAZLHFRNuCsH4C80+ghHUZ3ZCgn/ACajTa8eVKnPQjvVa/aRf3kZZoAh3xjHzHuc+lc7ZePNEl1e20iCeJ7lzsVQcYPp71SVy1TbV0dgFBGSBS/MG+9hueOwpZF2zFCQBnkd6B1HT6CqiuqMn5iFcIOxJOc88etM+9njJ9KeZMjIO4cjg9aj5BwAMjkGquQxpUOo5wo7Z6VHIVUfIASehFP2rhdvyyeuaaMsuCBzyDTQjl1+6Bk5H6UhBYjYMnjJx0pwztBBb7oxxxT8BOrZPfjivP5ehSYiqcYAxj07U8HceRx7U3I3HdksRnI607yHlfKKdq55JAU+uaTVtjRagG7RbXlBJVTwGOPXtXkXj34o6jHr8OleG4oY3jYLKHw37zPK59K6+Xx7pVn44tNHSRb61uVEbzR9YpjkBc+nFeR+PrK2i8Zvbxy+U6s3nS+WdynsD6/WqjDW56WFw3M7TPorTVub3TbKeZrd5pI1M/kSBlVu4BFfN/xqurjUPH16GvILuCFhDFsbAQYHy/nVDSIZop4YdOurgyvOu7y3MaE55BPT8az/ABzZqPFOptaDMYl+4Dkg4BOMdR1p8tpXR1UsH7F3ve59F/C+aO98AaVDb3kdxc2cbJcDflo8e3pUc/xC8J2mpxWMuqF52bYSi7kRunzN0r5l0bVL3TXnFjcTQfaIzE/lkgsD24qjJBLG+2SN1fOMMpBqZUk3dmX1RNuR9sOskLBWw6MAyOrZDKe/tT4yMAMMlTXOeAbC+034faDbaxg3axtIF3ZYRsflBroFBkfOVUHoXwAPxrCUbOx58o2dizGVJwAxPr1p+0FkJLbsYJHAPpXlni/x5JNftpHhyZRBDxcXeeS3onr9a0PAnidLDw9rt14ivZH06yKGO4Iy7Nn7nuc4xVRjdHTLAVVSVZrQ9Hj4AUKAxOSM9fenhgh+XqprO8Pagms6Ja6jaxMsMynKtztP9a0VP1x15pWtozllFp2Zn6foGk2etTavBbSreSEu5L5QueN2K11wGYsSG6+uKjUfMd2MHnjsfpTiRuyRwRkVcY20QVKs6lnN3HggLHklXyOfWkJycZxgk89T9Kbu6NnnH4UmQQNvXvin8zMfn5ht5BPOfpTVyWGD3wPanLyzg5OPShQSVO3AbrnoKS7jGEcEjjsR+NDLtBOwHGeAetP4Y5JOfX3oJ+ZRzheg96u19QTMPxWJ38L3qwhTK22ORWPVM8ge9eHyKLTUngMjDY3yqh5H+ypr6JESyzJG8SyBWDYcZBNeC+N7aG31y8uoAI45ZyAD1yDyRVqNz6HJMRyXilqZV0Vu7Vl3bUxuU9CDngH3r2jwB4g/4SDSLaaWJLaS2IhkRW+Y4GN/0r531fWDC4Jt5nOdzSD7p9DW74N8SQnUrOaR9sZfa5HAOeuauMOh3ZhGOI3+JeRDLqEtl4j197e5W6t5b7LQjgTBSfn3fjjNQWNtJqmiXojjsovss7TRySyYaTd/AvqRWp4w0+zh8T39rp9tKkbgNGzHIO7+WTXPLaB2aSZnRoXAwVwEPvVx1SCnDljoUvDx1Fo5Y7yCbZGQCTkCTHRTUuqu9nGt4YTMXYgwc/u175roryW4jjhSdnNgR+5U46+pqMtiNWCgRA4P+yO9DVjroKU4ezvoUtMsNLtreKTS4pvtUpDiWQcop9R2Fa/iCQCS309WjeNUDOyH75Pr6VQS7iiYfZmxzw2eWH9avWptNWAWwhEOqABBFnasoPce/tRFiq0o02rbeRRRDG1ujtJtSQSL6KR0PvXpGh6i17pEc0/zXKErnGAQO9cOlneS3DQSWbq1t/r3I+7XQ29wItPtIrS4cRx7t3qD2z7U0+xx4iCkrG+1yVUBTuG7eQT/ABEd/wDCuQ8WWEMP2SS1QCOUNJKw6s/90VrWV7Ne5jKKGJzgcZx3zT9UeC8tooJrlYkdt65UfeHQZ7Zp8vNqRSvRkmtjz3S/EomjfT3s/L0+Vtj7m+cN/jV/RoL/AMOahe6t4ftopYrVFjeabpCTyR9TVHxBZWelaiVvY7i1lc+YHAOxz6+9YvirVZNVtrTTNFNwbXJknj2lRJKf4z68UcqfvIvETk4cs2pP8fyPpXwL4rtPFemq0NrcQXS8OpIO7/aB9KZe6jp+r+KrTQ7sq0kEvmxLG4OXA6N6CvEPhLrp8Iaks+qTzf2cyFdsC+YS2QeB6cV0HxI1O1l8W22uaJvtDqVpt3QrsJTuWHrUcqTPLhhJOdlodx8Rru+sJYbzUws1tH8qvafMUOeje+D1rovh9qttqmiMLVnIikCr5jDe4bJ5rxK01PUtNtZIkuVukmKuUuPm6dBnsK2/hl4new8X263Atzazl12s20pxnGe4zTjHmeh1YvL5UqNpqx6Va+OrGf4gXHhiGF0ih+T7Ux4eXqQB6V2ZG1iuG3DBBr5513SdU8P/ABH+0IiNFc3AuYLlDmMhzwCfXFe/2twJ4Y3SZZyDtLr03entTSWkkePiaHs7WLLbHADgN0+X3HemvyOGyRycetIQwbLDDdyRQ53FSM7Tz81J2OSzOR+IGtX2lWka6akAlnikUySc4GOwr5+urS3spbOXT2lgnhxM91KcZl64X2r6X8QaFBr1sbZysUmCUlAyVwMkD64r5P8AF8ktz4iNvKxfySYzjgHB64/Cri7uzPVwnJ7LbyPpv4ZeKx4u8Otc3q41G2YRXCg8Fh/EPY12EWdpwcY4IJ7V5n+z9o8+leD769vImi+2zr5IkHLKBjP0r0yMDb3AyeD1pqWp5uJgozaQw8YCkjnODUbt5cZkVGkfgbVIGB361K+CeRzmmZwpA5PcdqaZz2IsiO58srI2VLeZt+THpnsaa5U/xEE9PTH1qZgWyBnaRxuPNVZAwG1cZ6kdataJ2Jtdo51B1znHT6ipcDcNxyMY9M+1MjwR/CT708gkrjBJwAvpXDYaFd0jtri4uGVLa3jMsrt/AoHrXzh8SPiBd+IdZkGn3M6aREcW1vkoAO7Pg8k11Px78Syx3Ufh2zlZIYl33G1sCR26A+oHpXigXEhGc/3sVUVZntYTDckVOS1Z1VrdD+xVnWFIboyZjdDjGO/51r6r4n1HVIYJHlt4/KwsknlgySuByWPp7Vm6ff2brpVxPC89vbSKs1sFAymeQD6muh8YeHNAtdFtvEPh+e8SC8uDGthKA3ljvuYdPpVfI9aTinG+unn/AF8jHa5MVvDJKFWMAP5UYypPcn61or/Z+tWks0JWG6Vf+PlVwIwegwO3bNYEcbtIZJJSkAUxoOxYVJoceL9wiuCIx58CdGPfH4VTWl2ZOH7zliXLbUJVtX8m3tLS4VljBSAEkD+ME9zTZGlumMt1dS3MpwVLAE5HT8qgtp9ykooXLEhWP3R6VNFEDcL5rcltz7eMD6+9ZbnfyRik935nrPwWhu7fTr/+0muZJb1w0UrkvtVeoJz8vWr/AMXNUlsvB6WtupM17KE83P8Aq0HUj3NedeENXl03xPaXDXcltZNMTMpJZBH6Ef1r034pab/avhHz7O7t0t7VzcBpDw6kcBT6+1RKOqkeJUoqGKSlszx7T7drazjKZMkjCKPIzuJOOK7LxnZ22m2Wk+GiiCaHN3eqGLNvxhQw6dz+VczoU08dvb6iEz9nk8q1Vz/EP4sH0qG5vQmq3SCRru+kxNcSs25nJOMD/CqVO57NWpD3UtIr8zodP1y+0DRd1r5qXc3ME7yHykA4ICdDx9K7DwF8T47+9l0zxZLDHOwX7NeRoVBJP3XHauX0+1/trwnqlpgm909/PswRnjqymvNRNExilkWRmDbeP4gTkH8KN3aRx1sJSqRutH3PsJ1dZjGcfKOi8bqXjIU+xwP8ag095ZdL0eSTEjyWaFpFOV4HHPrU6jJAC5/hrKUeXRnzklrYQgZ9+uPT6Uo+gGOjf41x/i/xe2lSbdHuY2v7K4Mc9o65W4GOQT1UCun0G/bWvDum6nJEkMl0jM0S52ghscVKlukzoqYOpSpxqTWjL4GCCOg59M0gcEsQpz2NJnnBPB7DtS/KAQW2kYPI4Jqr6HLYTcMAEHduzmjPLgHGTnikDDIBHBzyO5owCNuMsTz2H51SemgrCvkEFOMHIwOprz34oaGlzpyXVtbr5UZLSsoJbeeBx6V6FJlQcj075xVeY7dykBsYLIwyDVXOnC13QqKa2Pki5Q23y3OUxyd3eqFlcxJqSiMxmGUFWxwB74r6R174c6JrN1NOoa1ldfmiUbk3ev8A9avJvFvh3SdB8TvZaZcJdm3iBkYJtKE/wketVB63aPpaWKhiLRg+3qSafFd6rp6abazor2cm8PI2DMrfw+px1zmsDUmuLeae0vfPW4YgsrAjPr9frWlYhI2u5nlMYWAAADkksBwex61Y1m9bZLbzKGknIZXlXDjHUAntW2rKnL2c3FIr3sMcDWkVrc+fB5IflsmMnqDXP6tdT4jigYmL+Pb3HpWn4jjhstCgvLSULdzsySRHsOxHtXDeeMQbpJPMyVY59abWupbxCjS5I7svwXUm9YYX/cRNvEbDkHuPpW19paeZJYVxNGwaNkyTu9sVhQRQSzwmQsZApEmOmfeuv0gpZwfa2/cTxYEK44NPqKhFyg03odpM1w9hZXM7fYr2RPJuYPNJcjqGYe9XdzajNEmkWqvLMvlssb/xgcjmuFk1l9ymRlRnk5mblhnqSa0Le6Ns0N5FKxUPhWXjcfWjlsSoXu1uayzXS3DRWsWJUOwls4Vh1p4sbp4W82fhmy64HX29DSyO0f2i9vJY1llbdM33VGB2pNK1S0vRmOdZbfORtPzZ96fKzoVnZdWVNZ1O8isza3JSezVNkQePcyHv8x9a5vU/EbWVtZ3aW0YhTKCIqM7h2b1GK7S5RGeWOch1ZQUXqD/9ejw74f8ACtx4hkj8dZh0l7bEErOY1SUH5hu7HGOtKzeyuctdqlBtOxz+jQxa7oTXdglpYQnc0p8zLIR1HstbPjDwlqM2laJrumzHWLVrZYpharkwH2HeuavrLTrG/wBRsNGczaesrJbSf89kxwT64q7e+JdX0vSFtPC9pNHbxxJvuYiSYWH3sjpzTST8gn7SMIz3MnxDdRW2k3MYYi6BVTG6lHU+6nsK5nTtRKMtvdATRuQFfup9M16mvjzw74012w0LWNGjdLmNbZtVc7Zo5P73HBGfWuJ+IPgzVfBOuNazQNLbSORaTIuUmTsQfWhR5Hyy/wCATVxbxMvaJ6pbW6fqv6sdj4Lv/sOprFqIMtg3WG4JOwDutbH/AAsnWNCtJ4dOttPgtbyYywzSAuVXG0AY+ma460vkvi6o7i+05UDI3SQdx+FZ+sW0t5YQvasXt7NzJ5IHGTVy0H9VhXi5JX8v6sex+CfirZz6ctt4nLx3fmbEvYUJilye/wDdNSap8TrWz8R3iSxGTRbRxBmH5pJSf4wewr5/8N6pJFqs1pEm+0nbKpIOEbP+NdkTDZwPLNEW3T7ZChyv4j37GlbXb+v67HNDAUZpzT0/L0/4J6lp3xOklge4ubK1s4DJ5cTpIzvtPfGMVj+Ffh7FqXjP+3riQNokchmAeMZmf+79K561Y3kaxhFaMgnGMcev1r3Pw5C0Ph7Tocg7IvlwOx6VDSvYwxcI4SH7vqaMshmcNtURhQERRgKPahE3AsBjnt2pcHHLKWHUCm3Nza2oPn3KIANxRjjj0qoxtseFJuQNkL8zDHXG3vTMfMDjOOx71VttZ069kK2k8cpychWzir8ibULbMge+OParcXHpYza7kJI+UBgPXcOPwquwCuwGSB0xxmrTjoD8q9enWoZI2IyWHB6etNEHMdcA569V7095vs0U12EDPbxNKqk4yQOBUUeByXIH1qrrl3FZ6HqFxPH5ka2zZXGQxPAH61w92bUVzTS8z5O16/m1DWbu5vCfOllaRsnJ3E1n28TzzCNFLSOcCtfVooZoZLh0aO7ZgEiQcBff3rQ8MRC1je6eMpMiHbuG4se3Bqlqz6qNBuST2Oo0DTINAgle+MX29IV8uFiGAZj95x9Ogq0v2S90C40WJhbhLgXERlPLueMD8TXEanfm2mXZHnvIWOcn6+tF1rZnQSXEJBfoQQB+FXyouVlK19jQurS5sZTZ6jby2zufMQycAkdx6it/w5anSrKW+gtxJdzBo4PM425+9IR3GOBVCHW9Rv7KG1ublLu1i2+UblA5jUfwqeoFbFklzqN6Imk88vhDJnAC9gPQVEr7G8KejnNW8zJFhBBLLPebrkvtwqjaoz1JPam6h5bokMNmlrCuNjK+Sw7bj3rdv/ENlpSz6cAskZUwzFIx8p7jJzn68VjW+ltdaWt7bs02nRsAyjqH64z9KTTQU6lOV7ol8JvKb8yNAskOCku4Y+Q/ez6DHetabx5s8M2OgnSILxLOYyoZJj5ZjB+UEDqfrWf4g1nZYmwtIvsktz8tyFwf3eOFz6muRs4yUu1hkjjljHyocfMtCRlUoqq1KR3+q6jDql/Le2UAtLIRL5MJ6R8fNj6mqF7Ja+Hp7W8nWSNZl3vtwWfI+UL9DUGnXL3mkxXUyx5V/s3lr95iB94j+tOujb3zWsd6sUv2XlMNgkf3c+1VF8r0KqUY1acYp2Op+E19NDq+t6kVZrSys5bqdJl5b5TgD615wIJb/VUhijYuXXaFHynce3512ct3caLZwGGOQ/b932iIH/WQDjArq/gjounam17ql0krz6fMpt4wvysD0LHuR6VEtXzGdScKEZcz7dNz16Gz+wWtlZxgKLWBIiq8AtjJP608Fi2+Pt0GabuJlZnLFmOST70oLKPlTO0c4AyfpWTaPlpNt3MLWfBnhzWNWfU7y3u4LiT/AI+Ft5dqz/73p6cV0RMccMMNtClvbRII4Il6Io7U1TtJIHA4Oe/0pD2bkA56VHKou5tOvUqxUZPRC7sAEZHOc96GYMnzZ+VcHnoKSTHGeh79aqx31nNqE1hDcRSXcKq8kSsC6A5xke/+HtSMrFwMoAKtwF9eBSbwrHBwCcbs80xFBbPQE9fU0jt8vQgZxnrxVpiHttG4kgDqcnrVfduIBzz36mn78gA8YOfwphbCnDYJOcEc1XNYaXQdFvWVWGWKdicZ9q8W+JGjaBpeq3FzDq89xrd5cNPJDj5IUOMAnue2K9W8QJPNpEiWUjJLggMOoNePalpMHh+c3V9CJbrbuVWbdvmPQn0xxWia2R6uWq0udsyLuP8AsTTzc3qGK9cidYpB9xMHYSPU8kCuCuZ7nVZrZ7uaSW4uZh5eTwgzWzrl6L/VopNcklaB233Gw5d2A4A9s4qCxtZZZFvLndDtG20hI5VfU+lbLRI9PldaTX9f1+pc8R2szWRVCht4swhs85H9K5WOHFqqPEN/ILE8V2kipHaGJ4Y5IsZIBwWPuaih8PWQgbUUMgtQMrFJ97dnoPUe9JnS1Z7WMvSEtTLAq/IEHDnpu966G/tGZHTcgKcM6tlQfUHvWhbXds0EBbT4ClvkFFUjep7Mf60++kiuVkiggWzssqI7dRuJIHUt7/SqSCNXnfItvQwLDQI71/8ASHMs/DAbiFPpkDpW3cWz22xbq3ki8k/JsG5GH+NQ6dfJaLexCA5lZAsoONpB5z7Yreube6t5JzZzSSpHFv2yD5ST/Du6VS2uy0lFuKVvkYurqdTsDFHIWcHcOvze1cbaWkltqaFP3DlghjyQGPPWvR4Wivd26Mplc4HBVqzoY4Z5FlmgJSOTa04XIz6U7sJU4NpSeqL9kXkhtoH2pIGCCTPQHqR61e1e4giee0jaGcPJ88U5yrFB1IPqeaq3PkmFcbVxkBuhPpgVn3E8dxcvNPDGZURY0wB8+OuffFVFWVjKuva1OdbGfBazzIVEQeYSFlQHBGfStPTvDN/Il8b7U00XTrSLzp5ZGzuLdFUdyaiiiiM4cB4wWBWMcFR6g+1XGtjd21xPO80sUbLlXbO8jvg9xVcjHKunaC082ee+L7mylFlZ6TbNHb2gIa524eY5zuz1xXoXhnxCvif4VavYa1dNLd6Qq3FnM/LLzjbmuR8ZQsmmHzIysa8RuF9fQjr9K1PBWlyaL8PtT1PU2hSK/ljhgtHOJLhQckr6ChPmTTRwVaCpYlWf9M5TQrK8i1xmifLqSXO7qp5zmuisbvbfyTqJfI2MgCHC7ff1AqzPaWEttEI7G5tJF5dw4kH5d65yWTUrK4823hkurGR/TLA46EDpT6WOy31dK6dmztLLUrLUolivtHtIrl4wlvcQAoytnAkx3qefwxPFczWs+owhYwvnMxyXz0AH9ayvDt3BZ6vZ6hIj3cNrGQEA5UnoG+hrNk1WefULmK6cL55aRHA+bdnOM+g9KGl0JlOUFZvfqe/6B4StG0uze4JPGWUDDE+ldrEAkISFdsaqEAzjaPSs/wAL8+E9ELOTKbVWdsg7j71qrEHkweQe2eDU8m6ufL4mvOrK8yEho5pJnkZoQAohAAEYHVs9STXEfE68gcRokL+W8IO4/wAYNegypH9nnNyQLZULSHphR15rwH4heM01nU3TSAV0q2j8mLeOWIP3uTnFXZJWOrLKPtaqb2RyDXt1oGpi9sJGjQH54s/eFfQ/gTXF13RI59pJcZOTk4r5UutZMjSW16NxY/LJjv717P8As56r5q3liSSYJMrn0IqYXd4yOzNaFG3tKPzPYR93bnI7HsahkQ4wHGD61cmjxIQvOe1VnUfNlTtJ79c1pytJHzd9WckWKSDO7HXbjmuU+I/iG18PabHBs+06tKyyR2pBAKZ6tW1r+uWfh7Tze3u93bKW8Cfeml7AV4ruunuJbi+aW4vZJDIyOcsGI4X6DNeZd31Pay3Aur+8eiRTMJv9Qa7+wtZLJ97fzhvT6VbFvAiSM1o63QQqXScEe2FqUytFb759yHbiYt3IrjDrUkl1LOxyN20KAQMdq1UV0Pa9pUilzS0N+70PTb21AWaRLvAdo2XAz0wD3NcprVmdOmW2j2yb1zvPJHt7V0y3HnwReTH5r5G1h94sTwv1z3pnxLAt9Rgi3WzXdqqi4aH7pkPOPr60mrMqbTi31MLwlp91qupi2tGDSGMkhzgcdhXoOkX03hponvrOIQuSEfOTuxXO/DtYHsNXElu0tw0fmRlf4MHmt7TrOG5s3MjmScEhXK4Qrgc8+maqzOWM9OR7GX4ctUn0nW7wskl0JyJYmXJKHnKntU/w11M6Lf6rpdzlrS9hJh9BIPuk/hxVIRX2l31y1kYy8yGKRCMpIp7j3qXRLG4i1SF53We5ZCUATKg+mPWkjWVJt2IfGUcdv4sEaq5ijRA2OMSFc81z91bJJqscZQC4bl9p+U+mK6E6Pc3kU7zfu7sTEfZsbpTkZLH04FW/BlvHo80uq4hlltQ37i5XduJ4GQegqU9LHQ4bdRJJpfD+nXmjToqaq04lLKQ3lqVHGaorHGbRwAu8AgY6gnvXX6dLY3XhvxOLrTLWOOGAXMV0gzKsuem70NcXYalb6nJFbRIBcsu1Wxjcx7n1prVBGSpzanpf+v1N+/mf7HEjbmW2tljiz1bPJNe3eAtDXTvBFpaSSN5t+oum8k7THn7vPrXhcyN9iKZZrgER7Nv8fTHvX0bpLvBpOlxXO55kgVHZBwMDvUTODMrxpxUTQj8wgRllZguCccsfWpBuwAAScccZpLZDMqtABJG7Y+UdTXBfELxtPpfiCPw/oJV7iGPzbu5XDGM9owPX1qEmzxadGVWXLBHfknAG35sdcdKZI6K8cRkRZGBIUnDMB1IHtkVzfhTxfFrM8NndReXeBezZ8z3xXhnxT8Uzap45ln0+4kjh09vItpI2wQVPzMCPU559AKlwa0LhhpOfK9LHtnirxJdLfJoHhtVn12YZLtzHZxn/AJaP788D6ewOl4W8OW/hyzaKMtcXMzeZdXcvMlxIc5Yn09B/9cnlvgjLFeeFprk2sseoPOxubqUMTdMTkOGPXGcY7HPrXozq24HPzdCe2Kl6ImfuvkRG/RRlsE5wB1pGO4BFBBBzx0xUuWAIGGUc4ApjrkgBiwx6YP50tehnYY+G2hRuA6Hpmo2z8zH5SMY4zzUmAC3YDsKjYqqu7cKq5Jc44q15AkQuzEDg7X64HX61xHiPT4deuryzu323gJaNVHBPQDPrXaXtzFZ2f22YAQIMhs8EnoBXkGsXf2rVntjLJDCXaZp4JD8xByMH0zVwT6no4OnJu8Tk7rR7rTBNcXkQYws0aSEY3N3/ACqg4KjepDzscfP79cV0Vj4rsZru4tdYuWu9PuZQLqOdvnQ5wJFPoO4qU6fa+Dp7rU9at0voYpB/Z1t0ju1PRt390Vqrrc9qNXlja+xQ07SFkkSS7ferRglOnPoK2Z1jtbZijBdyNHs6lV68f41Al/FbQw6jdX2mRx6iN8UCH7vPKgdsdKg1eJiwKklHII/+se1P1RrFe0+FlHI8uKSBXIVWyvt2zVT7QdsSwSGTzOWXup71ZtxcO5tiq5J2g9q0LeyVdSCKyNHAcOyr0fuv4VV7ltey1W42TRpzpitbmSSRmEr4Xhc8bat2olgjSEu0iHKrEffqK1prswxKAmVU8AHqfpUmg263N1cTXpcTBCpC9eemPSqiuxk6zjF8yMqx07Vrk7dPt4N8ZwVmbAUnvnvU8lnqVnp2qDUAjTSyLMr25BhyOMe2fWu808R2MJePyzGykHjGDj+dRWSxLavLMkbxq6h1kGQVz3qkmcLxbcuZo8tnll2mJojGxUbt53E+4pIgIVJQKM8ZfnPrj0rode09U8R3ED7YIJJfMt5cfu2U87Sf4R2rH1SezjvJgBBCd3yxx8rjvzVxfY9GnKNSw+FJhA0pizBKCFkcbcY7g+tTWl35SSLG6hJG3EyjsP61W8x59Pls4tstqictnoD71nXYeSKKGFzMI0yEIOQPp7Vpz7idFSdmSpqUsVoIkjSbSxMWeCUAkk9lz0qDXtWbULhL65jzBZReXHDF84t098fzrDvLyIKbRZMTTL972z29zVrXbsWuj2kltD5DGJrYCIbWkYjneO9L4lfoRUcKLstX+R0WiXP9oWxMZj8ll9PvDNaKWlsZWaSPgjBdODXC+AryX7fJaXSqkITd6YNd3Ast1I0FnE7vnJOeFXuc9qV9Tti41KHtHoznL+0S3umtLaRozLn5++ewNcxJvu5tLs40dpxMUbHXJOK6zXFkg1PZlGTpFKjblLe5ruvgt4d0rXJpdZv2kkvNLn5thH+5LdiG7mhprQ8rF1Yez5k/1ue0WVoLLT9OsvLCyW9skbEHuAP61aj3FgNuR3yMcVCcSuzOQWJz6GpFUEjax4/iB5FVHufKTd3c4v40a3JpXggWdvkT6pJ5AOcFUH3vwr5ent54tU8kSxy3O/5EVuB9K+i/j06rbeHy8yLt8wiFhg/72f6V5V4c8KXuvaubXRreKe9k+Y3RXC2qHuxpOdrn0GBoRWHjO9up51rNrdS3UcXlZm3YATksfTHrX0/8CPBtx4b8MvdatE0V9dMZHRuqjsp966Pwh4B8PeFY4jBbC+1RV/e3043MWPUrnoPpXTM4ck5O3oQDwPwqIvW55+MxUZtqBXQmTEqoVHvxj601xnJOcHnipDwE2g7h1qJsYYgYrVLSx5Et7nivxUijnjsXyxurJTOseOJFJxx7+tcNp8cv9qaYArC5nk2qvqW/pg1Tv/iDNd6qTqDExB22xxLnardv5V13gfUbZPGVkLyMMFiZxI4wIPlyGI/T8a8/l6n1OHqTw+HcHucT4xt5473UNOmwsttMUdQ2QccnBFY/hzT4Na1ctqV0unaZHGXaSTjOOwHrXV3Eb6xqWoXzvEqXE7NlAeueTjtSaroFvqGltplsqRXfm7/NY5MgA4x6CqT0NefRa6/gQ2kmkeHkGoWE0OqlJALO3BwBIT99u/HpXE38/wDaF/M7ybzvMkpfC75D6e1aU2kW+mWyG0aWW8DBZNw2jdnsPT3qUeFILm5jSO4And8NvbjP1FJ2a0NouSSlUs39xZ+Ht0Iry4s1kCtNkSS7sAA9ifQ9K6KGSW3jfzFSNS+8qW+72BqnpfhqHSzs1C6CLICAbJPMJ+pp09utrdIVuVn2ncEfksBzhh6U7vsZqMJSvfUZdTwwRvdrcrJdjAhVUJLEnriq8LXLfMZCs+7e+DtO4fyqP7RJHqUl1BcsJ/vBnQEoPb0FYmtykX0FuZJBDIu98H77fWi9kdMF7z5juvCd9Hp+pXcs6bnniHlszbsNnnJ/z0pvieSOLQDJJCGmE4MlwE4buMmvPbfUpLK5jCSmVXOzy2P3TnrXfWmvJb6DNp1/ZRXNpI/711b52HXB9PrU6Mco8sm4/P7jF0aR4/DurJJIyw38G1c8DOe9QeEtFll1u2jlRoHtGDlhwAOoOa6ibWtEu9LSztrB0i8wM747Doi/41RF3LLLGsUY3bsJGp5J7A+vpV3a1M1TTSbL8bLPriXIhMjtOGSBGyXfPBUeleu7b7w9peoahqk+6W7UCNFOfLY9Qe3HtXG+DvC66fdPr2vX1naJBD+7SV9hicnqPWuc8T+Jb7WtUuU066e5ggzmXP7vH+wO+amzsctZfWKigtkXtZ8Wa9plzLbaRfRp5qdVPMZPVh78Vh6JLHpNrO+olBLO3mSySP8AvJM9T6msZL6wN75InP2kqTJIwyQcfdFc0kqm/MurG5mnU8YU4Uegp8j0TZ2xlRoLmhG7eh3MersNVtLzRb1bRULQvMVP7pXBGW7nGcivWPCnwr8O6NDBdzA6tO4DJLcL+7+oTp+ea8RsbW5uGlhjhIuNUkSKIHvnufevq+1sBp+nWWnsS8lpAkTE9GIHJrOS05UeVmd4OM9m1r+n4DVCBNoACLwB2/CpBzjB4wM89aVQx/hwO/vS9GJOcEDIA6f/AF6xtpqeOtRm3IGSo29803COSxz9Txil+XBYjjqcnmlBJK7gVA460Io5nx/4iHhPwy2qfZ1uZ5JPKhhDBTk/xEdcD2rhU8a63rtgulHToYDPHiedz/rVPRV9B71sfGDRorz7Fegr5y5IDy4Zl7gCvIRqOt2lybO0Mnl4KDA3BQeoB+lbRSs7/iethcPBpTtd+Ru+MPEUsekJp+tXUskltP5sdurAIo6bOOwrntP8UWZsvsXmCGAufvD51U9gai8S6PLN4fsrwYkPmfMM5ZwO3rmrXgnwifFt9cRzz29lpttF5lxcSfKEHYfWrWu2p6fsnRfSP/BMbX9G8p2aNFktrr5obg9mA+5n19q6fx7eXGsfD3wK7LHFaQrLbCFTulkkH8RHpinXtrI+nf2dZajYTaXFPui+bBlIH3we3pW3Y2k2heGbfSboRjUb6c3STlQ32aIdQhPQmrV2rE1IxUuZLRnmYsbe+uLRrmG6FpbjZI0Scqo/Drmu1svJu7WNRqkNqWO1FnP8PYsR6imXmrzSwvp8Uxjbzy4jCja+ff3rjddMUF1LaqphLdcc896dujNYyUXzxVjsJYXskhmby5LcyFY7qJ8ruH8j9asQTTRySTLKMudzHbgZ9cDvXNeBJryDxRY6KAL2zviEkhcfK6nr9MetdTr2kS6Bql/pz3UcgtnCpNC4ZWVhkKT6gYpJW0R0xqRqNqas0XNPk+222pR48x1Hmxtnhcda6jTZIr3TY5rYDz0X94o6kjrk+lcVppmb51lhRVXDYXnFLbeJhp108RdkI/jXo49xVLU56+HbV4s9AaFDGRG7GN8OUz19xSl4RKJ1j2RAAsu7+Id/r7Vh2GtRXoVBPG6qxZcfw5/kM1qv5FzauwfbOBucNwGx6VojglSlH4jF8XzxrbJCuTcY81txyNvpXm2kxSastxdTPGFZmjjQ9WPqPau78QKbm4ut3AwEQDoBjtXNLBe2ujR2EdnAHgY+VchsHa3IyKrS520qUuWPKr/1oULG8i0a3lmZTNBCmTFkhWfPQ11Nzq//AAlfhG916aGHSZ7ULDaCM4eUHhl/21P04rHjtjbWOJiJpJAWZ8ZDGs28tprYq11HKiA5XcPlXPp2FHMtjeWFbnGSla26MjUYPto1KWONUFoqeWoPzA9ciqoa51jSIZHuvnt3I8vHOfUmrt/b3DTmewnETuuxgeQfxrnxZSWtw0M7Osz87ozwRUKdtDPEUZe05nG611vv2O68PtA10hCLuEZzkZ5rT1q/1C30HWbHSllSW5CuJUHzPEvDp+oPFcdo91JavHjOI/lyDzXaWV411bpuZwc5EgHK/wD1qadtjqqw9tT5HocJ4QmlgttSjlgWeKSMKI5WK7ZM8EH16/nX2RoVqlholjZ29rb2kAhRhFCMAZHOfX61833Je40prl1tw7yGKJVHLlefMP6V718Otcn1zw8j3i/6RbgRu6j5Tj+77U4nzeZUnSppJ3R06KETLPuPOMdacih2CAjYeppNu48ZAGTzxgU6Eh+VG3PHJ60m7HiJdzxT4xTz+IPFkGl2sX2gwbYLaOMbvNJ689vevTvh94WTwf4fa1dkk1C5AkunUkDPZfw6VS8N+Co9N1qXWLqYySq7PAgbhSe9ddMxb5s8seD/AHqnmstTvxGITgqcNhmFBBXjPPWmRsTuKnGOmD1pRhyeC2c//qzTc7WYINpHUGqUjzmhHfcSVyCBjIqMn5chTjOMHrQXbzcctEoGHI+6fegnIO0jHv0rVSujOSPh7RNL1DV5kEMD+Ssm93I4zXpZtodL0C7uYWlGqam6oolwQI1+8w9OOlcMNXvpwFeYrGh2lYvlWPPRVA6+5NddLqD3mmQwNHH5seFYjOABgj6VxcqaPq6kZ3iya1dNJ04sMgKuFdsbuevHeo9K1NL9owIygGeSefwFUfEV1GkEMcrL8zEMSO2OmaxvComvtSM8A8mPf8pLYXA96fKmtTZpRly9TQunabUXW3nTaWyxMZB47VegMljq9m8bFSm4lk+YAEelRTyC41OedGYwSHiR+rY4JrW0GNZI5bt1EtvHKsbhCOnXFJLQU5JR94pSXewpFDgsVOwepPasC0vL+7t79RZCWWLkyN8phGeSfUVb1O5jTVWkQqkcEu6Jei7c/dqPULqC61SX7FJKsTrumQdNoGcDHXJzQlpc0cruKhodN4YurG2s7R7iWRJ5ZzLL+63GaPGAqeuTxTdX8A6ne6Q11cWbRzSytNDbggNGmTgH047VJ4imu/CHw68PaosaS6ncO/2WZiCtkh5wo6EnHfpWz8PfF76j4B1m/ujNd6xYKzzSOf8AWFjhD9RU209DhliZ894a3OKt/hxeWckV1cbUGA4DnpnJBI/A02a2jkjSWS/jzJlQqx46evt71YM2qajD9ov7ua5kRP4mIWPPOAB/KnT29zLo9zf28BnMA3zBE+6uOp9qm9j2qNFKF6kkn5EMVraxhftM5Y8oY0HBP1HU1pabfW1nCJNM0lYrpWBjuLhiWQ9+O9VLjSb630ZdVtJCbYRx3OFGVRT3z9aS1ufPVmmupFldNyOE3hmP8JHbNbRVzjrO/W5pXUKy3b3Otl7u/bB3XJ3IPQRr0xVTxFeQxaLOs0kcCxg7TEhXLn+ADtVi0uvs88FxBG0s8O0p5n7weZnpjoBWbr5t5vtC61K5Z5N7R9gx7k1TVmZQWh5ut3NEFKqg79OTXYeFpzHbeZdTEtMeI+rEewr0D4YfDXTdY0+71PVwRZIQECgliAMk8+3pV7UPEuj2E0mleBtP0u0VcF9Ru4vMkVh/dB6VDe6Kw8n7RKDu+3/B0Rn2tn/YE1prfiphZxRnfZ2v3pXJ+6SO1eseDvF9h4hgRbc7LvlpQ3MaD6+teW6z4m/t3wgbPxD5F7eWrqLO4EW2SQk9z2Fb/hjwT4htbVLieCGytLhBI0dow3yIT0b+lTpY58dTdTWto/6/rQ9bt5Yp8+WxOxuSOQT9e4pXBK4ORnBwP4qi0yK1jsLeOxDLaRjaA5JIPfPvmrCoWBdQWT+8O4rKXmeHbXQaSQCQCuew70x4zjByDnGT0qRciRCgGMnP0pQjF85B7KCeaFYm1jN1LTrfVIPIuo0ePcQGZfmUHrtNcj4k8BxpoyxeENOD3DZVzLKRtB6mu9kCoV3MiljtUlsbiOwH+FLyvzICM4PB60ct9Njrw+KnQalHW3Q+eF0XSvDerpY/EKaWKaNMRpZoW2Kf4mNXL3wXIPBJ1eyvxNor3GyKOJsu4LY3OO2MU79o3RZ4/FGm6pHc3EsGoRhZCwAEBU/dGO1Yfwhs9Yl16JInmmtQS0tozHbcQkkEqvTI65rWlGKVk2v6/rY9yWIqVkp2Vv8Agf1uc9qunzaXrc+l3ZAg8sTWzKMBlPc+9bkuq3Vxolnc3N4Lr7C4ijRxkkHpW/440fRzqNzDZ61E6wrhIr9cSREt8oVh1H1rLm8K+JNHtBetp0F/pDspka3cSKoHcEdM1qnZWeh0U+Seu/5/ducXuuF1ox3MjiZpfM9lB5z7V2B0QeJbGea3jRNWslLKeFE6dyM9TVu40y01SKGXRzG21tjrLw4J7E+n1rz/AErUhp3iW4j1g3W+NmijBYjyefT0xVcvNp1FOqqNuqZ0HgbTZIPFVndNPIsiblyBho+PeupudAvpTcXCSofMkPmburmq2kXUNteLLf3MbCXasM2AB9H/AMa6iaeWCdoL6EwZ4GV+9nkEH0NVy9GQ52neByp0ZjMCYXtsLl5I2yuO+RXPaj4bu7Jhcsm63mfajtyD9D2r0C6vBbEKZYxDtIIbksf7uKLO/htZJAIRcW0o3NbyZbacdj2pWsdMpc26v+Z5QftFjIwaOeFlY8qM8/Wul8MeJ9Sv0YyxArG2G3DGa9LsNMtLq1UtbL5SxhgrLuYj0NZOqeBmLM+nOYlPzlB0+tUm1uZRnRcrOWnZ/wCZnRapp+oQRYT7PfKSJ1kbhx2Kdqii0+GSadnlx5QzsDA59ABWM+n30Fz9jZGLvwmQCCQex7CtXSljhhY3FopvbMl5WZhtdM8fWrST2NbKmtHcbFbBS89vxs4x1C5q7oOrayZpdO+yW2owSKcQzKMhvr2rLvtdt4pGITYsrZ2dPpVe21aOG9WWTAO0oJNxXOfUihxurItqNm5PUrahZ6XpdtcTX8FzDbq2CqsGZTnoD61g6zPbx6Wmo6WVksHl8pGlXa5OOfxFdxqlu+taFe6TEhubr7KJrAomS75wyEnrx0rkPC/ge51K2vdI1U3Om36gTWkUy/KWH3iw7egqUlezOariKkXant+T9RdM0/c3l2UayTbS7KTgbe/NXNHmmtkv0Q4SYiNlI5UHrj0q/pFp9ik0/TrHyptUkRy7MflTHY1Tnv1n1K7tb+E216QFcIOS3Y03C2x1wrxq2hLQls7qErdo26b7HbstuhOPL79K94+EtvHa/DLw6qgNJLCZX75JOSc18rEyWetqruQtwjxO6t0PrX1p8MpGl+HegeZEIdtuEXauAVHeiylsfO5pJ8tn0Z0IAZTlcljnPenqSW2DqOenAPanIwY5wFAGDn0qX5RknJOR0HHsTStc8Fuw3O4bGOMc59TSMecENt9RUzZByMNtPJpm1t4JyQQeO1Q0FysY/Qde4pjjJbj5Rj2zVoFFPJBPv29qhlAOAMA9yBRbS47kZbanGe3GKaw+TavzE9R608gsVIyB0/8ArmmuduAACe3FaJvqZtHxBZRrceRaxSgIv76eY8YPp9a9Dg0wadocYupW+0ahIJEj28iMdW/QVg6Vare63DZxq5YMZp22bgqr/Ew+tdHc3j6pq/22R7dEmUQLHIMAKOp9ge1c/U+srS5rRXQwtUsH1F4Y9ymNgYymOpPce9dDPpdro/hi4i04GTU5SLb5MbFRuv44qpruqWOmWUEVgGm1qUsJJORHbxg8bR3JrHAkuiFld5h5m5I88AnvUXutS4qVR32Og8H+FNR12d47OWKIWp8seac89NuKp32u6Tp0t3oIv0RGc5ulhKtDIOoPqM8Vs+C9V1PSW1DSbO3MLXSGWO4LA+S+MZJ615Hc+G9T/tKaKRUlcOS8ofKk59ad3fUwqKfM0tj0Sf8AfPM6W8cNncRKvlsA5AHJbPuap28SHaloCVGThANqDOOT3zVjTNNlis1F5KkkcGAgk+6vsPWr3nYUnbtJ4Dn+EfSnKxVPmvZFbU7uVfCreHb/AOyXGmhjLA0rbHtmP91u49qxtBhg0u1ms7fWjDFccyGLB3lexPpWdqkEl7f3dzLEskqSCKKI9AnripYrG+u7Roo7D7O5YIZI1+XjoT/hS03ZrGEIvlUPz/pHRx2BCQvvb7POSyEHqR3xXZ/DZorS91Wza2WeGWBhOZGwpjxk1xlhDPaCC2njdrjiNSEILn0HtSJqVzJBqNhbpIt5dyCzBX7yqTyMfzqbp6M3r8so2RgBDMGhtZ71rADdHbK5KdeAfap4Wa2nWJlVS3zEZxj2r17QtD03TtQttJuIIYbgqY2yerY4J71574i0i61Px1B4f0pYDcyP5G/d8gPPLHt0qlUtoZRdJ3XbczYpZJjIlonzscZByEPTIr2LwJ4Cg0i2upNfS31C6uAjASKdkaY6DPWotG8IWfhixMkssU8kEhhuHLjGcfNt9/SvO/HfxM1M+KLGz0Tz7a2ttsLCTlp8kA5H8qb97R7HJXqOX8LTzPW9S8PX0N4dT0XV2tpbZC8NtJhYCQOF+navMfFPibToGe6tdDg1fWU+a7u7WMrbxseowOpHrUf7Quv3tleWnhOyurj7DFCk8iOPnV2GSCepH1rznwRca9beKrOx8OXJlu7lxGEHzI27ruB4xUpJ6bl4fnorme/dFm11TUvE+rwWsUQ8yaUIscaHIJP9K+w9G02bS9I03ShOJ5LSARtKTjcepB+leKa74+03wT4rttH0PStMFvZSL9rmVAzSz8Byremc17Nq9xHF4fvNUWVlUWT3iAE53FTgH/Cm17t/yOXHSnUnGEvxOG1H4n2trfXVppdtHOI3KLcSthWI+8AO5rntD8ca/d+MLSWSaR7Ysx+xqu2OJPVj6V5O+qW11M0Jtp/KjBdSHC7XPPJra8NePPsVrqNmljFBc3kQgMsr5BX1NTUg7Jx0/U9LCUsLH93PW/X+tD6fs9Q0rWHmk0PUbe8EePNWNslTU+eCxXcvJODya8p+DmifZ9Qsr20uRN5SM91On3cEcJ7816y4y74+6ck/7J9qzg01fY8bMsJ9Vq8id+pEyK7Asi/JypPP/wCo1XvbhLG1a4mVlh2kl8YCgetaMC8KGwY1UscdTgZOPevBfilrNyjRa7dXMkxu2e2s9LlBQ2wB4LDoQRk1qkt2Y4ai6zt2PW/EOi2nibQDaXCpLGcSQTLz5Z/qK8w+Jepal4PitdO0rTYYLaJd8F/GcSgEcgnvVb4IeMNY1PxeNA1K6DRtFuj44XA+7XpfxA8ODxFpu0hTJakyIG7r3X39avl5dYnZQk6VRUqj0/r+rHzA0k18st1dAF5X/wBY3JJ9DW3pL3MWnA2dzdo0kux44ZTtP/Aa3PCyaZFc6uNTsnniw626yfcVgOh981mXE1nYaOt1IgtpIyFVY/vFvUDvitIqVtz2PaU1ug8h2Fx5O+WReCytt6dQ1UPF+gT6vYW2qaYv2vIGY15lAGQVOOpGKvafqVpq1vavBcCW7chSCdpB/wBsd61vDhvLDVLmSyhc2Dq/2pYTzbsoJDj8qTvHc3l7OtTutb/1+ByWh6Ve3Phm1mmQxwiZ7cNKMKxz0OehFd/ol1fzW0Oi6yWKu37q8HMyBR8qfSun0bS5ZPhjBf8A22GSwu2N09mozjJ6+obvUtzp0T2kRm84SjbIr4+ZSB1+mKvXZnnKcFZrocVLYvcEwMfMlfcqk8MrD+Kr1jpWHQLMVmU7Djqx7mtrVrFENpc2PmJI6GQFV3bj/TPeqelahC/lWl2fs1sfnkAB39edp7GqjG50Kq3HQ6fSlktokmJ3IflXHUcdDVyWSa2QTfIYv4mB6Z7H0qk+n3NpZLe2dwmqaY+XEkf30BPAYdSa4zx3rd5FoVr9kn22ck+24lUYc+gPtVRSk7HHKPN73Q6/VdLtL25s7mWAxvB+9kjJ2lgO49RXM3Vgt3JMYUijVi6uVUgyhjkEj26VzNn4kuNA1zSYp77+0tOuFMaMzl8ZONuewrur+3muo3sZRObQMQk8T4eMnnaf9mrcFFm9Fvlunt/XzPP5vDmq6bKMRWuqWKEhoX++EYYOD61Tn0zULrSW0600toRvx57jhFPYn1ruE0e4tnIW/kUtkYHOAB1JqA3Wr2kMNvcRD7K7/LcD7wP+2PSjVbv8DdpS1X5/5/oUNN0xrVtMtop5YzbFdsiNly/97HpXQ3OmSXk12dRv7m51GSJlW4JC++39KrxRNZ3M4a4DORkSf89B22mtKxlsJEdr1JpH4MUkMmAo7kjuaLKxjNtu6OC1JLnSdR0/W7WBT9njMU0cYzuU/eJ96reM3sdQ01NTt7yC4vyA9u8fDsScGNl+ldlqBtoT++LSRk5GBy3tisRNNs3kkMNjGl3gyRk9W9qL6WsaqjzvmbscJq9kZGjfOyVQJNuPu46n619X+EpLNvBuiNp0yTWy2y4YHOWxzx2r5y1xFdrd2Ta6xldijbzXsHwLvkk8A/YjEyTWdwdx7PuOc1klZWOTOqd/3kUeip0yDyQdwI4p8W4qFKqB156io1xgZ65z7ipothxwQOuG6mi9z5lokwoBzjccZzRKS5bCqy9sHoaTC7CpJ5OMZpgztI4Zj0PQYpWZNiIuFHzYJPc+tNB+TOcYHU9zT5NiueuAcYJ6GmlmOC3UH15/CmtxtEBwOSuQR64FRbgcjcCg469ae4yCD0Pr61GxXOHOPoKEtQZ8safcvp1vcR2kzxNKP9Ku1+WVm7op5wvr60QIkRik2uZpSADIfujsR/8AXpqhgEdBHtj5GOcfWpEmnEkaqUdyMlF569yf6Vk1c+rqQVMk1zRobO4imvLkeZMu4RAl3HsMdjVVNtqrvte2hAZ1Oct9CasahMuiRI+puIrp8nbJyVXtgf0ri9b1qXUZ4/OWYWW7CAnBb6iosZ80kjsdL1LSbqQQ2Uk6SyRnewJBkHcZ5zVjT7VoLczx22yCQ4XDAkmsnwzp8qamkkiLtVSY4wAB9WParGqeJxpCG30wxmSYP5k5GVGeoUevvTsgs4LU1nZ5OHJjAPLP0PvT32vG4371VsvsOcgc8Vw32s3SwSm4aRE4aNwc/lXQ+Hlb7ConIjmDMUAPzbe2aUtEEEnsbWlXFjFq8RktZZVlX+AD5Pck10mo6bqSyW1jpDxwR3GwwzO4yZDnkj+7XNMrEhAJN7j5PKHIPtWld+K9J0M2J1u1e919VGba3bIT0JOcBvbtWLWt0RUcm9Nf8zr9OTxBbzWcWoGO5vLAmSUmNf3w5x5bev1ri/EPjdLTxJeXtppXl6k7B1hkC/uGPBYgdWNUdT+L2p6nHLYaRplvp56G8kbfJGv8s1x1nfxabdTagkq3F5Hli+d5LtxvPbj0pxjrdhSpTUXOWnT+kd98NPtGp/F6yu9ZuZLq8hiluJ2eQAoAOAAeMiuF8a6xeSateS2MdzbNqVw7RjbiR034HPXJI7V6Z8LfCl9b6RN4g8QvJp813KhWeVQTJF1Le3NWtb8YaZa+IL3XpdJs72W0UwaVIwG8zH/lpt6YFPd6EuXM3FdTzK7sdX0gNpl1c3ENwArzwvIWwxHP0PrVvVNNutcl0+O0h+0axasNxhYASKpyDnPJA71WtI7ia8uZ9Rkaa9uW85mkbJ3E5J/H0qe+1NRHCHukjeP5QkDAPwe+K1d2d0aSjT6JPQ6j44aU2s3On663nQTrbpDdHGdoA4JPr1rz6fVLTSoo7bw2k1tFINk+pSDEsmeoA/hH05rvo/FcGraGml61IJIZgUE6Nhu3LD2FVNB8G+DYYvtGu+JLm4tDLtis7ePLP6bj2qbWd7XM4qUY/wBf19xwei6e2t6lDBYIxht38ye5bkIgPLMe39a+m/F3iKzn+G8aaWtxJHqMaWVvK6BROqj53HOccHtXFeOHt7PwfbweEoYNN8O3AMV6zrieUr0FeZXniHVrvRdPtmaYadpqt9mKHhFJ5Pt1pv300ZqkpyjN/wBf5HX+EvAs/iq01fVdGhLvZusawy42v6npzXnnjALNrN1BYWqwrEux4UBzu9SCMiuv+HnxE1jQ47yx0a/SMN88KGPcM/xHmvTfG/h1fiNoXhjXbRYo9Sn3W2oXsaeWmB/F796zc7O26N6kJcnO7JS7eXR9jM/Zbv4m0zWdMkkQyKiyBRnOQea9pUDeAM5Xr9K4z4a+BNN8DwzLp9419fzj/XKu0Kp9u9dmuMYBYckcjGDSbuzwcRZy0dyYAKnIweq46/WuF+J3w+fx1PC0F+sEqKrMZTkFh6Y6DFdtdTw23l/aZRE0nCk/yqVkKuQVwAuPl75qnqrozpTlSdzyDwJ8MtU8L2U17aoZNdkkBR2YFUCnoR7iux8YeNoNEsr5beNJL9LchoypHlysMdPTJrodX09tU082v2+508N1ltx8/tmvDvjX4mn0p4vDdpuuZICqzTTIPMncjOM/3auDvozspWry5pdDl9CsbzU7TycNPLboZZWDbQzE5I96yNYd7y/1Awwbms0j+z73C7SxwTjvWZbeINY0ZhKjw+TIwykff1A9xXTa3pUOpWlnqduhY30Ye3uYyf3Lr1Rh71vdI9PlclyrdambfwjQLSwnMcPml9rxoMFw/Ur7gjrW+9/NYa5bX7HyyyIZFQ8OmcYcDqfUVj2+l3Ota3Fe6qY1jgXBQd8cn8a357K6uruDy4Y5ZpiJ44UO7bEp6N6HjPNGjfoW01F6Wv09Op6LBzrS/YrNYrG8hzLHCSI0I5yo7VoX961rZNK5Qh2ZVXPzHHYVz3/CTiC3dba3d2LbUyQAeOVJrDt7q7nliRI5mSJjII+rDJ5A9ahe71M1S9ozcvZ5orGEpdiONwsjxoc7Ez+nvXHXF/c6tqaiK5ECyzeVHJ5ed2PU10UrGWO6hktzHcuu0K4wxB6cVztrcwafbARxjzbe4WZo2HzY/iIrSOp0/wAOOhLoPifVPDHii2t7mNYLyHIRwf3VwvoR0ziug1E2V1OrXUUCWGqbpeem/PYD7vNcv4zs7e1SWcSfbbZyiWsoblCTkAD1wf0rY0yFLi1jsLhJIbjANux5Ec46A+x/nT3SuTTSTb/ryMOHQU0xf7LkSKKynuBKk7LuI5/h9M16MZxCs6oxKJsRge/v9K4ae9tbxF0nXZorSaclYHZjuhccY+ma1tP1qSG7t9I8QRPbXiqYfNUZE6Y+Uj36VSbdv60G6cEmtl+T/Q3FsXu7+WCKXblM49R7GnQafqARzFFBfWxbaY2k/eLjqQKyJZZIrgRRI8dwoyrK+CuO/wD9aq9j41lsNXuIJbWBr1lyPOQqdp7rjrV7mElNP3bEN1qkdncGRQ8tvvKLG4GUbuBn06VVstaspLkbXa3aUE4b7rNnGB6VFrWnSavayrZhVu2fzo0j/iJOSK5QwO8ezVY5IpE3LtxgpJ2Yeoz1pRkuu5rUjKL/AKsd7rVx9kgjZNjzk4QjlQmOST61x8sl3JITGksk0QBRQ+CB6iuk0Bp5tFtnubfztwO5UGSB6/Q9ax9dsbqykF7o0oubbGSuOcf3T6VOztc3pShKHn0LNpf2+sWRS8ZVmX5fMK/MjehH9a2vh54quPB2szadqsAfTbplRipw0JJ4Yeorj9PuIbvzZYUMMipuljcfNuzx+FX/ABBB5/hnTrt5FMzSOiR4w21e5NZSXK7sVWMcRRcD6eaMxyswbeCflI6sMcU5f72cY9ePyrkPhxqSanoFs4aQF4FZUlPIIGDj2yK66NmwG9B0NJ6O1z5CrDldmTHPydxjptzj3qOTf5YHH4cUuQQoBPTPPFMuWjhglluDthijMjPnoAOSadrmS1GOrFSoViT1I5FYXijxFpXhe0STXbr7O8y5hg2bpJB3IHpXjXjv4keKby5lXw3MIbGMZaOP07E153cSeKPGOupeagt3daiFwmBn5R2UdhV6Ldno0svm2ro+pPDOu23iLTG1KxRhBv2YYjOR3I7Vo7j5ZzIgA6ux2ge1fOPgLxrP4b8RTh42NtIpDxBSQvbp+FdpqfiMeJfDtwLWSUqJA6KflON3T6VaV0mTUwDVRqOx5dZyQ2sCwKyeYex5qWyiuWVnt43MAb53KkAH0z61oXV7HoNoPtEtnZLvO2KOASSEdvmPX0rPs/EX9q3UdpPc3Eh3eZHG6rGhJ/nWPKz0p1FJ6Ibc6KupXpn1C5lwRlVUglPqTUr+GdJ0vyGvD+/lAdEY7pMHoQvStMR23kgSIj+YGYKQeMf0q9AYdPgik1lTLMECpbnBlA7KF7D3NQ49GKNS7v0OI1XUxeTS2oea2sY2wtvF8zucdSe5qSx8H32rtG8doLOzhw7z3h2KAehOeua7a2nuLC1kmtLDTdPXzN6TXO15l3cbcd+/ap5rYahfRtq2t3WqyWsfnNBEmyJIx064Dc9OKnU0qSSv+v8AV/yIPC/g+wvrzfNAy2yR7nmkG1ZT3Gf4R703WJ/Dvh6eGPRbkXjFi1yI38wxjHQMferni/7dceVZak0ek6U6b5La1bfJLjoG6flWbo2j6Nd2xddKEUUh227XM5XeR1zgYB9B7VMlYxg3J81SVl2/4Jg6n4rvGj2aYwsrY/8ALXOZfcA9q41rNB5zi7Z5JPnz0Zz7mvQbnwXodoTJrGtyq5k2/Z7aHcAPQHPB/CrNqvgS0jP2Tw/e390VAU3sxCq3fIGM/nUO+1vyOuFSnB+6r/eeW29mxCiRkEZOdoOQv+NdX4S8PPJcE3FsJbEMJGizjzMdM+grpnWzvdNeW20q1gmZxCkcbYUjPPvmp7a/sLOaS3/tG2jmTnaTgfTd3NOMbl1Jx5Uoo3vEniFtd8OvoX9nXVnehh5redmMRKcgA98jAxXnuuRSG4luo7KCCN1CqV5aMDjI+tdsZbe7lgEd1HdpIA7FeQhHYN3ptjZWut67Bpl6BHBMxbzkPzIgBJJ7AcZyatR1MaSjSizi7uHTP+EetIrKK/j1WUZknP8AF649qybmwgeCKJLcwXMYKyMcAyf7Wa6+SXSYr+e30QBrW2LF7+4OfMA7RrxwaTTNb0Gx+1SeItLtr7I328ClonfPTJzwBV8retjaE4211PMFtJbW5dbxZSpGS6c/Suk8M6fealdbrXzPs8Kb5jIvyov95q3ovEOj680+3w9b6cuNgkhuW4wO+etbHw8igMt39onV7SVdlzBI2Q4HIKkc8VKjJlRUEk1t+JkWPj9LG1k0O+tZ9V0lQUWF2yI27lD2rAiexjmkWyuprUuDshlHylT1Aq34pfwv/au3Qri+08Fz57SIGCn1XBzWhe+ELN/Ctrq2h6suuyhyZ7YrsaAepHWqa62FCTi7Jp/10WjIvCun6fYaoLnU7ea5jMbAR2w6k/7XavYrL4gmz0ux0/SvCax2kMZMayzbvLYfxMteZ/BbxAyeJj4b1K0C22onYjMvMLY+905FYvxA03xHofjG++1x6nawqxWKdIjskAPy4I4qXGEXd9SJ1Y1o+zs9Ht69Tsbj4heJ4tdl1S01E2zn5fswtsRgfQ96l1D4keLr/STDLqdg4ZiZDHDslUGk+GPxH1rUb+LQ/Eui22pJIoCXL2W2ZAO5wOR78V7A3hvTNUCXMVlbWk4OGjaDCyKD0PcZ9aq8u6/r5HFOdCLvKDX9ep4bpfj3Ure50+PXG+3WNpJkk8OfTJr6B8J+J7DxZEz6TJE2wY8tWy4/DrXnvxA02w07ULSC08M2cTy5Ilg3zeYcfd2defWuP16HTdGsdP1vSRqHh7WyCTAPlbIOCcHt7HNNNS0a18t/0FVoQqwThp6/5q59HIzKdn3COCD3rx39pTw1b3nhe11+AiO+tZxFK+OXU9Cx9q2R8Q9XPhmPVtNttP16KNVFwsaOssfHLsoz+dZ0njPT/iBHa6LqqWdhp19hCUn3FZeqlgccVTpdt0c+Ho1KcuZr3Xvt/WjPn7QvDGqeItUCSSpaWanM125/dx8c/Vsdq3/EevLBfWGl6ZPJHo9hEEjVflMp7ufrXbfEXX7rwF4s/sTT4rVtNiSNi/kAKXAxvx6kEgmue8U+CjqVtp3iHw6hktrxSxhxuKMPvDHXbVJWjzdPyPTg1e0d9N+voYcWqGRoprSaQRrJ9xm5APcV0lv4rlsr5o4LZIUnj8ozjgyFiMk+gOMVhaX4cSxYyau6xGMAKjHAds9K6G6fStUM25beF2VdpRgcBfYVUYt9DSpJvSTszfk+zSTvcwwBkDYa0J5ibHb1pRPaxMl4u7dGN+0/LjjngVJLLZzWFrKLHZcRwBZZWYgyHs39Kz1P2xzEyskZlXDjkhAMlfrQ420sOEOZ8xZa9bVZXvzMYr4Mgt4uu9PrVG+gbUpfIFiJb3ed6H+56g+lF74lW7uZbXR9NTYoIjmVMkAcEZ6DnvR4VvpdeiezMssN9bFxb+W4GWHVST1BpcvLvsbq0lo9TD+0rBd7rS1G6M4jE/zqp6HHvV9NTuJbO2mSaN13MY1ePDK6HJH+FZuo2k0pk/sqOV4YwzOq/wCsikPJPuM1U0JLu9itrRm+Tf5pAHMf94Z9yAfwrRbmMnZJdfwH/EmygbULXWJI530/UYfMjlxjy5P4hx6GrPgzVv7dsBpWoHznhyLa5YEvGw5A+nSuo1BLaHwbaxXaPNcfbDJZb2/dpFj5mx9a42bxDa2WoQlbUIqOHFyq7A/tgdqzUGnY6Izjb2jdvlv8+3U9JngfXrCKSPZBqlvtSaJG+YkdGA7g1T1LTrx9TW8kjto7uGLyNxXJK98VXj+z6zp0mr6K8i3MWZXSJvmIH8SN14OMirthrmprb2k0rRak24xeSF/eNnnJPc1Vr+RzSfK7x1Q+z0h4ntbyOJzbpIr+c3yoQvUKe/pV2+sU1C7uZZ44080mWGNTgqD60lxG0dqLlZbxZGlYnS5mLiJT/EuOPwpBekndJB93AJHVPTIpRtYcpym+ZvUp2kd9od3L9lZWZkG6NuVI7EHtTpZbabTC5MFvqcZZ3CrjOWJ2n+8MVannimsmeKTdsJbygCWA/pWXavHfTiBUdZgCwMiYXHp7mi2yYuT7aZlz2ulwy3j6gjxRFPMVoxh19h+J61yPiTUm1G6s7bTWRbaMCMIDkhc9z6nvXZeK1On2lydVhMEUiMkIaQM7ZHZeoH1rybw8tzeapHZWaOfmwDjBX6mokkndGzqXjab3+8+n/hFfaXdeG7e2trhJb61DRuh+/Hkk9PSu+RgoGSc9MY4rx7wR4J1fQ9U0fVmbypriRhOufvRf7Xoe4r1q3nkuBI01sbT96VhEsikyKO4HWpSTd0fO42KVTR3LR5OdwOenHf0rh/i94mtdH8L3GmxMrarqeIEQ/wDLJOpb39K7eFSVIVeFUuWzgADrk9q+XPiv4kTWPFeozhmijjUC0z86kDgjPuRWqT6k4KgqkuZ7Iz7rxEtld+XPbp9odVWUPny5P9ogfyrorR5BbWsdvP5AdX/fQkfK39wdwK4DXI7zVtLtvEtqgNsuILpFHEbgdfoRWdourXL3QtBIyQ7WAMQ5Ddjmr0S8z11Vbnyv4XsdToWmwa34ys9AQNby3HmRC6ZyFLYyD9MjH412fgHwN4gWXWf7Zk+yxaa3kJETzKxYDP8Au45BrE8LWmoam1hqsumyi2gdYVvMbehxx/eJ5rtfjRqt54V8RWGsWF5Kgv7cRyJncrbBxwe/OaIRe1zKvUtLli/09TyHXtKv9U17z7SKNY9gG+VsAf8A162PDfh1Le/S4uGW6umUqpcbUXA5Cj+I9a3LOwleHzbseV5eSYRg8DnrWnJLpb6QXgdmn3Dy2BA289/frWDV2ZOolojDmCXVkk1vHcR3sreSkpwMjONoX+6O5qzq0MehaUjWsW++fc1zdk+bM47Yz936VXZ2vNRXZITEgIZSMZ9x6VoaSgW8SYSyE55iHOVPpnqayl5nTSg/iXQ53RtLv7ySK5ltkt7KOMs4wWkkJ7knvXW3OtR2s0Vxa2onuHtRCkj/ALuNfw71uQ3kRSU2UTdcHzGBYn6DoKz7r7Pb3DSB4Ud2EjW7ruVj0yD2o1MnP2jtJHHOk7XJvbt2e5l5aVjkH1wO1atz52m+FsQzMn9oSYKEZChemAehPrWjLNaR38c1npbXD7ir73+Qj6Dp7YrF169+2Km6aVwnyRRM33Tuz09sdaXqU43srFUW9vB865Eki5UO25j/AJ9ahu5IbKGOaaaKE7gAZGxuY96arRZ2IC5xkg9AKyvEulT6ra26ZCmCQ7mJ/hOOMe1J6s7pRcIWjqy/4h1CNIxDpBM80EDN56n5NzdWH0Fc3pOjXeqSJp9rZp9olUDzZ22qGPVmY9K7fw3p9jBaxgx3McFmhHmEcyEnI4784rfu5HuL52KFUCqCCOCe+4UXsYtdHukY/h3wbf6Jpstm93bz3gl+5BIHC54+XHX3rI8fazPpWpHw/pcieXtAuJjjMp7gt2X2rprq5bT5DNpq/Z51yEkjODjvn61z9x4QtNX8a6dbX00yw6jEDH5bBfmOfvE9s003sNQtG97L9Opk+GLqPU4JYJ/K/wBDkDFkHybSeT+VVfE0ml6x4ieWKRrfT1fbtQ7nZAe1a3iDwu/huFtLtBEZZGK3DxS+YTzwv5Vy5027VxGtkyx8/vcYz9DWqs9ym242Wp2OpeDLLXQ0fw8uJL63ih3zQMmyQMO2D1NZ/wAKNOjt/iJpf9qs0Nh5jRzrIDknByuPXNaHhHSb3SdRs9UcvBNAomg2Y+fB4z/eroTGxvRO243N1MZWZsB1ZupB7U4rW6MpvT39/wCv60POvF+jXh8T6m9ssUlu0zBAO654rc+G+l6lpNzcv5iiSa1mBiYZUgLkD6k4xXXWsjabhpbeKW3+bdDKN+0jod1cR4m8V31xctcou9Qdkkip+7ix0VQPr1pRi47mk5Ql7yvc5rw34mv/AA54ntr+Qyb4pCXQjkAnnGa9h8Z/FLxA2sxI+pPHpdxCJI0W3AU/TNectqX9qahp1xqlvBJeoMRyXCbUdf4Wb1/Guk+LLajb6Po/2j+zg6xsFa0XPy9wx/lVbR1OVUGpObfQ9dtvEF/c+HdT8U6PBC+p6bYKHaNVEcsWCxBHXdxnj0ryG2/aJ8Yi5L3Meny2xYFohABhe4Br1H9nTUrez8JrY3gmj1O5w6RyRErLHnjB/wAa4740/D3RLi6m1Lw/Z3OlXTSMJYpFxFK3XKDtmoleMvdtb5HI0q0nGad/me4eHNZtPFGjWWqWsDwtMglRXTDRHvg1k/FixtZvAOt6o1hb3N9awq0buuXxuAYflmuU/Zu1DxPdeEbmPW0b+yrSUQWjSxlZN3dQe4FdP8UfFum+GfDdza63BOft1vIEaEfLnIAH5kVcoJ35fX+rnJSlOnVim3puedfC3SZrHVLPWbC5i03TNSXYFuJAMjoysp6g9q8p8XaDNovjPWrSVzb3NoxkhZPlG3OQQPxFe6eA/B/hrxV4SOpx6tdXsBkVJGmjC+Wy8lQP5YrhPiN4J8Z+M/iBeDT9DmhXyxHHJL+7VoVAVeT3OM/jRPTV6P8Ap/15Hr0q1OTdrSX3a7f12ZJomsv8SfA9ydVMEevaMEW2utozOvTa3rxRNqN5pkH2XTNtvaWwEU8u75tx/uD0o8IeBr3wto+tNq17Zw6uuxLez3ggnPJz61i+KNLkhs11eD7Y9vKn2fU7QNj7PKfuuPVD61tG3xdy02oqL6f1+H5DNTuZwqDWIjLEsZITbzlujVnypZXummPTNOkTUSgZZFGCGH9KueEJ1ntpZ9ZupYrWGLahkGWcZ6A1u6xfW99Y6g+jqGs2jEW5TtKg9QPfqactC4JT8vIoaXq1oFOk3s4ur2aJfMMI3AOO2fX2rXjkktpXwJEuXlEsMQbkADv+HFcv4W04wI18yG2sLNf9a4A3jP8AM1Y/tya51G3kjiIN1MvkSSHChBwcj60rN7GykoRTkPgudR0m+MkVq9zbzTeefK4+Un54z6cdKl0S3mtvEN/qEVu0UVxcJLBCzfNEAcnOPWuy0iKXVlZVjCyoG80DjOD1Fa1vZQQKyXVxE4D7gsa8KB6n1qbtuzByglfUx/EWmHU9Xk1bSrRtPKKGiWI5bPcsO4NVLawv7i7iie2Aid8ySIMI2BzzXYSXOVWOKQKoAxt7tjj8Khie6MLJZ3MUMrEh4WHDe4PvVJcuhDbcb2/rzOb8T3cGs+Ifs9jE0MSQG3tYgAc4HzH6V5vC6R3PlatatJEGPlMq5Cr02kfh1r0VLW40zUPtEAWG7jLIodc8nsfTPYiqN7pTkLfLmexuxxvfEkDj7wKjtnpQ0raGlOXJJJvQj+FkD2d3p1rFE2y4vJJEjJxiEqQ2T6Guk8E2ix+I47eZG+zyGWMqpGU9x6Gk8MWJsSNQfzIyqkIxPOPYeh5zU9sGN5Beaa6Ow3RyoRwQe496nWxnUs24xdiW+ibS7ua3WVZGDfuzI2CRk8Z9eOapzarZRPG2pTKryjBG4Ale31q99gFw19YygeY0BuQZMkwY6Eezc15pp91p7+JLxNeEPkGNUjaVc7AQeQfY00+bRERjGKbZ3yXenzu82mTpLIQSynhiB2zVbV/FWYrXy7Ka1wTulmUHBx98Y7Z4rhBA9hNJPpzIBboDJ/duFz94fSuvme4uNItZNP2SfbGRQrLkBm4aP+tPlaNVytXuzi7s3ev6iDaq7xfxXEr8Dnk89q7u30TQ/Co0NZlkv9TuZwJ7i2O6KMejGma3pUVjr/8AYmjxSOsMccXlD5nDty2PpXT3Nu3hnwY1g6MkqAtHGcfKp9T3PtUJtu7JrJKMYxe53d1LbSxu7SM8AUuVTkHYM8fgK8TuPHMOqeLrXX7e4mjtraZoWgfnyQRgttHbFdz8KNell09rPcJtQiRikMh4bIOC3oOa8B8WaHq3g3xqz6hHs+1M8iGP7jg5yB+dVezsebQopOSkvL/gnqvxf+IglspdFsLiS30xlKzzxffu39M/woP1rmfGMEN78L/DNpYWcNurozrdKCzSOMZRj17Vny6Xev8A2JcyQJcQzhfIVueR1Dg9K0PiP4/0Z9DstF0mO6huLfP2mF4gqRydwmOcU2lys7I0o0Worb+uv6HlMI1my066sd7QWV2QZoyeGKnI49a9K8BfBrVdTtdL1i7vo7LTbv5njyfO2ew966f4Fa74SvLq3tLu0La8EeTfPFuUYGTs9DgVa8TfGW9jg1ZtA0qFgD5VrNKT50TdC5j9PSkqb0dznqOztSVzvdaXSvBXgvTrecSW2lWlzH5KSOA8jFjlueT1JNcl+0NoE3iDwhY6lpim4NtLvDocgo+AOlfNOualqmqXjT6xd3NzcnktO5JGfTNekfBb4nT+Gbg6ZrE7y6Q6kqjDcEIGRx6URcZ+4tH0OZQlTkpS+Yy38ST3F0o+zCJMgE78nJrQ8xGmxHCZZHOFWNcbz04H9al/4R7ToFkayu5ZDEAfLIwWY9SO+BVuLSpbSKK8uI5pI5CYbfYuCzYySfQCsm7anZzQtZMhUx22mztICJIUCsM/KXJ5TPfA61yV3eX1xqxi1JWNoseyONWKqp/Cu+udNij0W084QmGQEMoJDY7lfWqNxp9vAr3sikBOYVdC24dABULR3FBqSt5kfhS5kRvtcG+Dy02AdWYjjI9as3eowq8m1Y2I++zgfOT/AHRWTdarILa0iQxILqcwosfLkj+XOBTtYjjsrApOFF7vAJUbmb0H1oab3N4yp033Zf05pXuIoER1iuMowTgo2OorHhjH2h1Q70Ryi4XDDBwR69a17QzadYW0zKftO7LYzlff3NWrqOFHl1MTxySzqEW1iG2RGP8Ay0PYY9Kzemg6k/3nMlYwrpRYRXIkw0owqquCPX8apQTzS2Fxcwx+d5a5mg2ksif3s+1N1zzJrq0hjYyYBIZeNxrS8JQ2rWutEuYttuGkkY4BUjGc+gIxVW3NJ1ZUrO+praHcRyeHb10ldt5hRGQ/K2W6Y/z0rQDOlxcM+7evCtkYLAVjeFISnhKwjZN0stzuK+qqCRj/AL6zWpqXmR6fcYePbFJku33lU9z6iodkxNuTb7lRE3z3KxjzFiQNIwOSB6U3ToYW1K6ubi0YocLbiRj+6QDg57k89Ks6rbxaXpGi6bp1yl5N4hH2q6nwV8pIz91D6H3rmdTuLy/u7spJJbxodgXPcdM+2KqBrG1XbQ7V5dNPyNpe2J4yplzyT/ebA4rJ8U24vtJh07zDaJbJtgEA3Cb2PfNZNlLqNnE2xWEQAyiHIJ9RW9ZXVtLbwuv7xiMnjkkn+daeguRLRhY2urr4bsTqUCYhuAIrfeGl2gd+4HerNyA8MtwqmLADjLZO3PY9xTpdYe3ljCzw+fhopN452ehPqKxg8pYS2s4uIB8jOTtCZ7Yq0+5zum72C91W2sb+BJpC8IBeUA8OCOgH9a459PEaXc+j6hbm1uGcG0mbDH6D1ro59Atrq7b7dqMEsgOCPM2BD7+tM1jQNOeygfS4RZ3tpkud25ZPf86rfUtXi7f195zlnpl1qF0IdTljsbWKHYxZDI2McYHbNdpqMOny+FdDsp2d2W4MhLfcVccAnvTvDOneIoNVSS6WKF4/3vn3BCjGOhDdqZ4m8VnTY8PZW95J5vmPcrH8ijpgAcbanRltPdo29b+LkvgFItL0rS7K4neFGaZyQUHOAtT+KfiD4h1D4Spr1xpVuIrmYRxzOM+W2eCAevsawItE0vxF5WuaraeaEIKxxL8tweoB9F7YqLVtT8YJq0dlc2MKeGNwVLHaGgjj7A++KtaXjp5aHm1cO/ae1Sb72f8AwSv8JPGnxAu/Elqmm3E1/aRyE3Mdw37ghuu7sD9K3/jv4yh1PxDYaTpdnLeXlmrG5jTMsIZhj5VxzgHrXZWdvpel+E/EN5obpDYN5cUFrGNpjkb7xXucmuQ8W6lqugWtvKlmsl9Nb7p3+zgSYH3V3Dt3ocns9x08LGLdRaf1/XmaHwovp/C/gzWLe6sm8uZdyASbUt2Yc/Nj73tXfeHrrxDrrxpNqItLWO2RJFx5k0gXqQM/Ln1NebP4oTxD8PdLijeyjdZ1ubqxikBJIYfeHX8K9s0xoLbWbkN5a/aYk2lRjHFL3k7E1vZqnzxWr/zPIPiHpEFz4juNEj+0NLesj2iDAMk2Om4/dJ4/Kqvhrw9NpXhjVbrxlY3+ntbTDyFnbKShf+WTDPI9K734s6ZDNfaZqkLj7QzKqL0Ksh++D6156Z9U8XaH4ohR5L64hvQTdTyZ8kL1YLSi207/ANanXB80Izj/AFp6GJOT4lQIkCrHFKFitohjAP8AF71Y0yE6ClzG8NtcXl6xjjVxlVA6MB69a0r2907SFd4Lm3ihSFPLEkg80sQMtgc89cVn281neWk1xYMJJmBO4MH5H93HQmtbNbrQ1c4uyi7sbrHn6p4VfTk8uC4tnVkZV4lwc5bH8qzLa1t7wW80FjJaz2hErzTHgn+IKD1yegra0nfdXE7LIYBHDuZgufmHQEUXn2m/ngiUL94ZDHGPcetK9naxpGHPqdDosrNqBXmJWj3THHTd2H9a6C3sXKF0cBW/iAGGH0rmdC160eW4QRhJoX2SANkHHXPpnHeu2uHjgtrWcRk6ddDj5CAv49KlNt6mVaSg/d1uYU9hiR0OVkQHawI6+lUy8cbk3Azldu9Gxg+prL8QeILm01Ex6TYNdNGP3sjOQPoPfFN1DxJaweF7zU/IAMCBZLSTqxJA4P171VrK6OmMle1/66nRTGG8/tO3uZonNvaxyJMozubOMMfUVQurKKyuJorny0OQWkcbSMdSPUHjFedeAvF9zr902jtGkU87b1Cn/XY5Cn0xXV3VxNPA63a9W8sF8sAwOOfy/SpfkzOlaqnJbfkdbf3sV/p0ccZEM8gJUEj5QBwT6ZrI0a1mHnwlvlcAmMDGAPft9RWRY6hfRXI2xrK2ChMq/Kw9PbFTQ6jHFGEX7RK2xgCFIZieoHtTjPch0baHQXk+o2lrd3NkbdhJb+QhJzI5Y4wv94AVwWpaBcmNVmsiphXaZSuQT6e9ddY31noksM+q24llVMJCG3Mh+nqeKtX3jSTUrZxYaEkGYzlrk7greoH0pb63LpKpGXLCO55s+mX95eLYW0RY3XyQpGCS/qFz2967XRGXw/Ii6cU1HUbaI+bAT+5tWPGXfOA3HbNZniDxhq19o2k2dpFbafIiG3muoR+8znsf4RjmnyWFjNDp+naNdbLfBE7OceY5zlmPViTVq71Wv9f1/wAETV7qSsPsfEa+GdUl1C3ZdZ1mcbr24wRFACeIkPr71e+NXi6xuvh7oN1bzeZdagzEqvymMY5DH61St7K/1Cyk0KOxQSo2xVgAzM46E1xPxE006X4K8PR3qbNT+1TmSMHKqmeM+hpXVrIwq0lzqp1R6N+zERd6frc8sWblCkYuCc5U/wAP4da53xz4uGsfEPUrQRq+n6ajiz8wA+XIB/rBn37V3ngCTR/hr8JtL1i/umk/tOUSssa/O7McBQO4AHWvFjaxan8SNSuESS209vNlRZgSSNpIHvzSu0jLDR56znvqvu1Ow0q/fxn4ehaVli1zR5Qt0sI2ieFvuykj0PBridc8M6jrms+b4fha61GcsJbdCCw2kAvk+9b3wl1S20rxqZ7hP+JZewm0uN/Cgk8Z9a34En8OeMNR0iwaEX+tvHb2V+2QsUBJLEH1HT3q2uaJtfkvGX9Lpr+BV8FeDH0orZ6Vcrc+MLpGF5Lj9zpsfHAP8ch9BXpF/wDDjQdT0kW0zT22rRp5a6jGuJAf9oDhlNcR4m8TW/wxmm0rw5BDeXMJKtfXBJd5T94muMf46+K3mLGW3iz18qMD/IqVyxSTZzV3VUkoaIm8ZfDPxBoQjiv5dOubfB8udOJXX6HvXHrob2ciSLaS3NvjcW27WUnj8RXc+Ctd1fxffSWM8TXt/fEiKeUnCP3K9tuO1WPFXiBPDDvp2u6e13OGMBkhYCNwhByPxPSktHqzsXs5U057/wBeptPdeZerKABKoHz7c5HanyDzIUWSSaTYxkXJ4z61mWgey3GeZYlVD5kpGdnvVKPWLnUpkitprewt3TMbSqSZgP4h2Gahq+xwySTVzZWYzBrdpZSYhvjEh+VAeoHuafeQr/ZLtMZJJbgbVbdhlbt8v86ybGW5lu5oLtf9IiiDFgwAbB+Uj/CtmJgkUO9kDbm5EeSwP94msmaqNmrHMaRp2q6Q93ZtZCZ3mSQOrghVIOcHsfetS10pIrmS5vf9InbBRHORHj+vvWkwk8l5I4UhhVsFicAe1TNbOkSXDxmOOT5VQvkuTTbbLSjFlKdpmkW3tlDXMrYCg9vX6VieK9Tt9Lt00zTz9ougTvkAGXJ6j6f4VuJKmYpLmQeWqvDFsHze5J7jPT2rko9In+3X0hkIFymMkg4IPBHcCouralQg5yOcvri4WdZSQ+xcsvQqR6Gtax0m5umW4ur3OnXGP9HjJzIOuD6DNFjoCf2lHHqU/mFF+WAD7x967WCxWKJrdTuj29AuQv8AhQazp6Xf+f8AXoPsUZI7EIAI4JXQDO7Ocf4Yq3q7RSz21rjabp1jZyM4GeeO9UdVe50vw8s9tGY7iJDJGWAI3ccjn0pPDOqXN5bWGtu0ZvbGQic4wDkdahq+okml6ov6/dJrnjJr23tjb6RZWn2CNThflzzIMcDJ7Vn33huSIrcRzxzAgMUL/MAOgIrp7KOziv4vNtd1sQf3RwwMmOvWpzZwS2kEnlNETLtZCASVznJ/lVQepmqig0kcTHpk7b2fjjdtBKAe1aFrZzy3en24IRXLSMyAHIroNYaOzsZlmjaQspCIGVsenI9Kp22lzQ2lsk6O7SRb2jX5WGeRliOPpWqOh1Va+1zlr6yE8UmXFrB5pRDJkfNnGN35mqN5YPpelyw2Fy93MVJlMLcewX1IFdlquizGyEJk8y1U+ZGkhGCSOc/jxmude2mtrN9luCocAsvVT7eopq6VhWjOSmtjzu7s7OSwDSX8SO7EgAMzr/vD1q34KOpSTOty8i6e6EBXB/eN0GPSvSYtBR0aWOJBIuDMpA3lj2PHFN1CH+zntWke1tXkOAjzLkH6ZyPrVqLbuiZU4Rau9v611M3WLO+udBi1yyhiuntf9HubaVyzk9mAPUV5fYai7ap5eqfaHtHJSWFX2nHoM+le2WKw2Mo1u7vUtNPWXy2QklpmAyduAePeuZ8Saz4Q1S5WWa1S3ErfMIkJ2Z/iJ7Zo5JN3TMqk47N2sdl4csNFsPhZfavpd9NdATrHFG/37fHVSo7nJ59qg8NRz3+o6bcw3KXV1PcrCmn4yhTPJK/Tua6P4TaroGn6Td2FpPE5nYx7imdyFcZB6E/ka0fD0N74Zv7q00TSLKfUzA/lXBH79k6/Kf73tisK9KTkney/rQ3wWKVOlONrt7f5jPEOhWWg+NZl05x9lZgsMTvv+cj5gB3APT3rwvxXN4j1P4kzxamL62EjC1Y7WGyLp0+nNdX4F+Mc3h7xFMusaNby2LS7ZZjGTdwduCT2PXpXcWOka5qnxLtvEWi6g+rWdlGsnlS7VknjfPYnHAPX2rSKlC2un9bnFUmq0XFrVfK/9ff5Hm3gL4eaxZ+J7u/sgbrQrEGSeUHaZEHJGD1969sm8aWkVnZS67pYR7nbLpr203lJOOgTnke9b/j/AMQ2um+D59SKrp8tzG9vFHcEJhSPnbaOp9K8L8d+HD8R9Q8K/wDCGX9tfiOyWK4Bn2G12HklT90e460oRly67L+tzOTjUV0rX/rY73XH1Qaje6h4oBs7yID7DYRkNGCR97PcY4Jrn/AmmR6douqXQuH88LIEW3UEOr/e69ge9W/F6zXvhG/1a51OKSfRo4rCK23ffQEDOfc9++KseA72xTSPMm+ziW6ZY1SUY3Do2DnpW8YNpr+vI2VWMYpPp0/M8J8Ui8+3ysMAthwxXPQYwDTvhu1//wAJFGyTeVDIQshIwpGevpxyc17z4i8FWGj3rPaWwuLV0EkaSyEpnOD9Bx61y1zptjdia0VUhjnBRViUL6Z5qrOT5hxpKSumdt4i07Ql0zTLHREXyjJmS5V9271Ge+fWuREi2erJdQyCWKJzHgj7gU989cV01lp0WmeGoVtmVbU4UwEfOrHuvr9Kxbyf7BfxxXMRntny8LYy0T+h+vvUqCvobUp8nxa33GX4tC5ktBGbrU90wEI4kIOM57emK62G9ubnwmmmruW3tRuLM3QqM4x6VieD3tLrVPsk1sI3mlABhI44ycH+Grcjraa0uBJBbG4MckcgBPlk4APYn3q1HW3cmq1JJ9tTjH1kaVpI1iRftDSTFnWM/MilsYIqpqkul+J9MvV0qVvIvJhCokGJEbrj3XNT+OtFm0fVbpdFtZdQ0uWMLJFIwUncc447g8UnhPRdR1C/ttW1y1t9Ns4hsiggGGkI+6QOxz1Per5YtWMlOUZc3T8GYfw/+HepaXr41K+lhWSzkzFEG+aRh39hW1p+sXdjdSy2nlotxcNKsLpuaNiSCOfQ5Nd3r2qRabI8t4kNxPFtVI2GdzHtx3Hck1w+l263viIgq0AlmMioSBgk+vpWbio+7E68JBWcnojutMvpzDEsRiaWdsyxPFtVwOpZuxNRaiCRKY2aHJ+eW2wfLU9EHqKzvHy32jaRcQWsDi1kdZkYuGD44bB7cZrgNH8ZMuq20ayk2cuIhBIcEA9SKFBOxzupyybO/g01bESNqSFnWQOrtnc3pg1kajr1q08EN08i6dbO0sw+7n0Xiut8Qah9q+HkV7CjG+gkFqWfpOB0IPbFct4C8Hx6vdzaj4lMa2su5VRmwssn8OB3Ge9KxrHENx5p6Fe58N3uZdVC2yabMRIMv83lnoo9T71b0jRtLgtTcWNtd32qgjbPOcRRKPQd8816B428MXF5oumafokIlaMHyoWcDbz/AOgis7VrV/Bthpq3EyXGoTusclvEu5mXoWAHOAKcYp6GM8Z7RX6nM6jpt9DZfazM4vpgf36nlPTA7AetYnxlvLK88AeGbaeNmvIjl7qJgyyKByG77s10cmpSJ9vlt0E8U3mxbW/iBUjI/u464rj9Kgt7i0ulNtCrQxYnVW3bV7tg1fLzIHF3TloaXjtofEGg+AWaKVdGtbUKVXC7iD2/KvPr/VLie4ubyzYIVLYB4+TOAK7zUbqztvhtp1jOxlubbft25O2MMSuPbBrmtT1hdb0eWW20u2tY3jSHKfxMO5Hr71DjyttHRQtyez/rQ5vXZHutPs7q3UwsUO5emHHdfY11mp69btrPhXWtSEzWCQxyhIzliyrhhn3Yc1i2ll9qs0t71ntUPzJMwyisOoxWhquiNqHw+lttGuEv5dMuGkZY+GWJuSADzjOelC92NzSced37r8UOlgh8b3PiDUZIZVjdxJBDEcyBvUe2K8nvI2jncGNk54DDFamga/qOh3JNpK8ZY4dfWvf/AA5rGnXvhS8Os6NYXerGEtZSSwjg+prlqWnFtMcKccWoxinzXs9O/wBxw3wPJtNXs77UTPHZ2Uc08arxufb0H1FX01rQvinrtzZaqiaPOWMsLMSVkYdST2OPzrlTdXljrFoyXMjB51GByuCcEY9q7BdX0Twzrl9Kmg2F7DFjEyHLZbqe+KrDzVWNuhpjMG8K9Hqrdncq65fpLfrBeFRZMpSaX+6W+6SPbNaCajaSeHrrRNZW3t73RrdTC2PmnUnsB14wRTNS0O4lMlwjtbFF8uWZvmU57c1SvdJiub1NQ1W5lnvWURjYmxSijAC+vStXHQ8SUeeSadl/X5jfDccsxuLlAfLnkBRpfvbAP5V1Xl3iw58yMQxHJRhy34+1Zmm72jjeEOsajEbAcDHVT9Kq3ms3n2q3i0+xZopVcw3ExxHLt+8E9TmplHmL5knZG0rxosks+6MY/wBRnd5invjvin2d9HBeJJPa3E6eWyE7CAGPAxngcVmaPc/2pJFcFGhYRmJ1LZKkckY7g1qG2uJL2yglEmLiMzQh23JJj+76VHJY2UYPVszpI3KpHJ5eACoXPCgdxVaSWLLyCRWwdh2DC7fr9aHnjmuQGV1jBOQv3i3ZTU0t0dLurb7dbwsjv5Jiij3bN+Oc/XrScLnROcKVki19kRSqNGm/IIk6/TmtGGA28crb/nPBZVyB9axoEFpJf2i3DRzxzBkgzuQIepJPQfSn2tyt3IYonk3hsTbW+QZHGPUd6z5Wxcrlcj8exy2Wlu8aMzOieWGOFGTzj2/xrK+G0htn1BbxkaKZ1O3PyZrrJrCO/wBLjQS5ZFKuSckn0PoCMVk22lwabt2xeVFJyY3bdx3yaLcqZ00aXtWlfb89TZn0+fR9WmjurWaK0uuYZHzgsehFaJl2IIlG1mQbsdSB7VZ+0X+s6U4vBDNa20pSFZX+dx1GPp0rNBm8xFmiAlZwCr9QD3qqeisYWU7ua1QySyDa1ZQlf3TfMoboD1INcJ4v1PWL7UJp50mOkG6+zRi3cj/gWOpH6V3t7CEuikjpIIuT5Wfk57Vmy2MNtLcTQ3yKl6xXyioOST/AP4fWtY6bFSgqjTv0M3QbmfR7ttPuLhbiF5AGtJFJ2/7Sn+93xXYajbwxeHtTjKu8x2mFx1QZ54965fR7jRBrkkK30N1qEOQefMbIGCV7Zx/KtLxvqdppPh6V7GQyXW3IWNixYep9K2afLqjJqHtFyv7tiHwbqsN7qd1YBlEIVopCoy4OOCx/DivLL74eeIb9r7UdPj+12CTsnnPMA+c9ME5J+la3wyvmgtdbnnt5kaTaxnI4UZ6e9en6dc2t94RljtZC32WKeZyYsETEZXB70nTU0vQzm1JKUl1OV+HuheIbfTby21ySyjW3Ty4LS5YM8gk4bbjPY9awNR+Her6ews7TTDcXKsU3k4LRn1HTisGbV3gj/eidrjZvV0yAhz1+te/ajoF54jtBpukXUkGpXml+fFJM3LHGdvHQnnmqlBJc1znp1Iv3WvTX+kedeCdHltbVtJWa2FysnMCzLliOdwOfvY4wK63WfG1xpF7oMc9vHFd28+be9kJDygDHlsPT3NePWDaldaTc6TqQS3nspS0DlQsiOjYdAe5r2HU7Fta8FtZa0trHcTeXPCsS/vY9vViT3b0q3G8VJeX9eQ6clL3Wrf1116/0jpPFvhPwl45huNcjtTD4hSITzC2J2zEfeWRff1/Gq1jq0+ja/a31loMkSfYTFBGgJiQ4AG7174965uw0/VfC8ObTWWezaJtkivzjuhxVP4p+NPEzeCrE6VdukUYCXElsmGC9tzVk6caa7I0cJKLsub5/8D/g+gz4xalqusWmnWOuTWqarCpYW0gALqexx0P1rN+BGh3/AIb1a+8V6rYpHoFlBJDel5QCA3cDuR6V5zpV5DCsmr+K3v7u5uSPIjDlWlHdi57V13iJ9R8W+DbCLQnl+weeRcWxbASTA2sx/u44pqC5eaP9X/K5k2pxslZrpr/TsemapeaLqm3/AIRG58/RNSw0sWwM/mL0U55Gc1Q1fQvsunWk2s3dlo1hLJ5MZ/hU+uByfwrj/g34f1rw9f393fxfZbOVDapJI4CtITncp6cAH86k+Kf2nVvEwkvElm0qCy2WBQjbuHUkdCc+la017qa0/ruEnNK0lr/Wtl/Vzf8AF76rpGkw2Op3LThvltbpG3JLFj5WX1rG0E3DaOWucNMtvJOmByoAOP1FUvC2p3cmknRL52vbFEW5tBJ8xgbo49QDjoKtx3S2s0kdtDPGqgnOflII6f7orRxeqf8AX9eRrQmklK39f13E+E/xS1SXXYdI1SD7XDPmJZo490kRPQ/ge9d9rLfaLiS1kjVLyMeUVlG0sf7zCuC8M2Enh/xhp/iLRJLaBPmE0JHysv8AF17V0upa2NSsdZ1dLKVrwzAKiH5fKHR8e+axd2rvc1oQlCfK+u39bmgn/EoheCyuLdwibpZZgF3Tf7PfAAxU1ozanpDakjgTC+VRGW3Bh9fTNeb3ustco8hLNHtAKgfKvP8A9frXb+DtY0qbQpNMmY2NzIwmEjL+6BHSmtGdFamlC6Ormu7iC4e7SCzZkZVWFOi45xk+vc1CjSzyajfTQWkEnmmXyM4EeVxx7d6sWY8oyalrlxBst4ikKgAo4/vA9zmsjxTdPp3hUAup1jWpIzFb7dzLGpyAfr1q9jzra2Ilhjuoo72RUIuE2lAM4I/j+pFbE2jWmoXMV5BHGHTLKynBZcYC/pWW0a2Wnw2xdmO3LxbcAt6iui0qQDS7d/LIcxnkDCg56VEYpuzPRxLdKjGS6kt2LPUvDUtmWk8m3Jdo9oZsDqB7ZryLUfAtpb6zDdTtJHDbfvxFwD6qCe30r1yzMH9oJFLEWtVXzpFUYYH0/wBod6zNQvIdR8W/Z1t4UaR1kdmXeIY1HLH/AAoa1ucFDRuLWhla9Y3ln4V8N6FcK0k1/ctP5DDaV3HhQfTmszxKfOvrnTWUJ/ZSeUFik4MnotdTpurnWvE174iuPJOkaFb7bdXJKzHJCn/eJ5rltP0G78VX19eFHjJYzzyRj7pbkYP4AGojpodFGN05S0sY8Fzqdhfx3dtq1yskiBGmkPzADqFU9hV/QdWuovG+laldzz3FzGzRwygbjgj7uK0rjwdcAW9zfSBrmWVYrW1BwzE/xfTvXRaT4USxa+hsIINTmTAjupAUIkH3gPoe1Xe7t0KlUoQg7pczOd1yFkeeG2mEhkZriUuApSRjyteP6wLvQvFH2qwkMb3QP3zmNh0ZGH1r2JPmu5Yr9kFysmDJGOGGe34iuW8S+Hft2qXC3Ns9zFK28tH1I7kHtVyhZKS+QUYqvFxe61M6wvY/sEdzMsapGxiljblQx4Kr7VzOtaNceF9YWz1JHjsp2E0cqAsDGeQV9cela+t50Q2UOj20HlzyGKD7QMhAByxz0Ymlh19bwJ4c8ZQy28F0cWt35mfs7dBj0XPWiSvr1G0oPlb/AKY2w+1Wq+UUS4SVgCWORsPpS+HNNg0jUNQkjuJYRMoa2fPA67lb2OazdPS+0PVW8N6uVE0Eh8hnOEmU9g3oeorS1WBbnTSbZ/KnQFZYnP3W9VqFZxv0Nl79nbVFHxRcWVtLZCx0Kza4aIyzyEkrJhsfL7+tdB4PhsfEdx9lS4NpubYjluE46fhXEWdzDNbjSdevJbJoVZ7O8C5Cuf4W/wBk/pUul2N7YXshvJbZbO4AJlhfcCezL6VnKMXpb+v67hTr1E3yv/gf1/Wp69rHgHw94d0i5/tK/ml1tIyLWAnO8uOXAHTjvXztren3ug3zQSTgluQUfOfqPWvRtShNxI0s/iVbidUHlmIEtu6AH6VkeOk8M3Xhayn022uLfxDARFeqclJD/fB96xnR5FeOlvkYV5OcFzu77/oeoXLHzUgMiXUVugQAklc45bP97P1pmmx6ZFfwzahJcSTwuWSTy8pGCDwAOoB4/GuistFiksY5mlWO2kcLHCHBycDLH2ptzosat5e8xo42qSfmIHf6V03Z4MqtN+6mYOuXEt60X9kwCJPLk2RwjLTSY+8V/hHv1rjPD62//CO3Oj65eXUN39qM1usxZPspHdD79wK72e2uYGZZlaNIwSrpwX9gR3qK4TY8SrZwTl1BZid20nn6/wD16mz3NoctkjldEWa61K41Ca1ks7YhVjP3A7rwWB7A9a67SrmO1vSRN5ULgyW85YlYn/iiY9Ah6+1QTq0yiS4icWhG1ih3AqO2ByKvWD2UdmlpNZySQlsxvGwGM9mBpqDHVqXSSOdu7K3svFeoxXF5HHBPE0trc48yBi3OMjjI6VVi1eLA0+5XzXhjGy5i4DnrsPf8a6xbK1urlRrFtJPaxklLWIhFjXOPmPdjTL37Hp94ItBsVt4nQqgnUMyt3I/zxms3CyNY1ouWt7mPY6R5tjcJfzmG4mHzNLkEKe4P+NaGmWUS/ubJQyOAu4Yzu9Se1SvZW2mW7aj4huLeNXG1oLiQlUHoi9XP6Cp7LW9FlMH9lXKJCWCOjoYyx/hJOMVPs7vU0ljWtFqOmtBHGiKEV9rMXiPVl5yazL9RPdJ5kYjD7NnlniTI547VvSR+ZfsvnRnMMr715zxx/hWTZ2zG4ilhRmL4QnOVz2HsamdN7HoYOtrz9bHT6FZQTaMpkWNg0zMRJ82SDwRj7uKdcaT9qhYNcOL3J8ovhg6+nrmrPhuFf7ItfIPzKSHOejng7q1bMuw2PBFmNhtKnG09Mn1q1T0R5M60ozbT6nK6XayC4khvYVW4jwIsfcz9e9ZepNpWj+NdIj1G2JtdQjltRMh/1UxXrgjjg9c/hXQ+JYFW9gjQrv2sXk3YWUjkbfcVzOp+XcrvuF82WBxIjsudjgYDY9uRRKFlselhpSqK6lueZW/gj/hG/FltcLq+6OKQSo0S5cjn5TzgE9Oveui1a7Kag05iZluGaURwglcd4244rv8AwfaWa2fm3UAutQeTdH/EI1GMsy9/auk1Pw3aarHcfZ40icAI0T4HmZ53fL90VcItLTYmdfD0Zun17nkGkOmm2Szx3kd3FeKSI5MFbVeRyvUn0NegaPZeVodrp8Mm1IEWUSJg+Y7EnJz6g4x7Vzuu+AZtPcPDbMpA2lMcEeit071N4F1kQzzaPqKyQXwwkEzcsQOi/qRmtYJOWo8RPmpXg9O5M/hHTGla5+zGTLHaDOBCJO+70NWfDvmaNZRyvdzWt5Hc+ZBcMSwBb76DP8OMYFbVzpyCB7N7fzoQS7BuFDDorY7mvPNfuxqetGW8uJ3libNtaJ8sUIX+f41ty2WuxyaST7nXXMegv4ika8sBPq1+5nXUWhJiVj/EE4CnOPrUUmnXDagtrNI5mQM5fG0S+h/H0rQs51NjaCeN18yPlnGQxBBB+narNxekbp7+VbazVCwnuuNhA420+WMXaxcIzauixp9vpFlpt5pmuKqCBGeOWDvv6qWwenr71w58T2Xh3S20UFZLi5JTyJl3b4z0LE+tWV+IOk3WoJp+lt9tu5wqeacYJA/l1rg/hTZHxZ8drWO+jEsMM0jyIx4IUHj35rOfLHfUqM5UYc19z1C18Gx+II2j1/S4SI7dTD5cOQkfsQRj6CvStP8AAegWcK21noqfZUtyFHmECduuSM9c+tXLvxJpnh03NtK0twVlLRQwAM6L/dxnoPesebx+5Mr6Xpk01iyjypMfvFdhyNvpmuWcZTeisc86terL3FoeO+EdVe78QX0HjrybHwvb3DEQz8qvJAVcdc9z7VzPxI1O01bxckegXSjw7b/u7cWrYx/tBDz7e9dZ4u8NWWsWstrfPJa3eS8ZLEhZG6lvVcZz9a8/8MfD3xBHrdr9lksoo7SYTNqHmbkiCnOT6Cu3ltJXX9fcazpTXwu6O+8EXMemeF9Yk1C0hlEcWLeUx+XLID9e4J5FctqOoT34IluZbpYuEjiUKoBHIOBya6Px1qlxrJ1O8gdmeZlVGUbY3K8EoOwJ5qD4daFdCFrm8EXmyklIWOBgDqfStdLbGqpyuknoYd0l5NaRJFp92tkyBUbYcAg8jOOa674ZaHeap9qvoi0saN5E0CjBkTA4I9Bmuqa6ItoI0CO0XMNuWwu4nnH96qmqW9xZy2WoeHNRlsxarmWFR8krHsf5Vk7WtY3q0pRacXd/19xneKPAd14ft11GwhP2G4kCkIN/kgnuO/8A9ao/D1pAJTYXbxTSuCUCIcyE9uOldHf+KdW1EadDrD21rpLzBp/KIXcFwSWY9PpXawvZavqMGqeHo4zbbAUlgAwGPRh2571gk1uc88bOEeSpucpa21vZ7rq8s1ubGwDbLbJ2F8Z2kfXmvPpdX1G68SPd3ccf9vTDdbxu422sODhQO5xXrXiKy1G00nULqRobv7U5eVR8hjYcbkx19xXzha2d7datILaC+1C6aXMQgG51I759PX2qoyTd2Ki+ePNFXOx0XVLpNStrS8vI7r7SjShmHzIQeh/GvRROYbaBZ5WCrEH2DlSce3euF0LQNStmk1jVGsUnjAWO2XkR7jyWx1ruNDs1jim1vWL+L+y4x5ISH77SA9Mdh/jVtpJs0xE24qMunnqT6tqtv4c8H/2rdhBfzZMKs2MLjG3H61wvwwvLmbwfr+t3Lv8AabmZobaRzyc/e57iqHiaHU/ip44ltto0/Q9Kg/eSONkdtGDliT3Y+lXpNXGp/Y9J8HWxi0e0VobZWGXdB95j7t61kutzGF9E92bltbPqHgtodNCRxecu6JHDZx3P5dKTxfqF14X0/StC0ufy5rz9/eMB83bAPoDWlpWoaP4L8OSXLyxTalLnZYlwzFvf0xXnD3V5q08upahIZbu4BL7f7pPA9gKbv0OnDQ9tLln8KLWkajejxXoUt5eykJe7lMzcBRwSDXtFhqoia6020sJ5p97MpBAjLnncT1xXhcUc2o6rbWNuA7xsDGZeue/4V6sL3Ukt/NuIEs7iKEK14zDYyKPvGtEuZamOPw8XK0Uc3rVjPDqIlndY5J5jE6RHf85Gcgcelc0fEd0nlTtGJ0DGFsfKUI4BrpZ9YtNYtLzTrTkyKLxb2dT5rTL6Y+6uM4rkI7VpTdOy/PMVkVuqlu+a0TsjbCwb1LGsaMPE7W9qsRWS8YRoRnAkHRgeleZeJfDmq22qi012dy1uxjGUOeD/AJ5r1i6d5b23sZLmSG2UfvYo8gmQcgZHTJz+VRXTahci6+1p50FzFsuA4y0P90hv51m4pvc6KqU/iXp/XU8+8Qs/iO+tLO/miTU7eKOGOWNgQ2Bxu96fGNQsb97XUIHGowrjzAOJF9WB69uRXOeINO1DRdRSO9gNvepIDHLGOHHrmvo3UFN9pVnp3iGw05p7nTo0TUYwVKPgEMPXIwDUpJ3a3OadZxmk0eNT2JmVDq1t59qw2ia2+bym6jP9ap61Pa6c1vaQ2UV/HcfMGicqMDtn19qm1e31HRL9oY55LS+gYrGd3yuv06HPrSJANWsbh4o1hubRw9xaxkZVv+esfqD3FS4K2htGrzu2z/rT+rlHS7iyvrqK3hV7J3bbskXoenBrL127vILtdObbbpCNu7AxKQT8xPerxsbyeRJba5tZVWVZvPdxG6kc4KnvW1qktmZd+oFBbud0fmjIT16eppWstBcjm+WWnn/nY//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of an esophageal biopsy shows multiple multinucleated cells containing intranuclear clearing and inclusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10902=[""].join("\n");
var outline_f10_41_10902=null;
var title_f10_41_10903="Aspects MCA variants";
var content_f10_41_10903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ASPECTS study form and MCA variants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 560px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIwAVQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuX+JniI+FfA+q6pFzdJF5dsoGS0znagA7/MQcegNc18D/FV7rmn6vpet35v9V0q62m4aIxGaFxmN9pAI/iGMdhQB6bRRRQAUVyGu+M47fUP7M0aO3u77d5byzTiK3hfGdrP/E+Odign1xWJq7T/AGcjxJrlxLLhma0tN1tHgMQfkjzKw46kgEY5FAHos1zBB/rpo4/99gKhOpWIHN7bf9/V/wAa8jsJtMfTom/s/ToZ0UI1yxQbuo6OJX9D83QjqaL64Mj2lraW1rMZEIiltmidZGC7MF/IAD5G7b1yemOKAPXY9QspHCR3duznoqyqT/OrVeGStIdZOnzQTwXlwVeG3uLeCVYzkEj5o04IHHzcZPtWnCbiwuZjFNJZt5pJZJZLRRuYcYPmRNhdxzxnge9AHsFFeb6Z4y1K1iiN8sd5HIxVRLst53woY+WQTFLgHsVrttG1ux1hZRZyN50JAlglQxyxH0ZDyKANKiiigAooooAKKKKACiiigAooooAKKKKACiio55o7eF5p5EjijUs7u2FUDqST0FAElFcBceM7vWbh4PDP2WGBFMhursFnljx96GEYJBwcM5UHHGRzXLa5dpG/7+9m1S783Esd/cl41UPggLCViTKc/M2Rxx1oA9autX020OLvULSA/wDTWZV/marjxLoRxjWdNOfS6Q/1rzA/2Xm1+yWWm20IdMLI0KxvtYkjd5Tj5gQD8/YYxUC3+pNqb2umW1xMLdhvgtEVFKqCpKnyhlWJzuGRlaAPX7TV9OvCRaahaTkHB8qZW5/A1drwGw/0uUxQrPO1uH+0/bI7aZn4AUb3EeSDzwWPJBq5b302mo8lldSWxiUNIkdy9u0zlQSRG4kgyW4A3AYzQB7lRXmeleN9UtGC6pCl/G5zGix/Z7wpvKhvLJ2SZI42MCcjiu60PW9P1y1afTbhZVQ7ZEIKvE3911PKn2IoA0qKKKACivnzx5438SaR8RfExt9VuodF0i700OiCBkjimRfMBjYeZISTxsPHPtj6DoAKKKKACiiigAooooArXthaX4hF9awXIhlWeITRh/LkX7rrnow7Ecikj06yj1CW/js7dL6VBHJcrEokdR0UtjJA9KtUUAFef+LvEM19f3GjaXM1vbQsIbu6jYLJJKwyttBnjeRyzfwj36bnjfWZdM0+O1090XVL5jFbs/3YQBl5m/2UXn64HevMbyOJ5VtNPlaO0tLRWvJfmbCM24jBxmZ2PzZGcsF6bqAK82pQWNtiE2djFbojSXRceTbzBcMtoDyCwJ+YZZieoGGrq/DvgvU7m3MmpfZbISsH3Y8+cjggnP7tW98Ofeqml6XE9o32+zhzNGY2h27gkZ/5Z89f9o9zk56Y7bwFfw3WiG0iyrabI1kyEkkBMbOScnKFTnvz2oArt4OifUYfPvL660oQuslpcXbspkJXa2PTG4YzjkcVyfxB0S28MNZ6jp4LWU8v2e6spGLI8exmIGeeinqflOGGMc+sVwPxQuLe7GnaPNaXDvJcxyee1uxhjGGGC+MBjyuP9qgDC8K6DBrWrarHDGIrSGV1luWxNI8m9lVB5m4YCKrFiCSW610ln4Ct47y4a5u5JLY7RCqxQq+MfMGYRg4z0wRgVifCPUre1jFpc3ESTami3trk8zDLK2PfKg+4PFZHxx8eatoWt2lj4cvDBLYW39pXiCEyCdfMULCTtOzKiRsnHAFAC6jp50651ixthMRbsFmtlhe4t5Y5BlC2AdpxwQ3PcMAaRNViuobi8uZr5NSiBnh+zEGaNdoLfZ2Y/PHxkwv23Y3cV61ol1Zanp9vqunqhiv4knEiqAXUqCpJ7nBrkviB4UhuvM1e2ZYJYkLTsByAvIkGOcjHIHJA4wQKALvgvxRPqBisNaSNNReLzoJ4kKQ3kf8AeQHlXAxujPK+4rr6+flmmEzJdytY3S3fnXTxorLFKcbNQD8fKQFVwPlKsDjk49p8Lax/bOlLLKgivYmMN1CDny5V6geoPUHuCDQBsUUUUAFFFFABRRRQAUUUUAFFFFADZZEijeSVlSNAWZmOAAOpJryPxL4hk1yZLicwxaJG8c8FrPnE8O8D7RKv3sNgiKPB3NgkYroPiJqqXM66Grxm3AWW/DSFPMVjiO3yASN5BLccIretchaWdrq19PNezn7DLPKbaNgQbiUAb2UHgIvGBjGMDu1AGdPLNLJbW0StawagPKhEjF7q7jXJLzPjlVDd/lGcAN1rpLbRd18sUTNHDI8Uam1jYXCDcN2ZST8uPQLgZxVy3t47SCKCLzGWIbdztuZiTkszdSSTn+VTQ2NxfanorWuFNtepcS7nwDGFcHHqcsOKAOjbwVpFwztqP2vUHJGxrq5djGAAMLgjHTOevJ5rzfxJaQ+GNd1TTpwt5p91bPd2ySMd0MpR8ZK4IBMZB6bgRnOK9trxT4n3tvqeq30qW1zaz2MEcW+4hMZnBmwTGT95VyR/wOgDX8C+EoNX0pdQaV7O0ZyttHbKgd0U7TI7kEkuQTgYCjAFaVj4Ca4gebU7y5N4DKkcbiFo9m47MlUDdApOGB960PhrqVr/AGZJoRnjOpaVLJBPEOoAclWHsVK/jmvPbf4m3zfGBEbUCfC89++jpbmEhRIqqFmEm3B3S7lxngCgCzD4a1iLSWntoYJbe1uHe4sJn8yASRMfniOc4yMj7rj1PQ1rXVLYWMd7aT6jFrEGxDKqGa7iBb/lqvH2iAE4II3qCOB1r2nTNPttMtfs9mjLEXeQ7mLEs7FmJJ55JNeYfFK1t7bxXo7adDLb6ncrJJ9sgQ4icFQhlIBwGLbdx6dwRkUAdt4T8RyamXsNWgjs9agTfJCj7o5UzjzYm/iQnj1B4Pv0leC6e7xXVs8Df2deW07AKyqsVjdkklCxOfLuCdpXkKw47V7T4e1aLWtJgvYlaNmyssLfeikU4dG9wQRQBDceGdBudV/tS40TS5dS3K32uS0jabIAAO8jOQAAOe1a9FFABRRRQAUUUUAFFFFABRRXPeO72e08PyRWTFby9dbSFgMlS5wW/wCArub/AIDQB514s1L+07i61MsjW0hMUCMEdXt43wFIJyokkDMW/uw4q7a6b/Z6Wmnzsj3UuNS1B2dfMeUk+WrKOgHLZ6E9K53SIJbiaOOzS2LxgGNiN3zO223DDuFQxnHH/LQHk169p3hmxstIW0ijHnMv725PzSyPnJZmPLEknrQByaud3ykYz8vPOPf9a1vDOp+Rro07yEEV1CZhcDqZFwCh/wCA4IPsfSodR0eexdmcCRCP9aBwPr6VnHy7SaC+mSVjYv54ES5cAKQ2PXIJH40AelVxvxKvLWTQns0urY3v2m3KwGVQ5IlU9OvTmuwSRXjV0YMjDcGByCPWvPfHF7oWr6IL7SZdOvNSt7uPymj2tLvDYZePm+7uBHpmgCP4LJFPoEF0wR5jZ2ihyBkAR5A9uST9Sa70aZYC4vJxZWomvFVLmTyl3TqAQA5xlgASADng1558H7PzbU3C3s8ItRHbrZRgIjRiMFGcEbiTuODxwAK9OoAgsbO20+0itLC2htbWIbY4YUCIg9Ao4FOuneO2lkiiM0ioSsYIG844XJ4GelS1xl18TPCtrY63dT6iUi0a6+xXgMTbkl3FQAuMtkhuRxwfSgDiNXs77Rk0+a+skg1SyWR49snnR3doWLPbliB8yKxGCOVyR040fC+tHTPEVnNNKZbLUIo4ZLnaqrJuP7hyq8KVO6Eg+i1c+KHiGxvrXStJ0e9gfxHcSRX9jaOhJlRQWZW/uBk3jnryK4y0/s2CDUo557mGy8gTQvFGZC9s7jKMvGWQsrDHKsr470AfQFFYXgrUptT8PW73rq+oQE212QMfvkOGOO2fvAehFbtABRRRQAUUUUAFFFFABVTV7+HStLur+5JENtG0r46kAZwPerdcF8VLuWW3tNKs5kjmkJupN4JUhCBGrYBwGmaMfQGgDiL6x1LUNQjsXMYv9RlLzHCSBZHX94wOdy+XGRDj0Dmuu0rRtO1CK6vbUwzJou+zsEicM0ewfvGJz95znPPTbmuS8IaS+ravDBcRx+XMXineH92WhQAyEEc/vHdc98M9eu2Ph3SNOvUu9O0+3s5lj8rNuvlhl9GC4B/HpQBw8d1BdW0M1vKkkUqiRXQ8EEZB/Kp9OupI/FOgwxuBDdSypKuAQ4ELsPocqD+FQ3OmjSNZv9NSPbaMBd2x2hURHY7oxjqVcE/R1pmmRiTxr4fiLFXja4uBgZDKsRQr7HMoP4GgD1CvIvjLdadqMFm+n3lncXVtOkE/lyLI0SPPECGUHuRjn0r1qeWOCGSaZ1jijUszscBQOpNeHfE7VNH1DULWfwrcWF4/lj7YLN1YkLcROm8L/tBufc0AeofD6BIfCtoVwXkaWV36lmaRiST361onQNH/ALNi0/8AsnT/AOz4n82O2+zJ5SPktuCYwDkk5x1Oa534V2LReHotQbUbq4+3r5zWrkeTauWYuka4yoDEjBJ6V2tABUN5G01pPHGdsjxsqtnGCR615Z8Y59ei8beB18NSzG7QXtybRZSiXYiELGJuccruAJ6E1y/hC88ZRaP4yst2oalrT6rFBcPBIrPZJJHumaIO4X5eVUZAyVPQUAbOq295o89pPqMcP9q29pHBqSjDx30JAUzJuA3ENtBBGdwTt13fBOpvp/iR7S6mMsOoKgNydu2e5CAiYbeB5seOOMGM9c1zHw2W5134LaLq1+t7cXWnPdCV53Dtd27SOJdrEkkBTgZwd0Y4wATXjjt7SzuIDqMsN3BLFFbuiF459zZt3x1BEm0Bh/BJjGDkAHvVFZ/h/U01jRbO/jG0TxhmU/wN0ZfwII/CtCgAooooAKKKKACiiigArzP4hXMWoa3JZfaI4/7PtjJmRmA8yT7+CoJBWFX57GRfUV6VIyojO5AVQSSewrw5dTm1KWWOOMSXGpXIuHfIVlMhBjQgnICxLD3wQ5xQBt+CFtpvElmb+ZRPMj3saytgyuGMa4yfmwTMRj1B9K9Yrifhza6Ve6SNQRbW6vPPdjLtDtDj5UUEjIwgX65J71e8S+KH0m88m0sheiHyjd4l2tEJJAiBRg7mOScccCgDppEWRGR1DKwwQe9cR4g0m90u4kvbOKTUNNckzWsagzRLgfcHG9eCSPvc8Z6V2F/e29hCst1JsRpEiU4JyzMFUcepIpmsajBpOl3N/dZ8m3QuwXqfYe5PFAFDwdf2+oaBavbajFqJjURyTRlc7h2YD7pxjjiqt94StDrTa1pPlWGrOcyTCBXWbjHzg85xxkEGuZ8NaRDp2sXq3lpJoOs3lw8kF5BICl4hZmVX/haQbiCGGTgYJArf1q78S6Jplxdg6XqMFuplkZleBxGBljtG4MQAeMjPtQBX1Hw1qutyKdWOkW8iqU+12kTmbbnou44Xj13YrSXUfDvhK3t9LuNUtLLZHuSO6uh5jDIG47jk5JHPqap6HPr/AIi0u2vLia00yxuoxKn2TMkzxsMqdzDCEg9MMR61wviHxV4Ws9ei0nTrjRTNp84nuJdRny9xOudqB8Elg2CWPAIAHfAB7RXhXib4PLNpPizU726hTULi6vryDaztB5cjFo2lUIWLorSY2g43nGa9qgvRPpMd9DE8iyQCZI1xubK5AHv2pNGv01XSbO/jRo0uYVlCMQWTcM7TjjI6GgDyq4s9R8Uav4LvfDVxod3aaFb+aRcTzRPPvj8tiF8o/KNvB9cggU/xnpX9i6lLJZB40gzcRKrEjypSVkXnjhmOAOgkrU8Q2tz4Q1BrzTGAsbiY3KxKmBGRgzRDHRWQM/H8ae/PQeM1gmsbPUMCaAkW2AQAUnZE3jPUjggd6AMLwHqYj8RzwefFNBfKUDxyFszQqoBb0Z4WjYj1U16PXg1vd3umgRR2+65srozPsZVRJogWOAeSWi85OP7g4wM17pa3Ed1aw3Fu4eGVBIjA8MpGQaAJaKKKACiiigAooooAK8T8VX8ep6zfajb3QWRbg28ao7CQwxBkG0r2MjysQeoj6HFeqeMNSk0jwxqN7bruuY4iIF4+aVvlQc8csRXjFvcxR3EULp/oOmBvNdDljHCSinH95nDkjr8/HagD0DwtbDw7s82LfK0KRMBxs5LED/gTHP0HpXaW+pWk6BlmVc9mODXmMniOwil2zXP7wYJ3QyHORnPT3pB4o044InkOcZP2eX/4mgDvPGMFsNHn1C4ikd7KJ5Q0Qy4XGWwO/A/SsLw3Yx3niKx1JZ8i2gl8vaQVkEmzn8lGK5qbxNb20d0bDU7i0a4KmSY2ssqqRgDKspGCOCBj8+a2fhpoOs+HdSWz1DVbe905rRntRFAYjgyAgEHOAoOAM9D7UAejMoZSGAKngg968f8AibPpzapO+kTQNcWlltulgZCI8zKqhgOjfNJXsNeP/HCKKym0yW3t0jFyJEuDGiqZAZrf7zd/XnvQB2/w2dR4WitvlE1rLLDKoOcMHJ/UEH8a6muR+Henwf2c+sSRL/al9JJ583OWVXKqv0CqoH0rotYvRp2lXd4ylvIiZwoGckDgUAXKKxbI3drq6Q3Usksd1B5vzHKxSrgMq+xDAgc/dNbVAAQCMEcV4rqumTeH9XEaTSCK2k+zeaOCLeTmN+f4kwy5/wCmSfSvaq5XxzphvbYGG1WWaaNrYNjlWyHQn/ZDLz9aAKXw/wBQzf6nZytApuJHvYo4pN6od5SZAcDOJFJ/4GK7evD/AApqr2V/pNz5UpghkAlm+VUCyEQyqBncTuMEpJH8RP19woAKKKKACiiigAooooA5/wAfztD4O1QRsyyTRfZ1ZRkgyEIDj23ZryXT7can/o9pcbo2n8hJVmynlySBQVIA48tosL2475Neh/FGb/RtJtVe3Ej3TXO2d2RSsMbyZyoJwCFzgGuY8Px2KwaiFuRb3SzLbWLbDOxkibeq7VGWwI0z/s4oA9ZtbeK1tooLdFjhiQIijoFAwB+QriLbTxqni+VnCPALkahOQMbtg8q3U+oykj/gDU8PirUtRu30i10e6ttSMW77VMu2BM8eYA2GYA9tvXAOK0PBsMIn1m5g27TdfZl2rtG2FQmP++g/TjJNADPE17GusWcdwcWVhE2pXJ25JK/LGo9yxY/8BFQTXt5c272Piq0t7W01NTFA8T5Me4cRyZ6P05HGeOOM1IGXU7y2uWyRqmpZX5sjybcMVH0LJu/4FXRzWsOq3t7DdrHPaJGIDEeRlhubPvjb7igCnp6jXdCudM1bcLy2P2edl+Vg68rKvpkYcH/Coby4kvvAGrLfFTcx2lxb3GOhdVZSfxxn8axNNvr2x1iK4ZXuBMjxRqpy17Ajnaw7edGM5B+8p45FWJdXsV0/xRDGJ0a4YmCFoWWSZpIwvyKRk5cEfhQBPpVy9v8AC3w+lvIUlubKztY3zgqZFRMj3GSfwryZfBuvfD/XNVs9M0fTNS0zVnf7NfTPGJbdNhyGLnKhU3EkAg8euK9A0XV7S68GeEYYI5p72yNs0lkkX775IhkhT2AYHPQ9ual1Z77W9WuZLmMQWenpG13alwcR7g/lM2cBmADtyQFCrzk0AaOm3eqatYS3+i3S29tZkR2unFBulVR0mJ5UsPugYwCCc9KveDb6Dz7qztmDWkw+32ZHH7uQneuOxWTd9NwqbXtV0/QNW028uriK2i1GZbJ2bAEjkExZPrkFR/vVjyr/AGbqN1JgI2l3yTIcYBtbnAdfoH3n/gAoA3vG8Tv4cuJov9ZaMl0OQARGwYg57YB4rmra2B1Se80XSr+9sLCcpHby32yLzFHLQxMMHBZhyQM5x0ok8d22v3vjHw1Fo+r213pFo4u5rlIRCu+NjHgrIWO9csOOg5weK3fh8WXQpbeRt0lvcyxsfXJ3D9GFAHn/AIivLFfEcupZtv7PmiF20V2hUxSwtl8gcq4Cy+vLY5Fd58NbtZ/C8dukscospXtQ0bbgUU5Qg9/kKVw3xDigsPFkdxaTs6jbPMqMH8py2xyQc9V7HuM9zXSfDgz2Wq6jp93D5DSRRzKmV5MZMDMAAPvCNG6D73SgDv6KKKACiiigAooooA4f4qXqW+n6dDJMsKvcmZmaTYP3aMyjOD1fyxXFeEbA3ninTIbmR5VR/MDTkyPIsPAy3fJEbHPRgK2vifdlvEsCt5LQWNoJJBLvXl2L/Kyjgn7PjnjBOetZ/wAOrbb4ttZHuJx5NviFVgZkkEm5XDnGEP7mPnPJB65oA9jooooAy9d2uLCFmdRLdxj5e+3L4PsdmKdqa7dS0ucKOJWiZieish/qq1HqsgGsaLEwBDzSEZPcRsR/WneIgPsttIW2rFdQyE+wcf40AaZIAJJAA5JNeJfFI6GuoINKlgu7m5XddCO6MrLtnikHBYhR8r9MV7ayhkKuAVIwQehFeRfEWG1TXZhppt4xHbQxXAiwPL3GUKCB0yGP5UAdT8Krme70KSVr6zuLNpWaCCHmS1DMzeXK2cMwyOwx71ueKx5mnwW+Mi4u4IyfQeYG/wDZaofDaKO38I2dsuPNtzJBNn729XYHd6n61oa8c3uioWAR73BBHUiN2H6rQBPqcafbdNuJAMRSkBixBBZSowAOevfFaNY/ixvL0YyZICXEDkjsBMmf0rYoAKwPFGp6tp0LPpukSXsabGeSORdwXcN+EPJO3OMdTW/RQB4fqn2UanfRxrZNbXEnm2ty7tGEWdNoKt/vNDnPHy1674Zvm1Lw/p13KR5s0CNJjPD4+Yc88HIrynXCll41li054pLd2xF5YVlUuN3l9Cv+sxgHpn6V33w7umm0y7t5YzDLBcs/ks+541lAlVW9MeYR+FAHV0UUUAFFFFABRRRQB5x8SY3u/EenRG4EFvbWkkzspxJlpYxgHIxkKy59+/SqPw2WSG70Zp4U/e2lzIJFHJw0KAH3wpGab8RGD+Lrgr5z7bBLYmNyghdvOZSxBGdx2jB4rV8BRLqOrrcvDJDFplqiwRqSI1knLSS9/m48sc9KAOk8TosV3ot+ABJBepGW77JAUI+mWU/8BqL4eog8JWMqcm43Tsx6szMSSal8ayiLSIN2fnvrWMY9WnQD+dL4FQR+D9IRcfLbqpwMDI6/rQBz/g+YS3PhiAceRpc5YdBvDxoRj1BVh+NdRpSlE1Rz997mRj83oAB3OOAP8K5qFRpviSJw2IYNQmt3B6KtyqyLg5/56AD/AIFXU2zC31i6gY4NwBOgJPOAFbHbjC8e9AGDrCQnwPZLHGY7l1h+xiNtzJO2NpDcE4JJJ7jOe9VNdtJPE9tf3jTPBZ6duNjLb4WV54wd0gfn5Q3ygDrgk9qif7ROnm2MgaGN5LTSsOTvkckNOSTyEXdj6Me4rqb23g0vwrcwR/Jb29o6gnrgIeT796AOL8F6XNpXhu117Tp7i5mdP9Kt3cOJYUJUBOMhlUDHrgg9c1teE7mL+zNUsrh0aVGkujMrYFxDKS6Sg9enyn0Kn2qf4Zup8H2kI3B7d5InDDBDBz/QiuU8Rw6jpWvw6fp+m3M8TebLbSwlSr27fNNbup64PK/7wHrQAvxs0vWNZ8F+G30bTzfX1pq9levbiZEJCZyAzkDqQPxqW9vb/UF1WXUNLfR7y7s7a2e0mnjlKO1w6IdyEqcgk8HNdilzZ63c6ctozSQQhbzKjCjgqisOxzk47Fax51F5qj3pAZJtUgt4j6pCGJP/AH2ZKAMS38J6r4f8QeP/ABTqeo6fd2WtWgea0htnidBBEyRgOXb+AndwcnkYHFdD8N78anbaxdxo8cMt6kkUci7XRGtYGAYdj83Na3jQZ8Ha8B1+wT/+i2ryTw38V9G0Gw8aXd8lwxs9TihW2QL5kp8lIiVycEZgkbrwB68UAdV8WdJsre3j1G2jjtb26ZreaaNADKuwv82PvEeXwT6n1qj4JvbaXxJpdzBbW8EjB7O4YE72leBJTnjrmI9z1rD+Iep3+m+KtK8SXkF/deG7iIQ4ITy4DcRFFCrv3MwPJIXocA+upos1rHYaEzsTfW2oxbsydVLuhOM8nM2CcfjQB7BRRRQAUUUUAFFFFAHjnjWQS674humuJXhjdLUW6HAfEUYbODyR57EAgjjntXVfDWKSC71aCRw3kx2aLgY48hWz7kszVxOptJc6vqZWydPO1GYRzEttlKllKkdP+WYweT81ej+CLSI/2hqm1hPdXDwjJO1YonaONVHTAA6980AdRRRRQBl6kgbWNHY9UkkP/kMj+tQ+M8jw1ekDJAQ/k61JqrBda0UH+KWVR/36Y/0qLxqSvhbUGUElUBAAyfvDtQBtEhRkkAeprxz4oWcMfi12tTFBt09GljRVQSNJcYDOccn5Wxn/AGq9guIY7q3khnTfFIpR1PcEcivE/idoem6Fr0EscU0kV/HEZhNcNLt8iVWQAM2QPmagD0H4d2Fq+nPrnlA6jqMkrzz7iS37wgD0wAoA+la2vn/iYaCDj/j+Pf8A6Yy1m/Da3v7fw1bLdNbmzdTLaqgPmLGzFgJD0JAIHAFb9/ZLdz2MrOVNrN5ygD7x2MuD/wB9UAUfGm4eFNUZM7lgZhjrkc/0raFY/jAkeFtWwMk2zgfXBrXT7o+lAHERfFTwjLodjq0epk2d7d/YYcQvvMv90rjI4I5PHI9RV638d6Lc+Jp9BtzfS38E32eUx2crRRvjOGkC7Rx6mvL7X4FTW3hnSlS6tjrtu8JmBlb7MNsoZ3T5M72RY1zgfcxXUS+ANWm+JFtrsQ0fTbSG9e6luLKWf7TdoRgRyofkweMnJ9gOlAFP4i6XbaVr0EmjWi273IWZ0t0Cq8sTcMw6Zw4yfat/wDc2p8R6gtnDbQwXVuHjWJt24QyyR56ehTjt71R8daMIL68YT3Mx1CxmeRpZWcxmKSN8ICcICCRgY6DNO8Hz2h13w/Kuftk1lNBIS2QDthkwBk4GATjjvQB6XRRRQAUUUUAFFFFAHiXj29K+MtaWCK6d9sUXmof3KOPIIVxjOeTjnjmvQfArM9xq7OoVt1tkAYAP2aIkD8Sa848Q26v4y8TT4gb7NcpLIZd25V224wuOMHuDz0x3rZ0kWQ1S91W8a/8AtCfZLK1trSd0EhFurEsFIB+8cs/QKPYUAdn8R47tvC7y6cEe6trq2ukjbH73y50coMkckKQORzik+GMcsXgLRhPBPBIYi5inUq67mJAYHocHpWItzc3WyTUXO5olj8hJC8MZGeRnknnlj1x26VNZahc2swaKVmQDCoxO3HTpQBpCwN/r3ifT7vIt7mK2ljZThlO1lyPcNGCKrude1FotIvLCWCWPAm1eN1ETp0JRQdwZhxgjCk55wM6WmCa81S31J45EbyXhZlxtdcgjIPOQQcY9TV3xTcS2nhzUZ7clZUgYqwGdvHX8OtAFTR4orvUWuYEVbCxU2dooHGRxIw9uAo/3T60zxqz3Flb6Rbk+fqUohIDYKwg5lb6bQR9WHrRBrGmafZw6fo3/ABMJYYwsdvaESHgcbm+6ufViKqRXMOl6lJe65OJ9ZuVCRWlrGZWgizkIoAycnlnOASB0AFAHO/EW+vPDej+J/sl/Lp0ssD6nYTw7ctIiASRHcpHUBsDkgnBGK4/WtU1fU7nwnpEviaaxDaIdZj1GRoo5Lu7JIMAk2hVCqzcAdMZzjNemeK5NE1/SmsfE+nXNvZM4ZJry3Hlo4+62TkDv97jqD1quuj21rplvpet+FdL1LSLclrd7OzjeNc5JYwEfKSck7Mgk0AJ4WsL2fQra68P6xDLZ6lGk091JCvm7/wCN0CgLubnOeAckdcV0erTK2r6TYx8yl2uWG4DCIMEkderrVDwBNay2OoLp8TW1ql7IIrZ12NCuBwU/gBbcQOOCK6UxRmZZTGhlUFQ5HIB6jPpwPyoAqa5ZvqOiahZRuI3ubeSFXYZCllIBI/GvItG+DEd3oOvrrggttbvru7ktrqPMot45goIxlQ33WwTg4Y9MkV7XRQB5F8SvBmtNDpWp2viNRa6ILf7NYPYeYhmDKnnH94MtzwCDjnHXNZeiXEcfh1d4ha6iui8YZBvwLi33EHr3GR06V6X8QpJF8NyRxW8s7zyxxgqMrF8wYyOcjCjb19cV5xp6SwaYkO9Gs55gYj5uGkY3MAyEwRjjrkHtg0Ae20UUUAFFFFABRRRQB4RoLXep64N8FzC1zqAuI3abKPiQ5AUfd+Vzn1yK9Q+GsjTeC9PkkxvYyk4BHPmv61554fgW1udHvPkWIThN2xgd2UyC2cN1OMYxzXa/DPSYU0kaw4kF/fSzyy4mYxjdKxwqA7QBgds0AdrRRRQBk6wrDVNFkyBGlw4bPqYnA/U03xZtbRZIXbaJ5Yoc/wC9Io/rT/ESgW9pMQ7eRdwvhepywX8vmz+FP1tPNFjEYzIrXcZOP4dp3g/mo/OgDSFeT/EyeVPFHlMolDwRJDlQQhbzQMjud6owP+yK9YryX4nKtv4pt0Lu0d5JZTMhbG1km2gr9VY8evNAHd+AQg8F6N5bBh9lQkg55xz+uaseIWeNtLkR2VVvow4U43BgyYPtlhWX8ObKe28PxTPcA211unhtUUBLZXYsFU9SMEde+a0/FhKaK86qWa3kinA/3XU/0oAb4xZl8O3IXHztFGcjPDSKp/QmtoDAAHasvXXDJYwK8ebi6jUBj98DLkD32qT+FalABRRRQBxXxNVorOyuIGxO5ltAD0KyxNn8toP4Vk+E7m2kuvDrR7HlO1GYIFb/AI95MEnuPvY6flitX4orLc6VBbQwTfLJ55nAGxQqNlc5zuOcDisfwY7re6HDKYhypjVHydgtm5IxxyfU9e1AHp1FFFABRRRQAUUUUAeUeLLm3tPEOv6d+7A1AJcSAn5mMcIfAHuIWH4VLp8bqHvpIljW7SIrHggp5aCMg+mNoqx8R1Nr4hguBcJbRzWytIRGWaZYpQrxn/ZKTnPP8PpmsXwnp9tq+u22m63501tBHNH9ldmWOSVHB3SDPzE7pDtORwKALek60mvXbReGIX1by5Nk86NtghPcNIeCccgKGP0613tp4btI5Ulume6kjk8yLecBDgdhwcEZBOcZrXtreC0hWG1hjhiUYVI1CqB04AqWgArC8UYujp+lF2Avp8SqvBaJAWcZ7A4C/wDAsd63ScDJOBXnOteKFufHEGn6JHNcX/2eW1hmaIrBDKXUyMWbAcqq5wM5244oA6O5nZLg6J4bihtpUUNPOsQ8u1UjjgcM5HRfTk8YzoaPpFno0Di3BaWTDT3ErbpJm/vO3c/oO2Km0fTo9LsUtonkkIyzyytueVz1Zj3Jrjvi1p802mw6iLhTbWYffZyrujmZlIRiOhKttIB460Ad4ypLGVYK6MMEEZBFc49jc+HXE2jRPPpeSZrBeWjzzuh/qnT0x0ON8KrW/js5btrxJdMuc7LYRhBbyoxRtmOitjJHY5rvqAOcjuLQeIbHUbJo5INUgMLSoeGZPmT8ceYPX8q6OuX1nwxJI8c+h3aWMqXcd35TRBoS4Y7ztGCCyswJB64NdRQAUV8/+LH8Xz/EH4gR+Hby4Nh5dtaTgzECyRrZJDPGM8NhZF4xy4PasjxLqlpL8G/DU11rNynic2Ky2/mXlyjuN7ZaPZ8rykgAbs4HpxQM9Z8SeMNJvlvNIimu4dUt9zyWkkTRM0a5yxyMFCBww4PHPNcxoEHmyaHbJa5hkmtTl94O0PNN/uHGwdOfXtWl45vJJIdJRIpheT6b5ZS6UB38xoztb/azHgj1YVZ8G2zz6/p+wD7LbJPc4KkFfu28P8RByschyMZBBoEelUUUUAFFFFABRRRQB4pPe3FvZHSZY1kj0m9EkbxtueTM068joMMI+OvNdRpvi7SPCOktp2qm8Fxb3MyCOC1lnZkaRnRhsU/KVYc1g+I7Hydc122W4niBnedLeIZSQyxLKJG9GDQSBeuS2Kn0xZZLJHkmEm9RtA6JtwhGe+CpOfegDsrDxrp98ltJBa6iIZt3zzWxi8vAGNyvhuc8YB6HpV1vElntzGkzt2GAM/rXJogJB4J6k9M+v41pWmhXN1tyPKi5+Zhg/lQBY1fxDFdaTdwxQEyPEdm6TYA2OMsAcc96reFPFlr4q1e2ihWRJ7O286bKMI2kbCny3IAdR83I45UirGq22n+GbP8AtCZZb273+VZxMRlpGACxgDA6jOTkgZOeKj8DWTi+u9Qv2SbVJkAmnUEck5KgdlGAB7AZ5zQB1d9FLPaSxW9w1tMy4SZVDFD64PBrxX4jpfW3iGCHXdWWbEttcQyRW4iVIFdvMVhk85VT16E17jXg3xnlu4vEcv8AabQtbm3DQLCCCsP7zcWJ6tnacDjB9qAPUvh1eyXfhmyjk0+4tFghREaRQqTLjh05JwevIB5rob22S8s57aXmOaNo2+hGD/OsPwVb61Z6RaWusyWUyxW0aJLAGVmIXkMp49OQefQV0VAHLaBc3eoX8NteWV3bHSV2SvNFiOeUjaGjb+IbcnI6bsdc11NFYsnirQYrTULqTWLFLfT5vs93I0yhYJM7djnsc8YoA2qCcDNYmqeK9B0qWzj1DVbSCW8UNAhfLSKejADnHv0rbPSgDzjx/wCJNN1HThaaZexXQXE00tqRKsQztUMRwCSTx14o8II3/CWQQm0MSW0dwd5MnzECCPO1umcHG35f1rnPE9zHL4+1K2s4vIjle3S4KbU8zykZi3bJ2yEc9dmOK7L4ewzPf3010i+ZbQw2u4Ky4dszSAAk45kUYz/DQB3FFFFABRRRQAUUUUAch8SYEGm2V9KzLFbXAjmKjOIpgYWOMEHG8Nzx8tcVeGTStVnu47kvLb2/2u2edQC80Ssrg7egfbMDjuwPYV6xrNhHqmkXthNxHcwvCx9NwIz+teMt9t/sd57xPOubWdjKHYkZVkjmRyxJ++qSDAACN0oA9k0mS7Gl276u9sLxlBk8nIjBPZc8kDpnvWfrOuPFbyppSRTXeP3ZlJEeffHJ79OvTI61wdnJBeWenwvNLdjTlVIHnUqyHZwcdzggZ55B5q+8jMM9GBwPp9KANJr6+uLOEXlyspK/vGSPYrNnqFycD8aq6S0s3jfSoY5H8qK3nuZYw2Fx8iIffln498+lRrIwDZyFIzz2re8J2kD3lxemMG5jTyEk5yEJ3EenUA0AdLctKlvK0EYllVSUQttDHsM9q4zxJqVtr/hW4iCmG4iuYY7i2nIV4mMijBB7HsRwe1dvXE/EzRrVtJk1uKJY9UsTHIkw43qrg7HH8S9cA9Dg0AHweb/iiYULAlLm4BGc4zKzAfkwrtq8a+DOjf2p4cuorjUL6GCEwwiG1uGhBxChLsBzubI5zzgV7HGoRFQZIUADJyaAHUUUUAFYWp+I00z7bJfadqEVnagE3IjVkfOPugMW6kDkD+tbtcv8QL62t9EkjnMchBSVoWP3grZUH2LAZ9gaAOL1Se+1HxMkd7Ikd3lmghfEgt5CBtQKCN+MK7AHqj46V1/w6sreLTZ7y0iiitrh/LtljGFEEXyJgehIZuv8VcPYWd9I1vGlzi91ImIr8rMWdcvIcjKGKMluDy0xHtXsFnbxWlpDbW6COGFBGiL0VQMAUAS0UUUAFFFFABRRRQBwPj2y/wCJ/YXDu8dvcRGNnjClhLC3nRgAjGWUSrnP8XFcqJby3jOkaXcWwuVvEghNxGWVYpDgOcY6YVsd94HGc16R4602XUfDs4tVDXdsyXcA9XjO7bntuAK5/wBqvKb7b9isLm03NatFHHHMkexApBeCUfMT8oG0990J9aAPX9C0OPS7VUlnkvLjgvPMqgk4xwoACjjoK1nZUUs7BVHUk4ArO8OarHrOj294mA7LtlQf8s5Bw6n6EEVyfijVpNW1U6fZsf7NtGxdOACtxLjiIH+6pwW98L60AL4hWHUdaS+LO3kRmCBT91ckFmA/vHAGfQe5rZ8Jja83rtHf3rmRI7r8rbW9D9a6HwaSZrn5gw2jn8TQB0tzMtvbyTOGKRqWYKpY4HoBya8I+M+oReJLe1udK23NpNZTQJI2NoZpIhlRwSRuwfTp1r3s1458YNFtNJurTUdLhW3mvpNtyqr8khWRJAxX+9leeme+aAPUfDMvn+G9Km/v2kT4Bz1QGtKuD+GWh27+FtH1C5kuprnaZlDXDiNCScBIwdoUA8DHArvKACvnjXvhBrepWXjC7TzI577Ury5i04SJtvPnY20hbdhcCWQ4OP4c9K+h6KAPCPEXgXxiviP7foAuYbu5srCCG8hvliSyaIgSrMmcyIQCcAMM9q9X1PxIdOvvstzpWoHzZVhtpY0Vo5mYcfMG+TnI+bHStyeaK3iMlxKkUYIBZ2CjJOByfUkCvOfiJq1y+rxW1m48q2XCKhy0l0/ygcdCiknt80iUAcmkEF7rGqG+niu0CzPcvKuUMeS0rbNwOwrlARnHmJXrXg2xey0KFp41jubotdTqFxh5DuwfoML+FcDoGkyy6tBojkvaMRcXMaj5EijY4zlQwMsvBXkbYRXrVABRRRQAUUUUAFFFFABXnPja1uNI1x7ywhE0eqrsMJOFe5VSPLPQfvY9yZPRlQ16NVLWdNg1fTZrK6B8uQDDLwyMDlWU9iCAQfUUAeP6Ykkd7b2llIm0km13MCLlckMhbPD5BG7s6sDw4rejdZ1Dp0cZG4YJ+orE8QLdWN3enWCWmtIzc3KpG7NKoCqtxCoYDyzyZV6qcEdAa0I9ZjnjDSKZJCqOkhIHmIcbWJPBB6iQfKf4tp4oAvoCDy35fyrrfB8brYzySRBN8pCMGzvUAYPtzuGPauOsL6O5hE/lSxsu4SRSIBJGVJBBGcevI4PrXZeB3Sbwrp11Hapai7j+1GNDkZkJfJPqc5PuTQBu1xfjew1hNH1i4t9YQ2bRmRrae1VvLQDLBGXBycH72etdpXPePhM3hS+8mRUQBTNlclotw3qPQlc4NAHJfCGSVJ72CxEU2mFUeSYyYdJAoQIFGQRhMk5GDxzXpUlxDHIsck0ayN0UsAT9BXnPwfmSa78QeQAkSXDIU2gYZZZl49sKK5v4oeCtT8XfFSWG1sLVrObw2Lf7ffW7tFbyfaScxsBjzgDkDI4J7UAe3UVW0y1NjptpaNNJO0EKRGWTlpCoA3H3OM1X1XV7fT0KsyyXRQtHbqwDv+fQerHgUAW7m6gtRGbiaOISOI03sBuY9APfivG7q6XXNdVrm5D2iyyfvHBUTsuWwM8bEQlucfKOeZKdq2pX/iK9lh86M7MtLcxx7o4Iz0iiBwXZsdTy57BM519E0GLVdVezKYgtF8m+ZHLIV371tgehY8NI3Xop4oA3vAOmGRE1m5eWXdALeyadcP5GcmVh2aVvnPttHauzoAwMDpRQAUUUUAFFFFABRRRQAV5F4tsptL1G+04Lv0+XN5Gm4gLCW3SMvGN0Mn7zaBllcjtXrtZHibRzq9lH9nm+zahbSCe0uAM+XIPUd1IyCO4NAHlNlquraRpmqrpjLHc+UoliPGzO0C4jyOSqHkHquxv7wretLNbS3it7QEQxggc5J5ySSepJJJPck1zM7Gyv7by7a7juRcND5SR7vsUpLMIpHJ5Vi7GJyNpUlWOCca+narM9/cm64hIJ2FCrxOo5QL155Ow/MOxdSDQBoxj7ytxhufrW54JuS2r6pZm3dfJihkEp+628uNo9xs/WsOG4gmRZ7aUPFIMoyEYPvXW+EZPMiuDjB3DPOeeaAN2VPMidAzIWBG5Tgj3HvXlPxR0290/S7ae91ue9skdljiniRXV9hIYyKBkDB6jv7V6zXmXxvhkbSYpGuCLfybhBCFH+t8ssHz7KrD8aAOg+GYvV8Mwpc+QLNSyWewN5hjDMAZM8ZPt2rqEuIZJWjjmjaRfvKrAkfUVz/wAPijeFYBbsfJWWdY93UKJXwDXlngn4f6re+OtU1m6todMhs/FN7epcvA6Xd1GcbUViADA2Sc5OfmxQB7xRUN3dQWcDT3c0cEK4DSSMFUZOBkn3IFY174s0q3Enl3KTiIjzGjO5UyCQM/xHj7q5PtQBL4qvbGDR72G+8qVGhPmQvhvkPy7ip6rk/wCHNeP6RbQ29qpvbq7EENuzW8y4M2wPhpM4IMjMwQdyWyM7Aa3ru4XxLqf2y4t1htnwFTaEe72dctnlUySxztUHgljkbHgvQ47+7XUXTdYRMkkcvQXs6jAlAAAESD5YxgZxu9DQB0fg3SZrG0nvdRXGq6g4nuec+XxhIgfRFwPrk966GiigAooooAKKKKACiiigAooooAyfEWiQ61aqpka3u4jut7qMDfC3qM9QehU8Eda4G+s2sLpYtfhS1Zy5SVJCtpcysBh0k5Nq+ckjo2cZNeqVHcQxXELxTxpLE42sjqGVh6EHrQB43ead/pNxa2jySXYgaLawEV1GjblVkwQDnBYbM56lM81reHNfl0jTINNg1CMi2jWJI9ThIZAoxjfGBwMfxIMVvar4MdLVodCnhjteSNPvFLwKcEZjYYeI8nlTgZ4FY01jfxOYdS0+8gs02n/VLqcRIOSQxPmrwAMYwOvWgDo9C8Rutm41yS3e785gPsBNwmw/MvCjcoAO3LAZI96zvFviFNT0ybTtMhuD542tLJGYywzysSsN0jHpwMDOSeK5JrmyM7xRyabJ5UayEC/8iQthslYbhWC9gMnv14rS0ae+sCZrTTrqJ3TcpENnI7qNvBkVxz8xwP8AZNAEtja6r4QvYZAluzzktcb22Jdb23sofhUlV2faG4cN1BFdPe+LZoPLWPw/qrytyd4jjjVe5Mhbb+Geaoy3Ot3j/ZzLts3LiSa5toQuAOAF3ndnpXLT2un2+qP9snsY48jJaZIWAKnaUiiXfkHAIyOp9KANbVfF13dsluXjtVbH7izYzzSnP3RIBgenyhz9Kxo7GWSXyJYZ4B8vmW8CF2UMSMyOflVR3LFivUIp5rX06xuWlzpdhczQszhVij+wQ+Wy7dskjfvJNpyQQO9b+n+DYDCI9VML2u4yf2fap5VruJyWYdZDnuxx7UAcpoOj3Gt3Mb6cZrK3WERzXUMxa3jbPzfZtw/eSdQZz+GTXp2l6fa6VYRWdhCsNvEMKq/qSe5PUnqTVlEWNFRFCqowABgAU6gArjrf4j+HZ9Uis0nufKlujZRXxtnFrJcDjyllxtLZyB2JHBNdjXkFl8M9bh0bTPCsl7pp8L6fqX25Lhd/2t0EjSCIrjaDuYjfu6dqAPQfDnizSfEDzR2Nwq3EU8sBt5WVZSY2KswXOSuR1q9FrmkyrctFqli62wzOVuEPlf73Py/jXlWmfC/WY9YikuxokdrBqV5qK3ELyG4n84MFif5F2phvmwxPGB61lW3wb18aPdWZ1DTbaFGt5LW1DGdWMb7irymJXCH+78/IBycUAe2pq2nSW8U8d/aNBMGMcizKVcL1IOcHHfFSJf2b7dl3btukMS4kU5f+6Oevt1ryjR/hVMt9oLatZ6RJp9rqF5eXdm0z3SSedAqLgPGoJ3ruIwoHUZNaEfw0uV+Il3qgvIIvDzGW8t7WLIkivZYlieTGNuMBmBznJ6UAegprOmSG5Eeo2TG2OJ8TqfKOcYbn5efWrkMscyloZEkUEqSrAjI4IrwNPgvrcfh7UNOSTSPtL2BsYrwXMo81fORxvj8vC/cJPL8+le66Zp1lpVmlppdnb2VqhJWG3iWNASckgAAcmgC1RRRQBzvifw2mquLyzkS21RI2hEjJvjmjPWKVf4kOfqOoIrhGsLWDZp99YTWmoRQ+TbWXmr8yBeUt5WG2ZXPJSQ5HoK9dqrqen2mqWclpqFtFc2z/AHo5FyPr7H3oA8i0ceVJcy2EUeppyknlhknVUJUBlILgAggEhl44IHFXrfXbkW16mm61bWDThUU3lmd1sw4JLoSp5/vAAdK3dX8FXBES2csGoWsTBkttRZw8YAIASdCHA+Y8Nu61k3NneKyR6zZagiiTLNLZxX0QXOQqvEBIoCjAJHGec0AdVZeMLSS13zW10rquW2BZQ3urISCPfj8K5nX3n8dXsFjaJJBZxsyS4ZWZFYEO8m0kLldyquSSXycAVz7y26+WGbR3klGfKXVHi2MNxzi4Qgj7o57k1r2niG6ihSNNQe3UM6uFvtOwMKCGUBRkE5Xt05oAm0u81bwnqgtrryHgnzvtZJViDyDaPOglf5SGAyYyQQxOM1uz+OTFHMZNMaFox1mvINrH22uzEfQfhWNLqEk0Myan4ljSLauyJrmzeQ5HJYbMAA4HGawdKj0u5mYxtaX/AAwSK3jmvGEgc8sECx4ZeeRwfWgCXUtYufEU7xXH/E1iYLI1lFlbOIryDIWwWHfDlF45BqmPMktmudREeyFWjDzHyrCE4UlC64MgYHhYlwSMEtXQ6b4b1O/jVJrBnjMYj87V9ixqASVZLSLC5+bHzEHAwa6/R/CVjYzwXV0Wv72BdsMs6gLAPSKMALGPoM+5oA5fRPCza1ete3S3lto8oH7m5crNcgYGwp0hg4z5a4LcbuOK9IjRYo1SNVVFGFVRgADsBTqKACiiigAooooAKKKKACiiigAooooAKKK4HxV4vnklmsPD29/KbZc3UCCWRfmCskCfxuNwyx+VO+elAHU634h0rQwg1O9ihkk/1cWd0j/7qDLH8BWDN4zupJhHZaJKm5WaNtRuEtN+MchDl8cjnbXG6ReRaDG8MFtb3etOziS6imZvMX5lBknPzMcEHC7VUjqOKRVvdTvRdyPLL9nLeY2m2pkVSR8wLoyknpkCR6AOtOu6pdvJDdaVp24AiRJFnYDDhCM+Vg8n8Rz0rxrS/iRLP8Wdc0C68PaM2j2kX7tE0uQvGy7PmOEL4+Y5JUDGPx7u8s9TnsHv49Ajn0q4iDrIYAbhVYcOFDswPOfut7ivAvCp3fHjWY7Dz7iWa3KQb9kbbisfLDBUgAEnGBgZyBQB9D2esaK92gu/DmjGdZliEaOIpVZlyB5UyJgkds/rXX6brvh61aMvbJo80wGPtFsIA3tvA2H8Grz2OV7TQ42up7iSIcPeq8zwEE4wR5Tp14ypIzimmfyL2OJLTbbrhpI7ZGhLAbchkZQrjCAZ2AYz060Ae2qwZQykFSMgjvS149oOpT6eJJdOv4okzF+7ihbySXZsmWAkmJR8o8yMlec4r0Hw/wCJoNSn+xXcRsdUC7/s7tkSL/fifo6+45HcCgDoKKKKACiiigAooooAKKKKACiiigAooooAKKhvbqGytJbm7lSG3hUvJI5wFUdSa8q8V6/qPiK2na0/0TR41ZlWZzEJSApH2lwd0SMGysY+Z+M4BxQB2+peMtJtLhra1abU71ThrbT4zO6/7xHyr/wIjoay5PF+qz+f9h0mzVYQ/mCa+EksZUA4MUSuc4IOAc4Ncg+tW8dp5GkW1rZ2MCiMSSYggZyCrAR52knOMNub/Zot7CeKzie6t9RkW8dAnl2hVHc4VQcuiqOnLIP5UAaeteKvENtpl/d3qaGkNssqkGyuZGLJgfKCBkZYc9+fQ15f8HPG+r+KtBkuNb0rS9UujeNEs0miF1CYQlWkiGF+9xlenU11Hi/TL7S9Cc6zpSWETPg3dnDHIxBU4DElhjJAx8hPZj0PjvwFt3m8MX7xZgMN0Xku2nASNcIAuwg5ZicDgk9hxmgD6I0rxbpETQy2Og6I5dPM3WkqQSBAdpOJUTkHjG7NdhY+MtGkMUd08mmSynakd7GYQzegf7jH2DGvN79rp9PggktdWttxUKj29zOs0ifNjZIGB6Z+7ishmME+LiyeKAR5mgt4tiKMMFaW3dQjjMh52oM4yeKAPoQEEAggg8gilrxbQNRv9Pm3aBdL5TyFVt2ybJVCqR5ikl7ZmO7G3KdOtemeHPEttrLy2zxSWWpwgNNZTkCRQejDBwyHsw4oA3aKKKACiiigAooooAKKKKACiiigDw3Vr3Sm+JHiOL4gapqtjNFJD/YkUE88SGLaPmiEfDuW65zzx249yoqlrWow6TpV1f3IYxQIXKoMsx7Ko7knAA9TQBzPj3WnG/RdPldLl4DcXcsX34LfOML/ANNHPyL7kntXmuoaxBFplw0FqLeC0t2gHkD5ljI3fZkGTlztO9gfmKkn5R81l7u8up5Le1eCfxBqFw8UzDLNFKeJACR8ghULGpB6lz2rN8SJbQ3MdjpzlrWwUxBs4WWTje5UcZOAB6AACgDu/AvhdLr7HfX9vYXekS2cU9mqbsI57uG/1jbSuGIAAGAAK9JRERAiKqoBgKBgAV5p8GNYC2t14emPNoTPaZGMwM3Kj/cY4+jLXptADURIo1SNQqKAFVRgAegr4qv7RrP9qDxBany4Yp5pFkERwPKlQbhx0JViD9TX2hfQPc2c0MU8lu7qVWaPG5D2YZBGR7ivkE6Kun/tK+J7W6uLrU2isZJBJcMPMlkeFAuSBgYZx0HGKAPri/0+C6037EYVaD5AI9xUAKQRjHpj9KyPHsJudAMMSkXT3EKW8g4aKQuoEin1XJP4HtXM/EXX9Y8LeA7S3uNThHiC/uIrKK8t7YkJkgvL5fzE7UDE/hV74NeJp/FfgiCfUZjJqtnK9neNt2lpEPBIwMZUqeg5JoA5b4haXeeGLiz1K2v7i7nubkgERJC0ZCltxdAAemMEZOe+MVnvqj3V4qai0xuAI5BDHKEMeMs13bjnEgGSYwMMA3fK0vxLv7i88Y3amYtaWqJDDEGJAYDLttIxnJxn2rM0TT21CT7JC7x3xJn0+RT/AKudRuxnsrbfpuCn1oA9a8BeKU12BrW4lje+hjSUSxjC3MLfcmUHkZ6Mp5VuPSutrwzw/dyQi31K2uCuoRXM0i2TBjIZetzBnGBGygOo42uMDNe16deQajYW97ZyCS2uI1ljcd1IyDQBYooooAKKKKACiiigAooooAKKK5rx9rT6TowitJVi1C9YwwORnyhtLPKR6IgZvqAO9AHJ+Ndc/tS5uNsfnaNp0/kfMuYpboDJeQcboouMgfecgDJFcLqOpyTXtm13CI7e9uoseaCQzOVQ3M2DluRtABzjgYAJa1AI7kTW1ssb6HYRxzT+UOWjBxFGzEBtzE72zyGdv7orL1onUvtMs8as8y4WNDtGAMIox0xgAHtigD17wF4WWxt55tdsLaXWEuXH2kxgoyA5jMSnPlqFIAUYxg/Wu0eKORQrorKCGAIyAQcg/gazfCmqLrfhrS9TUAfarZJSq5wrFRkc88HIrVoAyPGFl/aPhPWbMRwytPZzRqkwyhYocbvbOK+S/wBkcK/iAQTgGE3nmBW6GRIZCp+oyxr6x8XaP/bmiXFmdQvrKN0YM1nIEZhg8EkE4+mK+Tv2Xbae4S+tdOnW31KTU4XguWQuIVjilLkrkZyrbcE/xH0oA+nPiT4q0vwdpVpq2q2lxeSJPtt4rcAybtjFmAJHAQMSewqDxOE8SReFbjR5pYjdTi4ivYMb44DCzHk8YYFRg5HPSk8U+A/+Eq1jSrvWdVuFt7C1liFvZgwlppAFeTfuPBTK7cdzz2rU+H3hybwn4XttFm1BtQjtCywTNHsYRliVUjJztzjPHAHAoA8h8eWs/gjxJZvpl/JO1yjuRsRDbqoGTJtADISem36g9n6frEMqS3UzXcN5bSG4dlOTpq7PmlgGCXhY43RZIAOQCOa2fixdR3XilLdUZTbQKrSMPlJYluPoMZ+tYmmRz6qwazfZrunRiexmCZaSJPvxY6EAMMfUjoaAPXvBniE65ZyxXaJFqdoQlzHGcocjKyIe6MOR6cg8iuS+Pd6LLSPCpnvZrKxl8Q2kV5JFcNB+4KyeYGdSCFwMnntntWH4dv4NKgsNXsLkvFaxOxt9rvKLPcDPFI3Q+WzB0PUqSMc17TDIksSSRMGjcBlYdwehoA87+D15dXR8RrFdXd74bivQukXV07SM8e35wrv8zoG4Vjnvya9GoooAKKKKACiiigAooooAK8/+Iuqg6rp2nRiOQwOLqRZH2p5mG8kMw6AFXkI/6Zj1Fd+7KiM7kKqjJJ7CvB9SvJdTupbtFP268maaMSKGCCUBI1zkEYhCgggg+dmgCez1RNNiuJYY5prq6tzbWhklYeVDyvmOTyXz26k7+RXM2dubW1hiwpljQJlQcHA4OD9BU+qSwzXpFm4e3jHkxyBSN6qMBue55P41UYORjJAz06DNAG1ol7FousWepylwtnudhHliylcOAo5bjnHqB6V7/BKk8McsLB43UMrDoQRkGvmvDSZYAjHf1/z/AFr1T4Qa491p9zo9z/rLAg27Z+/A3Tv/AAnK/TbQB2+qLftbj+y5baOcMCftCMysvccEEH35+lfJ9zNfRftMeKH1f7Ot4tiM/Zt22TCwlQoOTkgAAepr6U8Yw+I4ZINS8LzxTvApWbTbjiO4UnqrdVcdux6V82aRNd6t+1Lq1zcSWllfrbrMqyh0jDxpEwRt4B6LgnHXkZFAH1VbJYauLLUnsQZ4N5t5Lm32ywFhtbbuG5cjg46iob9NP0Gx1LUbe1traaXMs0kUSq00mMAsQPmPbmsbSPFl9q+sQ2djpCSW6km6vI7xZIYRj7oZR8znjgdO+Kxfi/qgWK001MsS3nSAdhzgH9aAPOp2eWd5ZHZpGYsSTkHPUn1NFuQHjKSkPnI56DsfrVaMiX5TnOOoOfyoCbSQCCM844zQBrW17JdrPcXaxCe5zaXYSVo1FwoDwTbxgjPykn/Zk616R8Nb3yftOjymVShNxDFMu14wT+9jI/2ZCcY/hda8qsLU3M81iT5i3cRjC4yPNHMZHoc5X6Oa6LStYu1ubfW7q+nY2CxtJbugASPiKb5upZl2S47FDQB7bRSIyuishBUjII7iloAKKKKACiiigAooooAK8h8a63bXuvakrmOZIIjaRQtKUOAwMjLt5JaTZGfZGr0jxXqh0Xw7fX8aeZNFHiFP78jfKi/ixArxEtbm5tE2CVbIOzSFVBlEWRjcPvK8vmHnB/eYoAXVby5GhRaZZRA3D3IutQuLiVgZHGcxrgcgZ5J43Z+tUoVBZ+oyM/d5FVLVGjtI1d/MkxlznOXJySMn1P61IpOdp4JOWweaAPWfg5KyeHrrT2B8u0un8n0CPh8DvwzMOgwMDnFd9Xknwo1BLbXZ7I+WguogV3H5mZMnA/Asce1et0AY3ixdZOkzf8I89it0EY4u0Zlb5TgDBGDnua+Vf2W9Qi0oT3k0FxO66i6GG1jMsgDQkbgg5Kg8E9sivpvxqviZbO5n8PXOmpFFbOxhuLV5ZJGAJwpV1AzwOhr5j/Y9uHTxPcKigGR5Ek3H+Ex7uB2OYxz7mgD7DRt6KwBAIzgjBpaBVbU7tLHT7m6lKhIY2c7mCjgep4FAHg3ie+l1bXb68mVQv2mSKIovDxI+1W69fl5/pVWBpLe4E1vK8cqndHNGcFe/4/41VuQ5LFjIZGfc29iTnqSx7kk9e9ML53LICUODgHAP40Ab+nvPNHvEO6fUQHIQmJFvY2w2MHhXz93oRIoPSvSvhvfrJps2miR3FiwEPmKVfyGzsVgehUhkI/2K8dhvHcJpryzKZcz2uwZ2zIM4H+0yBiPUqtdx4X1i6GrWusz3zzx3M629xGYwoiSYYVQep2TK3PYSigD1qiiigAooooAKKKKACiiigDl/iJO//CP/ANnQS+XcapKtkjZ+6rf6xvwQOa81vblLe9aSZbZ5IrcRbIY1i3uwGw5GThF2AHk/u8ZzkV0fxOvUufEFtpjZaOK0ZpNsZfb5pKksBjA8uOb5gcjPQ9K4ye9h+zLCsLNcu3nTEgkqrZ2qOxB+Y5HXvigDE8vLBWDcZyfSpBE0uMNweOcjJ9qnjSS4a1t4I282aRYULcgsxAHHfr+Ven+FvDGk6qdZumtNtnJdGK1KuclI1CGQezMGPocA0AeWQIxXbv5yCMd/YCp/D11q8XibS7nw5Zi6lW6+ztI8nlW5UoxkiaTkFyqjAHcLmu70jwbpV3fXV7qd5t0f7W1vaWrOEE23Cne/VwXDYUY/Gt680PTb3xOdMu4Ggghs45tNEDGJYCrsHaMLwGBKc46EdqAN238R2JYRX5fTrknHlXY8vn2b7rfga+fLYafc/ti6u179knszYBiZtrR8QR888V79YXEzXs+ia1Glw4iEsUzINlzHnByOgYHGR05BHoPn6z0PS0/bHu7L+z7Q2n2MTLB5Q2B/IVt23pnPNAHvf9s+cos/Ctolzt+Xz8bLWIf7w+99Fz9RXlviDS7+e7vb+K6i1ZGmKSXloo2+YuVKsoJ2lSMc/wD1q9cviuoXkuiwPJBFHCr3Dw4GFYkCMemQDyOQBx1BGTp1naaT42uhp6W9ppsOmRpdBXVVEm8+VuGc527uT2I5PYA8WWJoHI5Dg4II4HsK1Nf8Ka5plvDqc6xSaWY0Mioh81GbvnOMDALcDGeCcV6brekabF4i0rV4xGbaS6EE+wgosnIU8f7Y2n3NdrLGk0TxyqGjdSrKehB6igD5nKsHXYenOc5GM9Rj8K6e6PlavZ3TW0b2d8UvGjZTIQwDLMEAPDEGQD/eWrereF7xHvI9MtnlXT5mieFeZDGQGidQOvynb65XPfi5N4fvrDwT/aLxeRdRXIulhwdyqyqpBBzgkqpI49+9AHb/AA+uZX0I2Fy26402Q2jE/wASLgxt/wACjKGumry34cSDTdbht4fL+wXsTRRMs5lLbAJYSxJyreVIVIP9zjjFepUAFFFFABRRRQAUUUUAcD8Sr+c32m2Fm0e+DN+4fkFgQkKkZGQXbP8AwD2rzm5mjgsZ2SGIG9YIhUBcRoc5wOASdufoa2vHFz9u8RX8oM6CK4EcUhiJjxCmzAbPysJJpG4B4jORXMSXEbKkMG7Yi+Xjb1cZ3YI6jcTg0AVYlO4ZLbWHAbPB6f1p7xMzMTgAcMcU7mMlXGGyOVPWlkcmTKquScmgC3pWpf2LqFtqssbSRWsis4UkBUJAZjjOAFJY/SvooHIyK8v+FdrbXsWqRywLzEIvmGcK2cjHvxXoWiTNNpkJkYtIgMTksCdynackd8igCl4vg1q50eWHw7cWNvdOCrS3cbOFUg8qFI56deK+Tf2XhcWs2ozWMKXOppqVvHBGzbRINk3mgt/CAmTnB5A4r618V397puiXFxpumT6ncKpxbwOqsRg8/MefoOa+WP2WNSs9Kmvb7UpI7WzGp+SZ52CLGzwybQSemduPrQB9eQM7wo0sflyEAsm7dtPpnvXD/GLUo4PCjaaY7iWXU5Y7bbBGXKxF18xj6DZu59cYrulYMoZSCpGQRyCKxbNVu/EGsmRcrFHFajnsVLt9M7x+VAHgMynnLYHTGetQqhUBVO3A474Fa+uQGz1W7tVTMcEzIM8EjJrPAwwxliGPXv24/OgBWEsbpNC+2eNxLFJxkOCCP5fzrop7aOHUjYN9mXT7kG4jcqWdIpkC4QDuH8s+wiJrn0kjQlQuOOCc5yDXRG1gbwrp9/cyM8MV1LaXLJIVcQyDoDwRgM/A/vUAeueEtSfVfD9nc3A23W0xXC/3ZUJVx/30DWvXB/Diae0vL3TLvygzotzH5c/nBmU+VKQ3U/Misc93Oa7ygAooooAKKKKACiikdgiMzEBQMknsKAPE/F8UmreI9TuAD9mF75KkfOd8aIi7Tn5Cd9wMEEEisXXLKaw1m4S7j8maRIpM4IDExIWwfTduGKvaYsOqXFlEwt1e7uPMnmWNQJS7M5UOOT8k6nngEcdaoeKtZ1fxMJYr+8SOPzCUSCJFMQB6LJjd9eeaAJtFh33FzcqC0llFvg+YjZNIfKjJ685ckf7vtXsmprF4e8Jm201CjRwra2qp1MjfImPfJBJ+pri/CNvZHQvDMGlWssMlzfme7ZpC7OYN27c7ckZ24HYcV2mtKJ/EWg28mPKRproj1ZFCr/6MJ+oFAGLpmj2F0tyupoLjS9Ii+wQxyjKllUGWXH94n5QevBx1qG4F7Y2tpFMZHmhP2nS5mc75MAlrWQnksVyBnr9VrR0wqPCVmWUMdRuA7BjnPmyliOTz8px+HStLxDpkWsXFnZXUTtaAPKzKdu1gAFII5DAtkY9KAK2p3kN5ZaLrNjh0FxGVfuI5PkYHn/a5HYj2rxWL5f21Jv8Aa07/ANth/hXp40x9up2l1qs2nSWpS5ndQogmUEsk2D9zJX5wCASp9c18/wB1rmr/APDUlxqiWsj3kdrmGK2hZxPGIRyFI3FWXJyBnHSgD6Y0W8jtl8S6nd4RVvpAxBydsaKgH1ODge9YvhO2i8R3s9/OsbW8VwZJ1BDCa6x91vVYl2qAf4gT2q54b0TSNbtYNae+l1ZLmUXiDey26Sg/eWPsRgDnJBHrWh4Ckkj0ibTLmQyXOl3Mlm7t1dVOY2P1jZD9c55zQBn6hpyWOt3Gm8JpniHzGXH/ACwvFTdlfZgm7/eQ/wB6t/wvqEmo6RG90uy9hJguU/uyocN+B6j2IrM8ejI8PHjjWbb+bCrmjp5PibXo0I2P5E5UdmKFSfxCLQBwvxb1a4tdT/syGZ4ob2GEybG2kgNLn5hzzhPwFcbpOpPpSTxtJKmnXEbR3ULZKbMEbgueGBwcjrg5zXafFWOGbUrxnj3y2lnaTL7BriRDyOehNedRKcusmG4yRwBzQB0Gi3U9vNZX0z2oSxeJygt38wBZApYOODmKYDaeQEr3oV4RpGkW2qS3ljFE1yHC3MaiXyxF5kbRsemSBvXgY6CvY/C10194b0u5fG+S2jZ8Nuw20ZGe/OaANSiiigAooooAKbLIkMTySsFRFLMx6ADqadWB4/uPsvgvWZBKYnNs8aOBkhnG0fqwoA8Yty1zJbPfGBbedjLvi6kyEu3OfmIM/QgfdI5rKieTcDJtWQrvYKNqg9ePbNaurQolpqOwCPT0sZWTdEkZZixRc7c5bcyYPXHWsq5I8wgYJzgj057UASylXACt1P8ADyaUHeWPccNjvimCRTD8rHDcZPp6UKzeeQx2kZYZPX60AewfCeAJodzMSC7zlTg54CjH866PQdiHUoY1CiK8kz7lgJCfzc1h/CvH/CNyY2/8fDZA+i1u6dKTrGrQ4wqNG/TqWTn+VAEHiu71aw0u5u9IitJfs8EkrJPuLMVXICgfTua+SP2WTd3vim4WKO1YzXDO4uYjJGPkYnAyPm4wDzjJr638XRaxPo08OgtYpcSIyMbvdgKVPTb3z68V8sfsutNZf2i+n24n1GPVoo4rYuMOhilEg39sKM59QPWgD7BAAAAGAOABWT4fw0mqyAgh71wCP9kKp/VTWpCztEjSJ5blQWTOdp7jNZXhcYtLz/r+uf8A0a1AHkHj3K+L9TwOr54/3RXPMQAqgnhjuLY/zmup+J0fleK7obg25VcgDnoOPfpXJghVxnnGMn+v6UAPVuXyqjd1HXPYVrabfyJbXWnzsHsrmIkxtwBIuGVh3XoQfY+1ZIyUUEcN2Pf3FF15wtJlhYiZlOF4OGx7mgDt/BEy22taTeo9u0U7/Zn8mDYy+ZHzubowMsORjn5uc17DXhOjQpDotxfQMtzNpreY0jsY0Kh45Q/l88kxvjnjJ617qpDKCpyDyDQAtFFFABRRRQAVkeMLoWPhPWrogsIbKaTA74Qmteud+IRkHgvVlgOJJIvKHGfvEL0/GgDzTTCi3+nPewPbabp2ntJKWx+6TynwQATnmP26gYFciIwY1WNSE4xkc4PqPXmulu9Ph/svUxE0sTfZQoinHzrHK6SbXyc8FnBPuKwggURkkrn0z+tAHa/DQzjVtGikkDp/p0455AxCoH55/Ou58WQt/aGkSq7IJGmsmZRnb5sZ2n/vpF/OuI+GiGLWLCSMHY5nhJxjjYjf+y13/jVvL0F5w2xoZ4JA+fu4lXJ/LNAGd4fKv4I8OSrjFusG8AkgFfkbJz2JOc+la+pvFZ6va39wVSBYJYnlYgBB8r5JJ/2Dxis7ToxBfatoF2wVLhnurM8HdG/LgZ7q5J+jLUN5N/ajG01MKLHTFE2oSEfLI6jKqPbHzn2KjuaAKNpbS65qaC8VljupFv7mJh923Q4t4j/vEFyPYivK5G8r9tSMyfIJNPwpbjd/o3b15H6V714dtnW2lvbpCt3et50inqgxhE/4CuB9c+tfOvxV1G2h/a28FM74EEVvFIf7rM0mP/QhQB7nc7fDXimwMD+VpOryvBLCThIrojcjp6b8MCOhOD1zmARS6V8VzImTZa5p2Hyfu3Fu3BHPGY5D0H8Fa/jbw/B4n8L6hpUzGN54/wB1Mv3opVO6N191YA/hWHd3c2ueBNO16xR/7T08LeiFlO7zY1KzQsCM5I8xPrg9qANLxeoudV8L2ZbaX1Hz8jqBFFI/T0JABPbdVjwwJJL/AF+6mCgyXxjTH9yNFUfqGP41lWlw+s/EWyu7aWKXS7XRhOhwd2+4k+Vgc8grEe3HHrWCvjK40i5vreG3gkLXUsjuzk8lu2O1AEHxI1C3Gr+I0ikSSSPT9PgkVTnY7XMhCn0O07sdcYNeePHmViiA8jjpXReJNRk1O4u5HhijF3LDNcJGuN7RDCknqcA559B6ViOhQ4QjIA6DFAG5ZafOLzSEJV3vId8cWwHKxOXK8kfMfKUA57+1epfDzfHoM1rJH5ZtL25gC5HCiVivT2YV5zpU/mxaF5QMN0l5Nb75GwVX5WBGOQDuJ9a9B8AGXy9V+0NGZJLlJyI2LLl4IySCeTk5NAHWUUUUAFFFFABXMfEOV49FtY40R/Nv7ZWR/wCJRIHIHvhe9dPXA/GBFm0vSopIpp0a8JaCDG+QeVIMDPHUg80AcJrbSXOi+JJ5h+/dbe3CcFmlWRCOMnqsfJyRx3rm3Rd4JI4BOR/n8a6TU7eGHQF+V/OW/kjZsAlwNxQj0G2Q/hWKFAcbT97AHfP1+v50AQRRpgNhcZ5PIH40qxvHIDgEAY249aljUY2k5O4jgdfepWTLdGZlx78ZzQB7V8O7I2XhW13LtecmZhnPXp+gFXdMGPEGtfWE/wDjlU/hxK03gvTHdizbXGT7Ow/pV7Tgf7f1g84Pkj/x00AUfFet3+j2l1NHod1qFqkO8vbSoGH94FSQeBzkZr5f/ZUvLe31yS6uZY7e1N9IPMlfADNC21dx4ycH64r6p8b3kWn+Dtcu7jd5UNlM7beuAh6e9fMX7HMFtcz3sV1ElyA8jCKRAVjO2P5+epIJX2/GgD64BBAI6VieEuNPugOgvrr/ANHPW2AAAAMCsbwvgWt6AMYv7n/0a1AHlvxVjz4rmfbx5SclevFccMAAFFAbkYPAruvilOr+J3jAH7uJFYkZ68/1ritqxyKuAFOSP8c0ANaPJGTuHqOM4xSJ8/Ull42g9v8AOamK5IAxyck5749qUHa+8HAb/a7Y9KANrQLCW7u57VQJ2kR5nEqhixaJ0XacjaF83nr9K9l8LTyXXhnSZ5gBLJaRM4B4DFBn9a8y0IyxahaS2ksSzppqsBKzKrfvvmBI6ZCgfz4r0PwMskfheyhmO5ofMhzjHCSMo/QCgDeooooAKKKKACuU+J872/g+do+rXFuhx6NMgP8AOurrlPidDNN4RmFvjzFubZ+fQToT+maAPLNPj8jQdXaaUnybSMBmnErEL5GBuHDfe69KxZrgqdxXGD26Gup8UaVHa2Wt28DQfZoLODlEEYkdWgJO0euw/SuVljQsd2WCtzg8ZoAt6fql5aSQy2dy8bJudQGACtjk4Htwfau4/wCE7j1jQrvTdWg8iea3ZUuFJ2F8fLkD7vODXnCgAsMEDJJPHX3oC4RfLPGfTsc0AfQAhsvFmgWVxKJEEqLMjxSFJIWI5wwwQRyDVI2cMd9ZeHbFH+yQKLy7d2LFxuOxWY8szMMnPZT6145ZX1/abv7P1K9spO3kS5HX+4cqep6jvXoXg3UPEmsy3N3aPYlSqW9xdXMLLmRCx+RFb5sK4ySVGegHNAHd67qtvo2nvdXOWP3Iok5eZz91EHdia+VPilYQ6Z+0H4IfXo/Nl1FInvlT5vnllkTaPZQVA/3c19D3P+jasI7FW1zxIF/1twwWGyU9zjhAfRQWb6c14b8VdOuG/aU+HcOuXQ1B5VgdgsQiRMTOQFA5wCM8kmgD6F0nVhbXn9jas3k3iErbSSNxdR/wlWPVwMbh1zz0qvYH+xvGt1YkgWusK19B22zoFWVPxXY4Hs5rf1LTrTU7U22oW8VxATnZIucHsR6H3Fcf4z8CPrOgm1sNSuRcwTrdWq3krSRBlyNjEYfYwJBG7/AgHBaLrMvhC+8W21mXmlmv2gsTKc/ZbdVygHUModpMLx6nqawZ7l5bkyMFEhbJIz35zS3NobS7lgIVRDI0TeWpVcjI+Uc4Hp+VRiIcFSq9Oo4H0oAdNcl0YjCy4HbjpUcUrHPG5Omeozj9KYsY5yEHoexqeIrbpcqVLM6bQR0zkHP4YoA2NDnIutHJ4kF8rFgDyo2jI/Ij8K9N+H8kks+pSSEkulq5JQqSTAucg8jtXlehlzJEk6/bbUzzyNGxwuEiVhHknABIPXA+bmvVvhzai3tL87YkYSRQlIkCquyCMYABIx+NAHX0UUUAFFFFABXnfxetY7xdIhuApgLyl983lKPlA5bt1r0SuR8aiNtZ8PxzyLFDLLMruyggAJvI545CEUAef63dW0XgfT/MRftz3xiQqw+b93lmPrhQPTtXI/aHzyoByOvRhjOa2vFEYSG1R0YwwanPCrY6DyyM/wDkMisZkGS0bEde3WgBzSZA2jnGcnoKfHMXCEnhSQe3H1psKKUK4LKD908d+lNIUEBh83oKAPb/AIYymTwjbg7cRyOgC9huz/WtfSS7ajq5flBcKqHPYRpn9Sa4L4S34hvLjTZCMyAyp2weMj8gPyrvvD6x/YpZ4s7bmeSbrkHLHBHsQAfxoAw/ipfy2ngvVYIdMvL83VpPETAgZYgYz8z5I+Ue2TxXzr+yjfpo2kNqE6n7JJqclnKyqWcb4UZSFHJAKc46A5r6T8W+J9F0vT9Qg1TUIbRxbtkS5XIIIGD359K+fP2OE821kyEKw3lxINxGQTFCuQPoT+dAH1QjB0V1OVYZFZOhsVvtZhbjZd71H+y0aHP57q16xIB9m8XXY2ELeWqSBieC0bFSB+DL+dAHkvxOYp4w1CSMqyusanPqqjIPp1U1zbSM8ZJZc+xz/nrWt4zlW+8Q6hNDkK8rEbhgsOBnH4CsWELjnHHGB396AHJOPuoq5YcDpn/CnmUgg4UDsMZHPpTTCxc4bJ3Z64OaDGzRjPEZxg4x27/lQBs+Crxxfz/Y5tkiJKGYKZDncNoCryRz09zXsngsEaK4JyBd3QH08968p8O2UUk0MYsoXj+zqkiuFw7POoDkMQDjcDjOflGK9V8DCQ+GbZ5sb5XlmOBj78rt/WgDeooooAKKKKACsTxssh8Jas0Pl+ZHbPKvmfdyo3c/lW3UV1AlzbSwSqGjlQowIyCCMGgDxKC6s1ilbzFvY4ra5tpRGuxAV3vjB+9/rYlB781z0bLIilDHt2rIpznIrakMttY2/wBolkc2PlnHkFdvlMbd1yBjO6OMjJzhiemKw7u1FpP5MKMkQwItwwdn8Jz3yMUAOZUZ1YspHUDP5fWmBUC5LAdOd3eo1wwYg5BzgHuKjQlZIwwZB6ZoAvQhPMxu+bA53CvW/D0+zQLHS9IKpf3ERmklAyIVLEGRvViQQB3I9Aa8bWIiRiADz979a9p+FNtbL4L0+/t43SXUY1upi772LMOmfQDAFAHSaXp1tpdmLe0QhR8zO53PI3dmY8sx9TXy78WtTl1X9obwHcTLNokaqipNKyCVEEz/ALxlcEJ3OGB45r6ur5X+NcUdl+0t4LuNWML2UjQzY2F8RhyMMMHJypPHtQB6pL4fXxU/l6Hq+sG0XmbWZbmUmRgQVjhAKqVzliQMcAAnJAb5PjKS3vP7B1iKPXNNuPKvrW5Xz47uPAaJ1zt2sYzjIIDMvODnHRp4t1W+RJNC8I6lcWsmRHPdSxWqNzgNtYlwpAJyVzjHHNV7ddX0jWtJ1bX2s/P1AtYXotAwihBYtb/MeWIOU3EDJkHToQDg/EWi6pp9lJrPiNLS1SafkRuxUbzkZBzs98kgEHkjBrMEZCFsKWxwo7DPtX0Syq6lXUMpGCCMgiuI1z4d6ddNHJoxTS2DlnjijBik9tuRt55yuPcGgDyRwkeWbBA7A0igEMwxtxkjOG5rR1zQtQ0clNQtjDjpKmWiOTjAfAHPHB5rI3lWjDAsHkROCAeSAT+AyfoKAOl0S2tp7n7M8ggW4h+zMxZPnllYLu2vwTsYnGOQhr1H4fwwp4e+0WwTyry4muk2Hgq8hKkf8B215dpy3BaaW28uO9YsVTzvmDuTFBmPnKl5JSD/ALANe2aZZxadp1rZWyBILeJYkUdgowP5UAWaKKKACiiigArivivYjUNDsoHRGjkvEhdm/gWRHi3AdyC44712tYfje3kuPCmpeRGJLiKIzxKV3ZeP5149cqKAPJr270y40+/uJPMUT+RdwNIuwqWKj7vOGJmfI7VhsVBKgk465557dPx/Otu9h/ta8IaSeSK63QmZwcuGIliwSAB/rUHHAEeM5rnIlkW6aPafNXduB68df0z+VAFkYy2T8qE456fh3pJVyQzBQAOhGMCqzMwlUkggHjBxk+lSgrIhA4xkkZ/KgC/ZXrafcQTwfLIZ4olIHOJJFQ4/BuPoK+greFLeCOGFdscahVHoBXivwt0i38Ra1PdzI5t9HnjKns1xtztBz/CCMj1I9K9uoA5v4gXmk2/hPVY9bntUhe1k+SZlBY7TjaCeTnGPfFfMP7Jy2V4txZalfyWSpcSXFv5U5heSQLEpG4dRtP3f8K+ovGmiabquham19Z28k32KaJZ2gEkkalDnbxn3wK+bf2LbezvP+Eotr20huOIiplUMAOcjafX5fyFAH1kMEAg5Has/VtLi1JYt0s8EsRJSaBgrrkYIyQeCD/k1fRVRFRFCoowABgAUtAHkPivwhPo9sLqMtdwBjuKrgxjPf1Brigm6Uj5Vz2H+f84r6PuYI7m3kgnUPFIpVlPcGvEPGXh2bw/qJVCfsEp/cueTjHKk+tAGBM4LA85HcHJ98/rSoF3RheBkALnP41Aegzgc88Y5pJYDcFgJvLKANkDOQGHBHucD8fegDsomsYZrwpdebaW7ecnMXziFCxbnIZWfYcryCy16t4csjpugadZEYaC3jjbnPIUZ/WvJPCtj50en6VEsRguJYt4SXJVf9c6vHjC4jSBc9w2K9soAKKKKACiiigAooooA8v8AEaNp2v6rpkrulnqrpdRONqxxNIBExYkgcSCJu5Jfp3rh9TE87wyzqqSxW4s2j/iTY7HB+m/b/wAA+gr1v4jWIfS4tUWLzW01jLLGBlngIxKB/tBfmH+0grzrWrZHvhKk4lhu1CSyM3AlVQVdm5+8hSTPo0h7YoA5cks5xhgRgk8cetNKcqy/MF5xnnH+FTgbmfgpKjFGjZCrI4OCGHqD/jSMGJPRiDuI/wA/jQAtsg34GchgOvGeef6V7P8ACQ5+Gnhz/rzSvGRJ5Sb2BZEy5288dTj8BXtvwwtntPh74ficg/6HGwI/usNw/HBGaALHiPSr2R11PQZlh1eFdoSVj5NwgOfLcdvZhyD7ZFfMnxK167u/2kPBt1qVjcW9xaTwxmxTEsqqHzgbeGyWYgjqK+r9V1G20qze6vnaO3QgMwRnxk46KCa+U/i9rGjt+0z4K1a21K0e0BtDPMHG2LEzA7j24x16UAfRh8T6s05ig8J6rI5TzUzLCg29BuJfAJOflBJAGTjjOF4uj8QXPh6+1TVnisfJijNppVu4mzciVGjd5No3tvVVCAY5PXPHQXnj7wxayeWdWhuJOAEtFa4LEnAA8sHJ9qq6nfR+JtT0nTLFJ/JimW+vxNE0ZiRCTEjqwBDM4VgD2Qn0yAdNq2p2Wj6fLfardQ2lnFjzJpmCouSFGSfUkD8ai0PW9L160N1ouoWt/bq2xpLeUOFb0OOh9q5j416FqPiX4ZazpOi2/wBp1C48nyot6pu2zRseWIA4Unk9q0PBfhP/AIR261m9ub97/UtWnWe5m8oRL8q7VCoMgcd8kmgDf1Gyg1GwuLO6UtBOhRwCQcH0I6H37V4fDo9po1/qVppt1c30slyLO2muiGZQqqJiMAA/OQpPs/vXqXizxO+iTxWkdlNJcXUbG3mJUQhgCW3knICqNxOOnHXArzTTZLZp57q+WSa0S2k8sSQkmVAwEjf78jNtHP3pH/u0AdT4Mtv7RvdKUFJrOyj+2eZtZRlgUgXDAEHZvdh/ebI616TWJ4R0+ex0oy36qNRvJDc3QU5CuwHyD2UBVH0rboAKKKKACiiigAoIBBB5BoooA8Y1OGaCC60N5PK/s95EtBvAysYMibF6ljDI447xjvXLa6sk2oPfByVvG89m7M5AV9p7DIOPavVfHtk1pqlrq1uGVbnZZztHwVkDbreQnjgP8hyRkSYJxXnGs2QkvnjthI0W5p7UE8uh4ZP95SpGP+mffeKAMpUPByc+oXr+NS2dne6je2Wlaaj/AGm7lVDJ5YcQICN8pBIGFHTPcgVZ021mvJo7a3ieR3Pyqn8Q7dPzzXrPw68PSaRp73V9C0GoXSgSwuUYxBS2BuUkHOc9e9AG/wCHtHtNB0e203T0K28C4G45ZiTksx7kkkk+9aNFFAHH+P4PEItzdaFIbm2EZW508OsTyKATuikIOG7EHgj0NfOH7I2pppd3qJS0nu7m6keDybcAyABUYMQcALwwznqR619Ta9rtlpbiC+W6VJImbzkt3eNR0wzKCFP1r5R/ZMuLe18TahNd3EcNvHMwDyPsUFkbHOQOdvQ9aAPrzTLi4urbzbyyeyk3ECJ3VzjscqSOfSrdA5FFABUF7aQXttJBcxrJG6lSCOxGDj0qeigDxrxd4HutJM1xp5eewVd+c/NGMjg+v1/OsZbbZpsUWGRpAbmeRF8wrGAdq7By2eTtHJLJXsOv6rp2mi8N9cbnNrk2obllyQMehYttHT9K8x0/zUtJZGss6zdTQtp6NCTEHYN5WCf7mDISOiqvrQB2ngawL6pdXkjCRbOP7EkgLFZJSd87ruJIXcVQDPATHau3rP0DTY9H0WzsImLiCMKznq7fxMfcnJ/GtCgAooooAKKKKACiiigBHUOpVgCpGCD3rx3WtDj0S4ubKZJWRVDWvlkl5bUMSqoCQokhd+c/ej47mvY6zPEOjx6zYiFpZLa4iYS29zFjfBIOjDPB6kEHggkHrQB41LaR6lZJNCYGvYML5sMnmLdxj7uDnDEAHaeSyjHVSKwoJFkCyIdxI3qWOARj/CuwXS7pdUubF5GhuY4lB0uCFfLXnJltwSoeFuC0f3lY5BBHOPrGnJNDBfJuU3O6WK5Te0VyOmw5Ayc+oDjn7/NAGJLsMEwVFZmjZOuMkjHBr3/wXDJbeDtCgnXZLFYQI65zhhGoIrwueC4s4HklhIjXgzRfPED/ALw6dMYbBB7V7l4f1iwuNH0kxXUTNcQxrGm75ifL3Yx1BAByO2KANuvj/wDadn06b45eF44hAREsCXhVRjJmJIbHU7SMj0NfYFfJP7RVta3P7RPhGABysotluBbrucnzTkY7sV28dxigD6c1jUINE0uMafbRvc3DeVZW0QCiaUglRxwFwCS3YAmpPDekf2TZOJpftF9cSGe7uCMGWQ9fooGFUdlAFUPDVqmoXX9vySwyxyR+Vp6Q52Q2+cg4PR243emAvbndnvIILiKCaTZJKrMuQcYXG4k9BjI60AWKxfFuujw9pi3X2Z7uWSVIIreNsPK7HAVfU/0yegrl38T6mmp3c2n3FrqOjyL+5nn/AHEcMmT8gIUtLxg/KMjufTnb+/1DV4J5lknn4YvMi7skAjy4IwepB6KSTnDsPu0AV9Xv7nxLrM5aRmZP3bx2zq4Reot0PRnZ1+8eCQP4U56TwTpMmozwvcKiadp8gbyUXar3CjCqOSCsQO3P8T5Pas/QNO/tBU0zRoXtDD/x83bcvablwwzjBuWU7Tj5UXj0FeoafZ2+nWMFnZxrFbQoI40XooFAFiiiigAooooAKKKKACiiigCnrOnQavpV1p92CYLmMxtjqMjqPcdRXjGqWbadLci4YQalDOGu5dwRfMK/JdFs8JKEVTgALIAe3PudYHinQjqYivLMxpqdsrCIuMpKjfeikHdGx+BwR0oA4bwnrMGlazcahqEYijvQI7lwu37O6naXI7Ixxux91+vysDXoUPiHTHnmhluo7aaIgMlwwjJBAIZc9Rz1HFeQWNj9nWWOV7tltmL3YuX8y4tWJ2pFIAN8nLfLMuQV4YEDFWrT/iR3zC90i1YzQbZLS7G+NmU8CJ+Qq4JyUBX1VKAPYdP1C01GFpbC4iuIlYoXjbcuR1GatVy9j4x0lYYlu0k0yMqNjTqBCfZZFJQ4z61r6frWn6leXNrYXUVxLbKjS+U24KHzt5HHODQBemdY4XdyFRVJYnsK+Pf2U7e0vfEesRX0EM9oLyNwJRuVpNsvl8HgkEEj3r7CldI42eQhUUZYnoB6n2r42/Zpv49P1vXr+bb9htbxLiZz90RfOhf32eYrH0BzQB9OfEvxbP4R0/SJbS1tribUdTh05ftM5hjjMgYh2YKcAFRnjpmrHw58VHxh4ffUHtFtZYrmW1dY5fNjdozgtG+BuU9jj1p/ibw5pPjjT9Ga9keaytbyHU4fKKlJioO1XDAhkIY5HGfWrmoahpGhaOQ0tvaWca7EjgwuM9Aijv7CgDZrm/FniZdFkt7W0iiutQmy5heby1ihAO6Z2wcKDgepzgZNcNH4o1vSVuIZtSjbTy48m6v0zfBNoHMIwqgno0hUkHOCeDRZJpfNe5humUFZJoYpAbiQluJJXfGxQDnc+3AzsUYzQBFjUNVvGuboNfg7iS/7kTumdx6YjjRSfvduM7nOO48BaW1w0es3btMqoY7J2TZvVuZLgp0VpCBx2UD1NZfhrSn8SRRGaGGPRVQJI8KFFuiCD5cIPIt+ASerkelelqoVQqgBQMAAcCgBaKKKACiiigAooooAKKKKACiiigDN1zRbHW7ZYdQh3lDuilRikkTf3kccqfcVxOu6VrenJIzu19CybDfwwCSbAUgfaLfgTqMn7uD32mvSKKAPIIIIZWkvdElljgiBL3lhMJIo1Gch1LCVMAZKcgZwFNJEVvbzKwaVfTqAyXFogiukOAxYH5HBww4Cnrz6V6RqnhvStTm8+4tFS6HS5gYxSj/gakH9aydY8J3N7aSW6ar9pgdSph1G3WdSCem4bXxx/eoA52/1bW4UFu99e2sY+UySRbAB2zJ5BA/DP1rwz4sRacvxY+HY/tCOa3edGneBnAjzcAlt7fOWOSSx9uABivoD/hC72GZWt4bNVVeBZ31zZqG3bs7AWUnJ/p0rzzx78KfFmu+OvCWt24hki0l4/P8AP1SSR3COGyCUGCQO3fmgDrJpra0uJ203VHu5pWPOn3EkEsrdMtEEZGb1YAZ64qlcWbwxRSXIVDcyKDc6tetMJHbhQEIxk46eXgEV2Mmja3Ppi2iWOn28SrtVH1CaQ9c5Zgm49T/F3q1Y+FrqJNjX8FnCCxEWm2ixbd3J+dtzcsSeMdaAOIu7M+TaXt/O5S5UqJ7tfL8tcEAJb/M8pyB8pwuCOK3dP8L3uqzNLM11p9qVKC4k2reNE2C0UYXiCMkA4GW69K7HS9A07TJmnt4C9033rmZzLK3/AANiT+A4rVoArabYWumWUVnp8EdvbRLtSOMYAH+e9WaKKACvEvH3xL8RaB431mysUtTpemfY2kMllJIoSXG9pJVb92Bng7Tmvba5TWfh54Y1rV7jU9T01p7u58sT5uZhHMExsDxhwjAYHBBoAx9X+J1vpvjS30NrD7RbzXkFiLuC4V9kkoUruUDCjLYwWB4yBjFZVr8aLB7XWbq70ua1i06IyGB50F0T5qxKrQnBUkuOckDuRxnr7rwB4ZudbGrS6aftwuY7zclxKiedHjZJ5YYJuGBzjnvmmW3w68K26XSDShMtzAbZxczyz4iJzsXex2LkA4XHIHpQByMvxKvtROiJZ2UumTP4gtdOulkAljlhkjkb5HIGfujOACCKk0j4m3L6Jon2bSrzWtR1GK9nTMkMBCwTMp3dFHHTGTwPeuvtfAfh62W2CWc7/ZrqO9iM15PKUljDBCCzk4Advl+7z0qTTfBPh/TTYGy0/wAs2Mc8Vv8AvpDsWZt0g5bnJOec47YoA4i5+NdgILKWw0W+vPNs4r2dEYB4lckBVHO9hgnsMd88V6xG4kRXX7rAEZGOK5N/hx4VaCziTTXiW0g+yxNBdzRP5WSdjMrguuSeGJ611qKERUUYVRgD0FAC0UUUAY2v+HrXWHiuPMms9RgBEF7bNtljB6jPRlPdSCDXAa9pOp6YES+WI2eSz3ENqXtJCA23zYVO6A7myXjznHJFesUUAePW9tJEPtmjz3FrDNKUE1vJ9shn5Y/MYwSowM5kDYzjrSxzXh/0iyks2ZWKtNp7LbynADFWA2k8HO0ocZ6ivQr7wlo13O1wLQ2t0x3G4s5Gt5CfUshGfxzWdf8AhCa4Kn+0YrvaGCDU7GK52huo3YVsEDByTQBzN4mo6jsi1OfUIoSBuiuLeeZWHqUjQK3bhmI9Qa8i/Zci0yfRPFUOoNdRzxX6yQXFvbuzxHYwPKqRgjgqeCOCK9q/4QS+g2tax6Osqv5m6J7q3ydxbB2yHjJORXm/wT+GXi/w5aeJItX0rSwLm7UxR3l1IY3CkncFjyCM7cFueKAOnu7RdNsXS0t3aFC0jyWhu9PUL3JViIwPYECs+DT/ALDMUsoLPTruWJjDbafE1zcuVUNtDgnZlSMZkAr0S98M6vqM0M15c6OkiMW/483n25BUhd74xhm4xjnpVyLwfHLEkeq6nqF6igL5SuLeIgHgbYguQOmCSMUAeeJpEdnqiW8MMj3cZEoW1cXF+XLAkHjyoFI4LE7uvJ6112g+BvMRX11EEBC5sFkMplK52m5mb5pyM8A/KPQ12mm6dZ6ZbLb6fbQ20A6JEoUf/Xq1QAiqFUKoAUcADtS0UUAFFFFABRRRQAUUUUAFFFFABRWP4z1KfR/B+u6naBDc2VhPcxBxld6RswyPTIFcv8HvEeueJtHkvteyBJFBJCP7MktFG5SW2s7ESr93DLgd+4oA9ApGYKpZiAoGST2plxPFbW8k9xIsUMal3dzgKoGSSa8q8U63c+I/MQMtrpCQ/aEtroMqXKBlBa42/MEYE7Ihy+OeDigDqbrxxDPM0Phyzk1YqWD3IcQ2qEAk5mbhuh4UN0NYmq69rkF9HHqesQ6dHKjlRZ2alAVxx5szAMTnghcHBrmG1y5tbaysdKu7xLKSRmt7iVPNuGXnIRFGFVQ235Rx0LA8VdstP8m9k1GWInEeWluZ2jmYgZAO05UeuXY0Aaq63cxSM0+q6g8C5/eoWIb5gAcC34BXLdevHTms6fxZfBCLbUHkuFCnyWuXXcMtuwfs/UAL17kjtVzSvDmuaz4ctdahvfstzf2ySyaa7SCLDAfKSXbPBx8ykHuBXMiM3WhT2kxttN8qcwXMD2iu0IUOzNExO4ArGw2ZJ3D5SAaAOhs/E2uCYqt9K4Eq5KvbXSeWVJYhR5cvBGMYz7dq27TxzeRTQw31hHcFyAWt2MMvRTxBKAT94fdZutcvqOi6lpPhLzp7TbpUG11t55YzMu5gAMNE+DkjgscVh3OqyefbSWZbZGwZ4LorJHuDAggYC8EZwAvTrQB7jpGuadq/mLY3KvNHxJA6lJY/95GAYfiK0q8OhMZuEiuYZ4bwmJYTNcsphUsdxgnPzKx3DCsShwBmu40vxZNp19/Z/iGWOWIOI1vkwrRMThUuYx/q2PZh8re1AHc0UA5ooAKKKKACiiigAooooAKKKKACiiigAqpqupWWk2T3epXMVtbJwXkOBnsB6n2FQeINYt9E017u4V5GyEigiGZJpD91EHck/wCJ4FeReIrqbU55NQ1m9kinRpLeOK1JY27bFI+yt90sCdrzMOuVUdKAOzuPGmo3zxx6Jpi2qSkiK41ctEZMAtmOBQZG4ViM7aw59f1G4luorrxBd29zCTGsCW0dskxKBgVGJJQO2ccEGsGa/wBQ1Se5s5GuoolVY/s1orFgFydskjEYbk/ePfGypWsJ9OgsYY4LNIri4htmVpZn8lpXVN21SiORu/ur+lAFm6uriFJ5v7T1+V1kZY1kvbiNGX5dpOIlwcb+B6Cqo8QSyzxxW2rSQszneW1C7Zwgf5WXKMpJXqCOvetPxV4M1HRtAeb7SutWFu6zyWtwjDYq9Sg3EZ5PK7WHXJ6HE1K2j1Q6daxv9ptp4UaGyS1iSZ5WdlEbyDglfLcs5GMKPlJNAGnYeMNZkiV4tQmRggZ499tfkvvChAiFJMNkHPYZzW/p/wAQ7uGdLbVrBLi4OMpZB458Hd8wt5QGI+RvuljxXOeMLHVdE0vTxrVpBe20s6WaCK5ZzCNpIc5i2gDbjsOlc7ZtcXE0VvG0BdWKJb3siukgZWBCMduxsZwF2+gagD3rRdd03Wo5G026SV4jtliOVkiPo6HDKfqK068CsGF/qsKIbm01AO4VmkK3MI2hUSCY/fGVJMcucgnBPWvRPDnjB0vF03XpoJHMnkRajCAsUkgxmKVc5im/2Twe3pQB3NFFFABRXkd3428SS/FvVfDliAumWU9nHui0qW6O2WNWbzJFYCIZJwxGMZ/umvXKACiiigAooooAKKKKAK2p2Nvqmm3en30fm2l3C8E0e4ruRgVYZGCMgnkc1leFPCWjeFIpo9Ct5reOUIrK91LMAEztCiRm2gZPTH6Ct6sTxfq0mk6M72uw387C3tEc8NM3C59hyx9lNAHLeNdS/ti+utMT/kGaeu+5Z1JinnADLE7DpGgw79M8L6iuZtS2sNm8nmWKQvKm9S3nSYAaQg8hAThVJ4+6OjE0rWzOpPDpkM0kGnopnubkyq3+jj53l4OT5zfvDnp8grq/MtpZBLahhbMiCCMrt2xbRtX1Hrz3NAFbS9KtbK8muUubuSWWJInEkm5QFJI2jHy9egwvtS+J1D6DqyIhaQ2ky7VXJYmMjGPWrKptyxDkHI9zT5pZbaM3MNpLdyxkFYIvvvgjhfU0Ad5pjeVpNn5x2EQoG3cYO0V4h4keKHX7hkkM1pLqT3JcJkERvljkcEAyMM+i17reWsF7azW13Ek1vMpSSNxlWU9QRXhOsW0en+O7/StMiW1ghhuY4FVQEiEy2wbavT+Nz6ZNAHpHxevrfTvAd9d3QkZI2j2xx8vIxcKFUdyc14vp99b6pYW17ZsywzpuUNgEEEgg9eQePwr0L4t+EB/wh+jW9rqF1Hp2l3SytE8jvJKcbY8SE5G084wfwxXleh6WNGjuIY7kzwvK0yKy5aIHGQWyc80AbCMI4HjjC7XOV4+6ccsB2Ofz962LO88iezSVoXkuo1t4LidVIniBy1rLnorZxnquVI+XgYYzIqJk5IySTyP88VqaTJZmK507WJY4NOu12tKw3eTJjCPx6E4PbDEGgD0j4da4QV0i6kYqwc2ZeQSMmwgS2zMOrRk4Hcrj0Nd9XhFoz2ltLBcq9prFjcqZrppQsMc68RT7ccmXPlMRwRgnqDXs3h7VI9Z0a1v4lKecmXjbrG44ZD7hgR+FAGjRRRQAUUUUAFFFFABRRRQAU13WNGd2CqoySTgAU6uG+KWqeVp0elKflulaS6w+0/Z1IBQHsZGZIh/vn0oA5nXdd/tKaXW2kZIBiGxQo4It3GGkRsDbLJg4PVEXOOea9jo92+oR3GoSlSUHMblGjxwqIB93GCSff1LE52liZ7u71q7gZltJRHZ27FWWW+fgAFeCkYAXt8samuuRX+zxpLKZpcAyOx5Zscn8Tz0oAbZ2NpY2aw2abLdGZ9uSxySSxJPJOSetOlsW1MWVvBKqOl9bTnfkDEcqOR9SFOPc04MQduMgDPBzmrGmL5t/aj7oLjJ/GgDqfFlxaQeHNS+33SWsD28iGVmC4ypHGe/PAryfwPEbXx1pa3A8vyCYCrEDZJJC77SPXO8V654h0jT9Z06SDVLK3u41VmVZow4U46jPevCfhyo8U6ium6i0xglnhmuGRzG0hitgyYZSGHzOCfpQB0vx/wDHd1oCQaPpn2Jne3N5epcHDeQJEQCPkZYksfohrkG8qRYpiytF8sqMG4II4PuMdq9V8c+HNEstJ1PUn0uK7u7yKK1nluXaU+WoKjG4nacE/dxknJrygpb2VpDbWUbR28S7Y42YsFHYZPPSgCrqFnFNMblXcts8vZ1DL1wobhT79M9fUbulX73KfZTDBdTXyb/3iBV1VEUqIZXIyjqejdQwwc5VjlkB1BXnjvwB14FT6HNY6gt1pN1drELna1tO7fJDdjAQEjpvBAPI+6O+KAPV/ht4hF7aRadNdm7xD59jdu25rq3B25J7ujDa34HvXcV4dYXskFsl4kRtdVs5t7rLLsjF0PlMSJjAE67s8hd68dOfaNLvYdS062vbVt8FxGsiH2IzQBVsNC06w1rVNWtLfy9Q1Pyvtcu9j5vlqVTgnAwDjgDPfNadFFABRRRQAUUUUAFFFFABXlfj3V3uvE8cFu0yw2G6AyQjcwleIvIV7bhHtQZ6GXPOK9M1G8i0/T7m8uGCw28bSuT6AZNeGXAu5pBb6is8E9wRNNMEZf8AWkSyEE4DKu6Nc448oigC9pUjSrd6eZJrZ9Sty00qAbipH+piJGAAh3EDnayY6Gt6CAwwRxKWYRqFDOdxOBjJPr71t6b4ei1nwdGs7+TPcOby2ljALWhP+r2n/ZXAPryOhrGi+2ojLqcH2a6V2WSMcqcHAZD/AHWGCO/ODQBKA5yTnp3p9jZjULm0hl3hFuI5dyuVOUYMOfTjHv8AjTWZiqgHoemOvpVrS2LXttuY5Mi8HvyKAOt1fTodUiWGS4uYJEIkV7acxOv5dR165FeJanp0un+LfsCT3V7erNNDDJcOGaVpGgeMu3oNm047DpXrPjDwuuvLDcWd9caXq9sD9nvbc/MoPVWXoyn0P1FcvJpKWoxrukazNqm4uuqWTfaCz5DBhtxtxtUAFMdueaANj4gNdP4Fdr+OGG53oZFicuind2JAJ/KvFmG5coCuOoHWu+8ZTeIpNE+06peSW2j74okhmtVS4uZXYBdwUnYozn1J6gCuNs7K5vr9LKxgmvJz8wjjwSF9SeigdMk0AVIWxIFLAPnjP8QqfQI7jxLN5fhuFr1xK8M1wQUgttoHzO5GCDngLluOlWfE/wAMden13wt5aRyXi/apwyozW0LIsTRxzOB0chlPqOnSpvDHhSbw34H+IOk6vZanIZplS2NrBMrXUxi+9EIwCyeYeg4xweM0AWtUt77SZpItSm86W3jFnPcQR8T2kq/JIqkkfKQ45PVErvfAss2k6zPpd1FFGl4DMnkNmLzlCh9uTkB1KSAH/arl9L06eb4YeGZJbK+tZdPtlsL+K5tXhdItg3vhgCQjBHBwR8pxWbp5msZJ5obdv7atHj+YBmMkkW4qh7BTCJI89yBQB7zRUFhdw31jb3ds2+CeNZY2HdWGQf1qegAooooAKKKKACiiigArw/xHr15eazeXEENysV7tS2mjACyRhnjjXcQepEkoA7lM9BXqHjy9ls/DdxHaMFvbwrZ23PSSQ7QfwBLfhXkEPnNqKQ28BX7O/wDo0ToUIc4ih3544URtkYzg8ZoA37PRru+8OadLFeXEGn20zG3W1CKN67lMshIO7cSQFxjGOuc1sqmwHPLd8jmuvuPD9pceF/7DdpBbeQsKyKcOu0Da4P8AeBAOfUVx64WS5hZpHa3laF2kXazMvfHv1BHBzxQA0qd4DZ6chup/zir2khv7Ut8nJEgyO/1qo7FsnqMY57CrWlBjqFqsZYYkXPHv/hQB2Oq2kd3ZyrIZeEbGyVk7f7JFeGfDy5u5vEn/ABIbKAakSk7pcMyQrCLaKJhkAnduxj6HNet+MPDcOt2dxIbzULa4W3dIzb3kkKA4OCwUgHmvMPh26DxrpLxxGEPHtkYH7+633KCfTAXjuVz70Aet+LLZ7zwvqEIz5hhJAUZ5HOB+Ir5/cZHIAYDn69K+krzmznH/AEzb+VfOCoMgtjKAfLuzzQB5zaeN9Tewsh5MX2t5gZGKnZ5JIAI56kkj/gJrWufEYPjC30mBIZrKSSS2lQDMjy7egUcjLEKPUg4rrdJ8H22pi30izsGeBHBSMuw24O4EtnOB9TXsfh74daNp19Y6peW63OsWbO8U+5gIy67ThQcHjuwPqMUDOAFtqNm8SatP9mvJVWx1By/mbXG1oZSe+QFJOP4Zcc13/wAPp57W4vtHvII7cqxuYIo3DqoLESKp9BICQDyA4Bqr8TtKkme1uoUTyZx9jumY4AycwsfUCQ7T7SNXH6BfpYNBqphY3kF0HuJF3MXG0R3G7suE8pwvqrUCPb6KAQQCDkGigAooooAKKKKACiiigDjPifeRJpNpYTsVt7ucNckZyLeIeZJ055Cheh+9XHadZvq2rQ2gbMcmbYsx3ssbKzTMSc5Y5kXJ/vg+1WfiRfrP4t8h/wDVWsKQ5LsPnfMxCleQxEMY54wx61o/D7TYtTllku1kddPmDRTI7x7p2GXPBGeNoI5HJ9aAO40TTY9D0mO0W6uJ4IQdsl1IGZV7AnA4A4rKmutN8S2NzPpchnntRjCoVY8bgMNjIYdD0OetO8d3ixaXBp/mtFJqU62u5eqx4LSt9BGr1L4Qtgtnc6mzJ/xMnFymI9nlw7AI0I9lAz7k0AcpY3UV3brNBjY3y7SCPLYHBVgeQQQQQe4pt1dwWT2v2i7msfMlWJbqEA+Sxzhn3AgKSADnjntUNjIGuNTu/K8iS8unnMQAB28KpIHGSFBP1qWa7gaSOB1bZcKyDeuQ3qhz3IzwfQ0Adkt/qlkAt/p5u0H/AC8WJByPUxk5H4Fqonx1pX2z7IINTN1u2CEWMm8n6Yzj36e9U/B2oPZ366VNIxtpkLWofJKMo+ZAT/DjkDthqe6KPjHE4I3HQnB4/wCm60AL4gs7vxJp7Lq7HRdDiZZ5cyD7RIEO7DEZWNfXqfpTfhrPYrZXNrZw3NvuleeFLmJkkaAthG3NywwOpJIyAa4/4j6lqfiT4l6H4Q0i9gs7aPzLi4kniMqSSxqrhdgK79oZTtyBk5OcCuotNYubK/8AN1eSO+v7aP8As9RZR7PtdwzbiEQk42oFLZOBluwoA7f7RD9q+z+Yvn7PM2Z525xn865f4h6E2q2dpeQxNczae5lW1zgSqeGweocDlWHII96r3WtTLfRXV/aCxvdOkVLqMSB1a1l48wNgZUMATxwVNdqDxxQBz/he7TVdBFvc3a3soiCyuAVLowyhYdmKkZx3zXm+t2LaTrln9kvpJ7iMxwyncY1NxCFKq/fDAx59dzV1ckQ0K81i40+8trOW3K7/ALYpEMiSEuq/Lzw7MARnOSMdKy9TFhrPhXVpf7Qt7vWI5RezrGrJ5JACDCNhgoUde5FAG38K9Tt7rSbmys5hLbWsu+2YZx5EmXQf8BO5P+AV21eU+C71LbxNYSo1z5V8JIGWaMAJ5ii4RVI4ZQ3mqCcY6dq9WoAKKKKACiiigAooooA8z+Jt7HPrVtZPcNHFaw7jsbBE025EJI6bUWY/lWP4N0WXxDdN5s72dplbyQWr7JdwZhCu7khRhzj2XtVLxNc/bdbv7rfG0M1xIUO5w+1R5A2nhSMJPxzyw9a7j4b6NH9mXWpvO+1SjyYsvtXyV4X5Qccnc3POWNAHbxrsjVMs20AZY5J+tcT40tRp2rW2pxRwpb3jCC8kwd3mYxCfTGSU7feXntXcVDeQLdW0sLkgOpXcACV9xnuOtAHnxhup2lFnAJiiCSUM2zCk449T1OOOn0zf8P30MfiKzspmczTwySRDHB2bdxP4OMVZ+HIuJNN1A6lCI7yO6e1lxkq/l/LuGexyT+PrWn4UtrZdMjdEMksUs8ZlkGX3CRg2CegyvTpgCgC34g0uPWdJuLCe4uoIphtdraXy3I7jd1APQ4rxLwXPca5qKW0F55F5JcWqi4hAJhEMJJYD7uWC7cYI5PFe1eJLfUbrSpo9HvY7K6wSsrwiXscDBIxzjmvD/AV7HYeJI7mytbjULhpIGNpbKDJt+yFZZMsQuBI3OSOuBQB7/CHjgUSuZXVfmfbgsfXArw+z0a81q81AWKxrJbBpykincRk4XjnJwePUV7op3KDgjIzg1z+hW6v4m8QagrMQ7Q2gXgKBGpY4x33StnPtQBJ4P0ez0vR7b7I7TvJErPcuBvlzzk44HXoK3ayfDMgbT5IQc/ZriWDgYACucAewGB+Fa1AGT4stxd+GtTtzby3BkgdRFDjexI425IGc4PWvIbucW+owXrh/s08ZuLmORjEgmVGS4jkHsDMcf3ile16jdLZWE9zJnbEhbhSx/JQSfwrx+S7jm0O5vorqS+u9K1ZpZHMWzzEm2vyh5Vc4UZ5+XHrQB6H8O74Xnhe3iNwlxJZk2rSqciQLjY+f9pCjfjXTV518Op0ttdubNJrqcXFtv8y4g8tmML+WCT0JKNHyOoAr0WgAooooAKKKKACiiorydba0nncErEjOQPQDNAHh2tN9u1TVNSMk22S9lRVaKSNWCkKp6bZAPs5B7gP716Los1v4TlvLLVZDbWrsk0N5O37px5aIVLngMCmcHGc8d6840CCYtoSX0MqQbEuIySWc7QshaQZxyzzLjAPHOa9E8PeGNH1fwpp8+p2UV5cXlss00843u7SLljk8jrx6cYxQBleIr6HxPc+ZYPFNYKFsLe7iO4SSTsqyBT0O2MMCR3bHrXW+KLlrXTrexsZEgu72VbW3O3O3PLED2QMfwrF0pGln0DTrhkl+wXFyHOACzRDahIHAJVwx962tVZE8R6XJMQI4ba5lyeikeWN35M35mgDkzGjMxheOSNSV3IeOCQcH6gj8KpSCS3miPkzTw3DgMQCfJbHDeycc+5Hqa6C2tIo/CmmXSKxkmiVm8sZXL5csfbJ6/SqbAqo+VsEjAzQBUP7m+0+4ZyvlXUJyOMlmC4J991bM7xj4v2oynmHRJB15/wBenasDVI7c2rxXMLzxrtVMHc7OTwq/7WcYOep9qzL3w/q//CV21vL9jOpXCvNBfyOTPGu5WAZgvVRFtGOPnP4gGlr1h4c1Gx1ZfEEEV5qUOo3M1tGsrRyxkKuCGjYMq7FUscgYHOeKl8B+G4ZtI/dCaylscJp4LEPEp/eGVsk8ysxJB524B6VdkTT9lhYTWAsvOvBb6kerswBeMPJ1ZZGA5PXOO5ra8Y3U2m6P4gu7OUxXUekzTRsATseNWIbnjOSPyoApa7JFf2Wk6syAI0hsL1FbI8uU+U6k552ybfyrZ8JTznTXs7xi91p8ptJHPVwoBV/xUqfxrxC48R3Go/s26jqUWstDrMEEV3O8PlZlkZEYhlKYwWLE4AOV69RXqPwuMklrNcz3k99LPa2kktzNt3PI0W5s7FC8BlHA6AZoAj8QQNP8S9Ijlj8y12QyEFcjeguSp9OCc/hWv4801rrSHvbWJWvrNWdDu27oyCJEJ7grnj1CntUnjOSOOxtbkYL2t7bu2DyoMgBz+BNaHiDTJNX017SK/ubEvkGW327iCCMfMCMc0AeE2WoQ2UEN75032i1lQg/aGCSGKQTFTHt6iN5+c84Iwa+h0YOispyrDII7ivEdBML3N9a322zDqiswg372BMD7QQSuTIRnjj8a9V8FXTXnhPSppCzS/Z1SQsuDvUbWyPqDQBtUUUUAFFFFABVbVLpbHTbu7f7sETynnHCgn+lWa5r4jlj4M1GJE8x7gJbKmcbvMdU/9moA8ZiE1hYpc3AupfLhMkkM6sMkKN3ynqrMJcMo7g17l4MsbrTPCmk2OoFDd29ukcpToWA5I4FeRXdu93cX7ywJloVhaKEnCtNKoGPmPylZicg9c9K9ws7aGztYra1jWOCJQqIvQAUATUUUUAY/hXY+ltNH0nuJpcehMjZqTQ94k1ONzwl220YxgFVb+ZNJ4Yi8jRIY8k4aQ8+7sabpTMdc1tCcoskRUemYxmgCn4602W90K+mt7+9tZ4LWVoxbztGpYKSC23k8j1ryvwXpkcvjzTBb/aLe2RZMvHM6SOcFwrEHlcAAg+gr1/xPoUfiDTzaTXt/aIc5NnN5ZYEYw3qPavLvD81zq2v28cU4tdQuLiOdbqOMHytkLlwFPHzBguD2PsKAPaaxvDABg1CUAgS305wfZtn/ALLWtCrrEiyP5jhQGfGNx7nHas3w2MWEwH/P3c/+jnoATRSq3+swoAAl0GwPVokY/qTWtWTpzY8Q6vHjHywPn1yrD/2WtagArifiZYBdMbVoFxLCohnCgZkiZhjPHJVtrD0wfWu2rC8b6ZJqvhq9t4bqW2kCGQGMBg+3nawPVTjBFAHmPg+6t7fW9FuS22d5gj7pWcMpUwFlU/dy6w5xkHIr2uvELV/+JLfrE5hmhlFxbJboG4AEqpuxlQPIPoCT617bE4kiR1+6wDD6GgB1FFFABRRRQAVjeM5JIfCOtSQHEy2UxT/e2HH61s1zPxJiE/grUoWICyhIzlscGRR17daAPNbHV1tr1b+S4juEsrCSRY4wyrN/rYihJJA+bYPQ5JwK9Z8I6dcaR4Z03T72aOe4toFiZ402KcDAwMntivKdKFtepcyNHBJn7JLugH7p/Mlty4Ge2ecY7mvbaAPNfCzyXXjYTPLuKXOqq4B7rNGigj2RV/n3rqfFlury6VOy7kFwbeUbtoMcyFDn8Sp/Csi3eCHx+0ZdI7g3Mx8skBmVoIcMB6EoR9RW541cReGrqY9IWilP0WRWP8qAMjS2kn+Hdl5nmLNZxiKVQCzboiUYYHJ+6TWRKWEe5HYFTyc5Ht/OtjVZH0PUL222MbPViZYnGP3cwUeYpBPRlG4Edw3tXMTx3H2yS5lRmitvktoUP+ukbo2PXkKPfcaANnwlbPqWvefM2YdOUbgjZVp2HQ+u1ef+Bj0q5rZ2/FDw8S2A1vMuN2Mnax6d+ldF4e00aVpMNsWLy8vK56s7HLH8z+WK4/W1FxrWpa8q+ZHo9xbRgoGJCpuM2PoJecf3aALvj37AsB1Ge6j+xRIYNRVZBxAxGJMdmjfawPUc+tM8DavbeJrfUFvLmz1H7PEtnMyMskNwh3HzMejg4IPGQR2ryubQLvUj8VE8M6Dd2V3qUcTadcNpz26zQAp58cchUD5/7oPzdecZrc8AabZPBe22keHL/RdTtI8ss9p9ke/tGY/umz95h93zMHkA55IoA373wT4Zi8G6jHHoGhf8TW5CwCHT4goDPshI2qM7VYsD23NXUeAdOtNMt9Xg06CC3tV1CVY4YECRxqoVQqqBgdO3fNTWSSazqkFxJaz2mm2BzbxTR+W0spXG7aeQqg4HqST2FT+DUUaJ5qhsT3E84J6sGlYg/ligDltbmni1nXY1/eNPqGmRxKrYwCVz/Jj9K7rVftosZf7LFubzH7vz87M++Oa8k+MdnqEfxE8FXfhuIvqpF1ctAH2i78hY2EbZOM7WkUHturC8L6oum+GfHp+JOpahPFb6hF56QXEit5jKHMMZVgQu44wCBgdhQBc06xlnu9IbUD9l1C5e4+2MWIWK4SaVuxHy7wpxnpjmvUvAeY9O1C2aUS/Z9RuVDD0Zy4H0w4rxb4c3i3em6RbG++1L/ac5ISfzfJjkWJli8w/eK7iCfXPUV678O0EDazbmSSVxNDIzysCzFreLk44zwenFAHY0UUUAFFFFABXHfFG5jttDsjLcG3Bv4G3gbj8hMnTv9zp3rsa87+M95Daado5lltonF4ZFNxGZI+InByo5PDdKAOZtbaTUYruwtpP9MvpYLWKfaSi7WaQydcnb5BGM+2a9pXO0ZOT3NeR+DlK+ItJi2KYG1C6liIU42+SWHJ9PNIr10UAFFFFAGX4Zbdo0OTkh5F/KRh/SoNKyPE2ujPH+jnH/AAAj+lO8JKU0UIwwy3FwCPT989GmRkeItakyNreQv4hDn+YoAg8WW+tPZXU+janDalLdmWKW28wGRfmB3bhgHoeteP8Agu4a18U6fqVr9t1G23YS1hTfKkZtgN+OAV3Hkk/xcZr2vxXcy2fhnVbm2XdNFayOg9wp5/DrXlnwztobXx3GLJtyG1mSSUtvDBH2gKe2dof/AIER6UAezqdyg4IyM4PasfwsT9iuwSTi+uRz/wBdmrZrJ8OIY4r9D1F7Of8Avpt38jQBFYZ/4S7V/wC79ltvzzL/APWrzr4ieLfFGh/FCO20KGbUdPj0ZZpNPjjDFpZJZY0kzjOA4iB5xtya9I04bvEerydwsEf5KW/9mrQFjaDUDfi1g+3GLyDceWPMMed2zd125JOOmaAPALTxH4zvPh9p11/wkMa38Go3iXsrXFvbPNFFxiPzF28H27816b4e1PUvEPw0sLvQ5pWvLq13rc6lErMTkg7lTaCeOMYGMH2roZ/Cvh65tFtbjQtKltlkaZYXs42QO33mCkY3HueprWiijhhSKJFSJFCqijAUDgADsKAPGdBtILnXLW2ic29q9jHNEXcj70ao+4ZALEu4Ge/Y16d4HkaXwdorPI0r/ZIgzt1YhQCT+Vea2MI/t2OxkMsM9lYtZ+ZFJsYMkx2sCeDkbSAfXHevRfAsSW/hyK3iOUhnuIlyc4AmcAflQB0FFFFABRRRQAVyHxVdl8IsFGd93aqfp5yV19cr8TLY3XhV17LdWrt/uidM/pmgDzvTcQaZfJGrwXEn2aOASwCHbKZLcRkp2AbBKjsDXrekrq8ZVdVks5vlbMlujR85GPlJPbPftXl97d2K3l/dwtMsGyzuII/m/wBVFJCC3PX7jD8DXsdAEJtYDci4MMZnA2iUqCwHpnrj2qLVrNdR0q7s5OFuImjJPbIxmrZOBmgHIBoA4rWb+VmsNO1FYhfrai4lCOGw/wBwkcdM5wfwqHwzANS19zKp8rTgsnXhpWB2/gFyfqfana60E2vTyW8LR3CqsEr7MNJtyR9VG7g+5qLw1pUmrPeajcaheW9j5hgSC3mMayqhwzu3U5O4cY4FAHQ65rTxTf2bo6C61eQcID8luD/y0lPZR6dW6D1E9hFYaNp0NhNdRZwd5mdQ0rMSWYg9SSSaw7WOXVIRaeGCNM0ME+ZfxAGS4OeRFnt1zIc+3rWzaeF9FtQ+3TbaR5DmSSZBK7n1ZmyTQBmQ3cnhVUt5oJrjQD/qLqEGU2ynnbIBk7B2YZwMA+tS6xfWks+ianp9zbTSfa1twyOG3xyfKyjHpw3/AAGpJdDuNLma68OS+Up5k0+Rv3Evrt/55t7jj1HeqEunaX4jsJr/AEu2Sw123ztlMYSe2mA+64HX3B4IPcUAdg670ZckZGMg8io7O3S0tYbeLPlxIEXPXA9ai0i9TUdMtbyPpNGr49DjkfgcirMsiRIXldUQdWY4AoAdUN1dW9pH5l1PFAmcbpHCjP1NPM0YkCGRA5G4LkZI9aq79O1aJ0DWl7GjbWXKyAN6Ec80AeV+Ir23k8dve2zC5tIbiN3lhIcbhGnyjbkscDPHr611nw2aOQ6nJEJApFqMyFiT/o0Z/iAbv3ANcXfLb6d4ovF0dIreC2kupfKt4dwRhFjcEXGfnHQY5rvPh3HH9l1WeGSWRZL1kBkzuHlxpGQcknOUPWgDraKKKACiiigArgfibA1zqGiRiJplxOWRY1ckfuxwG4J57131cL8SLy20vUtA1HU4y+mwPP5+BnHyBl47/Mg/KgDmdIeRz4Rt9OaKHU/tUzLJKu5Ej+zguCo6k7kA5FetWazLaxC5dXn2jeyjALd8e1eVeF1MPjCzbfsWLUbmEr0+VomVR+cFet0AFFFR3E0dvE0kzhEHUmgDO0LeralHKeVvHKr/AHVIDD+efxp2jFJLjU5o23K90V+hRVQj81NZHh/WUuda1V2ga1tZEWZGm+VmKDa7MO3ATA645OM4ra0FWGmRSPjfMTM2F253EkZHrgigDI+Icesy+G7xNDexQGCT7R9pDZKbTkIQeCeRk9M57V534WnnHiX7Volt50hvpBHaiTankNAjSb25wQWXHYn0rvfHWuahpWk6kw0K5vLMQEedbzpwCCGLKcEYHORn8K88+GtxBpHimd9XuobaH7TcW0EryjZKwSAfeJ6nYSB6CgD3BSSoLDBI5Gc4rI0Uqmra5Dn5/tCSkc8BokA/9BNbFYNzOmmeJ/NuHWK2vbbG88DzIyTyfUox/wC+KALOjuk1/q8qqysLkQtnvtjXkfnWrWF4Mvba+0VZ7abeZZHmkQtloy7FtrA8jGeh7Vu0AFZOo+I9G028W01DVLO1uGxtjmlCE/TNa1QXdrbXaeXdwQzIQRtlQMCD1GDQB4lcXEcnivUXRJHtJDO0RTcd/mSqpbdHk4yTyM9K9X8Fqo0VmXo13dN/5HevPLTT49O169iGbezt5BBClvGXAiecPsCqQQNu7nPAycEcV33w8jCeC9KKuXEsRn3HOSXYuev+9QB0VFFFABRRRQAVieNrZrvwlq0UZkEot3eMx/e3qNy4/ECtukZQylWGQRgigDxGPzraLbDa+QJIbi2gjlbzDKjB3jOSeN3ngnsNoHau/wDD/g/Ro7XTtQsvt6TbI5VkN9KxbgHDZYg5zz615+2ky2un3RSKHdYT+UWaT5mlicxr8pGSDC8LE5/hFdV4M8V2thqWkeEJIrqW6nge5tp9o8v7NyyZbjkcptHOUJ6UAejVz/jrxEvhrw/Ldxos19Kwt7K3Y48+4b7ifTuT2AJ7Ve8Ra1Z+H9Jn1HUWYQx4AVBud2PAVV7sT0FefTS3Wt6jDqurWkVtcwrJHbQA5eCNiCQ5yVLnaMleB0BPcAtbriSPzLoq05A8xo87S/fGecZ6Vp6TCuqWcGi2kiSaRaIEvp0bP2iQjJiUjtk5Y++PWs1BkgfxE8H1Ip3wlnTQ4P8AhDJVkZ7GFrm1uWI/0iF5GzkZyGVjgjGMbSOtAHoaoIoQkKKqquFQcAYHA9hXl03ijxRY6slrPF9q1PAlfT4RGIipL5RHxuzsQsCTyTjFekSalZx35spLiNLoR+b5bHBKZxkZ6815Tcs7fGzTZYpt0bXkkTAcjC2rHGfq350AevwyebCkm1lDqG2sMEZ7H3rF1zSZzdLqujssWqRLtZScJdIP+Wb/ANG6g+2RW7RQBx/w/wBetr+G/sTvt7m0uZD9mnUpIkbMWXg9hkrkZ+7VP45adcav8MNWsbK1nu55ntgIYELuwFxEWwBk8AE/QVwvxBuhL451dbdmZoWjifgja3lq3B+jA1b0Xxvq+kRRxKsN9bKP9VM5VwOPuvzgADoQe3IoAoaH4Q8QaL8TLG98RR3OsQx6Tc2vmW0TOnkRoEijJIA8xwGYgnkvVv4eeGobvxd4rnXw3d2OiXMERtzPYHTvKkUttRIwfmIDf6wYOQfWvRvDfjrRNdeKFJns75+lpeL5chPH3ecN1/hJpPiBq/2PSJLOzlYX9wOBE2HjjBG9+DkDHAPqwoA8/wBOt7aXVYoJo/NQQw2lwkmH/wCmkzNlgSSUlJPJBYHkV6b4GV/+EWsZpkKS3Ia6dSu0gyMXxj/gWK8ts9NmvraKFnuI2vHaGJwqEOZhtY7iS4ZIVdumMS9TxXtsaLHGqIMKoAA9AKAHUUUUAFFFFABXKfEe0S60e0aUnyY7yMSqBw6SBoipI5APmdRXV1l+KdPbVfDmpWUZIlmgdYyCRh8ZU5HuBQB5XDK81ybXVYFiNzLay3ENvJkowdFcBwc4DFxnOT83vXsdpbx2lvHBACsUY2quScD05rxK5tzPa2t26pa2V0SUZCC0YlQsCUABXa5nIz3XOa7iw8bz3Jn0/wDs24i1OzVEuZp0xb+bnDqjD73HIxxyM45oA6nVNZstMeKO5l/fykBIkG5yM43YHRRnkngVyd9dXOppGdQWBnhkLokakqvXawz/ABYOM+uelUktQ95dXZ3Nc3LgyuzFicdAMk4Uf3RxzSsrI4YggEYFAGF4rhu5bfSI7CKeRv7Xs1lWJS37kzAShv8AY2k59q9mAAGBwK8j8WS3Vl4e1K7sJXhuoLeSSN4/vKwGQRx14r1mF1liSSNg6OAwZTkEEdQaAOT+JPiCLRvD99FLY6hdefbsga3gLopb5BvboOSOOteb/DYrY+KL5bvSbm+jiSRJNkIlNs6uF5U85O0jIH8NeweLrCHVfC+rafcvGkV1ayQl5FDKpZSAcHrgkGvIvgJq02peMddnljaI3llBPJFzhH3MTjPODvBwf73tQB7jC4kiR1DKGAIDAgj6g9DXPfEO4s7bwjfSX4TYQqR7l3fvWYKmPQ7iBmukrh/jQpf4e3oBwftNoc+n+kxUAeV2F/faLqP9oaVOtvdhcSDG6OZOyyDuM9COR+OD7Z4V8UWmv20W39zemMPJbnnaeM4PcZPX9K+ZvH4vDZaZHZXEkE8t8kasHwMlWx9Rkc1zcd5r1rc+IZY3mtr97NZhFE3MClx8q46HaBnFAH27XM/Eq2F14I1WMbvNEW6JlJUq+RtORyOevtmvI/gN49gt/tWm6ukEURaMLqpuZTHcPtHyt5rN+8yf4cA+gxXffFLWI59MWwsJ45AJFe7KP91OoTI/iJAO3rhSfqAc3bzxvb6heWlrCFBdoFSNSFZU8uHCk5U7pQMgEHBzXsNhbLZ2NtbJ92GNYxxjgDFeTeFdOmmv9JshNJJAzrPKh2NGFiJkcqRk/wCteNCDjBjNewUAFFFFABRRRQAUUUUAeaeMYF0vxTNJJF5lhqkaySoFLEsg8ubHIA/dMrEknAjOBWRod02nXn2a4uG3xsIERRlHJJZHDDsx34z/AHl6cZ9D8bafNe6MZrKIS39k4urZScbmXqh9mUsuPevLNTns7+WG6t3faY4xKyNh/LbBhkAzwflKdfvxKOhoA6gWzrPcySXd/cmVt+y5uGkSM5J+RTwvXHHanoQBxkdgOvpWfp+p+f8Au7gr9oVQWAbKSqfuyp6owOc9uh5FWlmyC23gng+/YfWgCynDk/MzDkkY4FVtWu9RsraO80lXa6gnhLxxKrNJF5gEic8crk9R0FPWYMfmUZVecHANOachc4HzdBQB2HiLRbbxDpyxtK0My/vLa8gI8yB8cOh/p0I4NePa9c6to3jS0iuZVu7+1nLxNFH5UUxf7OkYxk7B94NjPJJHpXbeCtZltNNvdB06yW6vtLKPDbvcBPMtpCSpDEYG07k29AFHPNcl40vWuPF5vrrT7mwe1EMrrO6htqOjF02k5GEYcdcUAevaUNX82ZtWaxEZx5SWwclfXczde3QCtKq9hdxX1lBdW+/yZkEib0KNg8jIPI+hqxQB8++MAT8QPE6BSf8AS4ifbNtDWfA+HwoB6ZDc/oK1PF8cVv4s1gqmTLdFnLHcSSBzz6YAA7AVh73VgQpcMCOoyPegCe4gikEaTQxyfOJAHG7YR0P4c1raTIWspdzOpvpfPmlwSy28YwpJGTgkOw/3U9aybVBPKY5JZI4o08yVoSC4XoAvP3mOFH4noDXWaPJfW+L5LRBd3oWG1h83bh/lMMeOu3aBIT/dRQepFAHT+BdPM+pC4mjeIaYrQmNphKRcyYMil8DcI02IvXAJHavQKz9B01dJ0qCzWRpXQFpJW+9I5OWc+5JJrQoAKKKKACiiigAooooA8i1nTWt9Y1PSAn7ks0sAYKEAlbfFlmIwPN8yMBc/6wZo8L3STpLuJZnO9j1wwCqwJ6Z4U/8AAu/Ndb8RLZILWDWSoKWmYrrIyPsz4DMQOTsYI45GNpxXBw6nt1e8aILDFPOUuIhwI7leWQsRjBJDbv7suf4TQB1IJUEBiEzk44pz7QhBBwB1Jxj0rOttSWe5eELJHPEB50JXBiY5+Vvfj8uehq1JPlCAeT1oAdPGk6PFIm5ZFKyLn+E5yP6Vu/DK7Nz4PtIJGzPYM9hJkYOYmKqSO2VCt/wKud845U7ck9GqTQtTTw/cXcqW91cwXs6tJDAFPlvgKZACRxgDd34zigDovGfhhtejt57O+ksdStSTDLtEkbZ/hkjPDLnB9Rjg15T8P7q/g8VWtvpYghu508mY3PzJtSGPdjGGLb0yOg5PpXr17qmoNMr6JaWeo2oU+YpuvKlDZ4wCpBGPUivJfCt8th8Qba5ms5xLJJJA9pD+9lgeRnG04PKrsJLcgUAe2aZFeQ223ULmO5nLE744vLUA9BjJ6eua5v4peU/hV4J1Zllmjxg45Vt4z+Kiuvrh/i2QPDtvndj7QOhH91qAPJHcrIMKrKecE9vxxSMMNuHmLj/vrNQySfPl9+cY65H1pVk+Ul8sgHOf8KAJUeNfMknCiILudm6Bepz+X6VvxJPfaZY2UNluaIec1s5bDXEh+VXZRleCgLdsv6Vj6f5UkNxNL5jRxyALbAbhNIMHYw67QCCQOuQv8Vdbp1teXMv9jx+T9q1Fiz3UbnzYEGVuH6cY3GNSOCzs3SgDsvAVpFIk2rRlmilRbW1LvvPkx5BYseSXfexJ5PBNddUVnbRWdrDbWyCOCFBGiDoqgYAqWgAooooAKKKKACiiigAry3xVo76NeNDaxqbO8lZrPcxWOOSQ/vbdwCMhwWZPR845Ir1Kqup2FtqdhPZ30KzW0y7XRh19/YjqD2NAHkGkufKthdG4jMBdohcjEsaPy6SqOVPCsw7EBgCpONGW9so7qOFplaaY7Y40yXbvnH93HO7p70mq+HodH1OSXVAFE/lxjVZNxjnCn5RPtI8uYZwJu4GCeSDFd6TdgW4WHFxs88R71M0MjA5A2jEmVyT5ec/xIetAGjH++lmj8mRCmPncYDk/3T3wKmWNS25hyOADzj+tZun6jNJMFC280Lr0LiKbI4I+Y+Wxz2DKR6Cp7nUY7S7giu7W9txKcb5bdljQ9tz/AHQCeAcnk0AWFaew1KDU7R5S0SOJYEVSblMEiMk9PmwQc8HPYmuS8ZakdX1O01x7S9sY3aKFbe4AR3VI2lfK/X5RnqRXbShfLV1+6Odx4AHrXL67FBr39mPDKfLtJnuGn2EqgKmJW913t16YVj0GaAPZ423orAEBgDgjBrwT9nyy8S6hFoOvS3N8ulNbXKXklzqDzi+k81lj2xEny9mMZ4zj3Neu6H4psdQt2W7kFhfQt5c9tdMI3VgOSMn5lPZhwRUsvirRkkkiivo7idCVMNuDK5IGcALnmgDxfxS7S+ItTM3GblwX4GcHA/lVG2svtMjqGRVix50jZIiB/vcegOAOT0710Wo2Vtc6hdXV/NcQyzytJFaQbXlOTnDMAyg8/dGW9hTm08C3mtHa3tBFA8627s0cYYYDPcSA/L1AIJMh7bRxQBm6JpyXSt5UQSyVnMU10vyyyBTmaQA4Eagfdz6oCTuJ9H+HmjOIo9VvGmcbClmJid21jueYgk4aRuQP4VCj1qp4b0WbXYYZdQjVNG2IfK8ry/tZHIGwjKW6/wAKHk9T7+hgYGB0oAKKKyj4j0YWV/eHU7QWunytBdymQBYJFxlXPYjI4PrQBq0UiMHRXU5VhkH1FLQAUUVRj1axk1qbSUuFOowwrcSQ4OVjYkBs4xyQaAL1FFFADJ4o54ZIZkV4pFKOjDIYEYINePa/pNxpdz/ZRhknKpi2kVQ0l1bKDtVAzbfMhLDI4Lx9e4r2Ss3XtIt9ZsvInLxyI3mQzxnEkEg6Op7EfqMg8GgDxyDUpY4kuYXt7x2KpKYpg6XEYyqMj9NwHCk8MBsJDLzu2+p2l0k32d5Jmi2iZEQ7oyQcBhxhuOnXp61WbQm0u/Szu7e0tJ2LmIRoIYL2VyAXjl/5ZMV+9CQVbHAPWodQ027sblnhunllhhEUksClJUUlijSREEgcMBkFPTZQBuRAEbmR0zg7DwR9R6inJjjaPmznp1PpVG2vpZLWHy1hvJ2BLRwsIXxjqFdsNk5+6xFW2vNsxhu7e5sWChka7Ty1f1CknnHGfr3oAkkFysJW0vJrKV8bZ4lBKYOeh4IyOQeorj/AFvq9j8S/N1lIfts7LLLDCrKI/OE5JwSem0Z6cEV2b3dtDEPNnjy5wiodzufRVHLE1zyNdR+I4vEMdqQ5KQxIj5SaWMESRBzwCwdgCeC8ZANAGh8ZNd1fTfE/hDTtJvdUt4dQS/M0emQpLPK0cSNHtVlPRjz7E/UHiNtbm+F2hP4pVV1pmT7UqgD5iG6heAcYyBxnNdY3iLwndTW2oXtxp8d5ZB/Ke9QRz2xYAOBvAZCRwQOvvXKeNvEFn4otbWPQ5bme2iLSSzGMxQDgY3O4AzycDPrQB528Y2EZP3cEnpitDT7Jvllu4mTTlQsZdw3SEfwoD+rH5V71Ysbe2S+hKzyajdBWJiUBLSMdt2QC2Ou5iin376gX/R11A3sFzKTEIZ5IWmglJJIW3Vcee454G1FIHGfmoAZHpf2FTdODp0aR4iWOMt5Ck/KiqR800m/ADYb5ix5wB6X4J0L+yrHz7iJYrydETywSRbwoMRwKSTwo6nuSTVPwp4cmDW1/rKuJIV/0a0lk8wxH/nrI38cx7t26D1rsaACiiigAooooAKKKKACiiigAooooAbIiyIySKGRhgqwyCPeuK1jwRttGh0ORVtCCDptwzCEA9fKdfnhJ5+6cc/drt6KAPIdVIEsp1mKSydQcJqUe13PJ2R3aEIVIAA3g46kGlkgubKweaCa/s7HaWfLC6gcDbkboj3JI+4ScHoK9cdVdSrgMp4IIyDWFdeEdEuJHkSyFrM2cy2jtbsec5yhGaAPL5RpLzrHNPpm8sR5X7uCViWKjCTRKMbgRznnvXW6Lr1pZ28sUNgk7OFM0kmpW8jOpHy7ju+7jgAcY6VuSeE1L5i1fVlXZs2SSpOMf9tFY/rTrbwnBAYiL25IjACL5UAC4GBjEfGO1AHF3k8b6atxaWbWmlyriM3UsE9ui56qCrsBx0HHtUSWFzJpdu8b3TaaX2NBawLaKq7mDFi4VcKQT93JB79u8uvDRuc+ZrOqA9irRKVGQcAiPI6D8qlTwtpHn+fcWpvJuz3kjXBHGON5IH4UAef6bZR3UEEOlwLdSYaO6isPmiYHcNj3b9FwRkR85zxXWaT4MhDCTWRbTASCZbK3j2WqSYxvKnmV+B8756cAV1qIsaBEUKo4AAwBTqACiiigArxvxP4A1m8+I88djBGfB+tz2t9qxLqNskG4lNmckSEJkgHk9sV7JRQB4jP4U8XP8UU1mPTHggTVJGNxbXUaxy2hQhS25zIWzjK7Qo7A1jaX4B8bw2GrQx2ssccscW5rm9VLu7AmVpIvNjkZSGQEeYwVugwATX0PRQB482ieItP1TSNQ8PeFbi0sY1vIJdNfVI8oZEjCSn5ioGVPyqSR17kVjaV4M8Z2mi37PpiT6jJ4etrILc3SkSTLOzOhZXznYcgkhScAnGa96ooA8E0bwJ4qWyisJ7XUbfTT4itrsxfb443S08l1lIMUny/MR8qnPcZxmvdLG1hsbG3tLYMsFvGsUYZy5CqMDLMSScDqSSanooAKKKKAK+oWNrqVnLaX9vFcW0ow8cihlI+lcJrfgm5haGXS5JL62tyWgtZ7lo5rYlSu6G4HOQGOFfcB2Ir0OigDxzUBbmbbquYLhpdu3UY/sDouSdwnUNHKeFHPXqaRdOmitF8lNTEMxZliSL7ZCdigk7ojtwc4BKZJFewyxRzRtHMiyRsMFWGQfqKxJvCOhSyGRNPjt5DnLWrNATnqfkIzQB5naz2EV8onuLOSRiIsfaJLEMdxTYT5G4nPH3ufpXSjxdbSaT9mh0zSJ7Hyyv2aK7Z8pu24EYhyeeOlbzeDrYRCOHVNbhQEFQt87YI9N2ai/4Q1uceJfEYJGCRdLn89lAHGazBqdvEtvZG7gGW2WkV1JffMAzbFBQbThTgbh2HFU9bsEtJIZdYunknmi2rNqd55CxsVBX90paV8sdpXI6V6I3grTpVQXd1q92V6mbUJfm+oDAH8q0tK8O6PpIX+ztMtLd1GA6xjf1z97qfzoA88sNDutVaIaVaGXT1Csh1C3EFkjZBDpbgeZIwI4Lke5NdxoHhe00uVbqeR77UVUqLmcAeWp/hjQALGvsoHvmugooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     (A and B)",
"    </strong>",
"    Right hemisphere, observer variations: lower and upper ASPECTS slices show as shaded areas the minimal and maximal variations in size of the cortical areas of the MCA (M1-M6) chosen by six expert observers. Left hemisphere, ASPECTS study form: A = anterior circulation; P = posterior circulation; C = caudate head; L = lentiform nucleus; IC = internal capsule; I = insular ribbon; MCA = middle cerebral artery; M1 = anterior MCA cortex; M2 = MCA cortex lateral to insular ribbon; M3 = posterior MCA cortex; M4, M5, and M6 are anterior, lateral, and posterior MCA territories, respectively, approximately 2 cm superior to M1, M2, and M3, respectively, rostral to basal ganglia.",
"    <strong>",
"     (C and D)",
"    </strong>",
"    Cortical MCA area variations with change of baseline. In the right hemisphere, the baseline is parallel to the inferior OML; in the left hemisphere, the baseline is the superior OML. OML=orbitomeatal line.",
"    <strong>",
"     (E and F)",
"    </strong>",
"    Normal vascular variations in MCA size on the two ASPECTS slices. The right hemisphere shows the larger normal variations described by van der Zwan* (light shading). The left hemisphere of each shows the smaller, textbook&bull;, variations (dark shading).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References",
"     <br>",
"      * van der Zwan, A, Hillen, B, Tulleken, AF, et al. Variability of the territories or the major cerebral arteries. J Neurosurg 1992; 77:927.",
"      <br>",
"       &bull; Osborn, AG. Neuroradiology, Mosby, St. Louis 1995.",
"       <br>",
"        Reproduced with permission from: Pexman, JH, Barber, PA, Hill, MD, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 2001; 22:1534. Copyright &copy; 2001 American Society of Neuroradiology.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10903=[""].join("\n");
var outline_f10_41_10903=null;
var title_f10_41_10904="Management of adults with idiopathic cutaneous small vessel vasculitis";
var content_f10_41_10904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of adults with idiopathic cutaneous small vessel vasculitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/41/10904/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/41/10904/contributors\">",
"     Nicole Fett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/41/10904/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/41/10904/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/41/10904/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/41/10904/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/41/10904/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25558599\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous small vessel vasculitis (CSVV) is a disorder characterized by leukocytoclastic vasculitis involving the small blood vessels in the skin. By definition, vasculitis affecting other organ systems must be absent. CSVV may develop in association with a wide variety of factors, including drugs, infections, systemic disease, or malignancy. An inciting factor is not detected in around one-third to one-half of patients. Such patients are designated here as having idiopathic CSVV.",
"   </p>",
"   <p>",
"    Idiopathic CSVV often resolves within a few weeks, and thus, the management of most patients involves confirming the lack of an identifiable cause and the alleviation of symptoms. Systemic immunomodulatory therapy to arrest the disease process is usually reserved for the subset of patients who develop complications such as hemorrhagic bullae, ulceration, or chronic or recurrent disease.",
"   </p>",
"   <p>",
"    The management of patients with idiopathic CSVV will be reviewed here. The evaluation of patients with cutaneous lesions of vasculitis, and the clinical features and treatment of specific disorders that may present with vasculitis involving small vessels of the skin are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=see_link\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"     \"Urticarial vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=see_link\">",
"     \"Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=see_link\">",
"     \"Treatment of rheumatoid vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=see_link\">",
"     \"Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368130\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other terms that have been used to refer to CSVV include cutaneous leukocytoclastic vasculitis, cutaneous leukocytoclastic angiitis, and cutaneous necrotizing venulitis, all of which refer to the characteristic histopathologic findings in CSVV. The term hypersensitivity vasculitis has also been used to refer to CSVV, but is most appropriately applied to CSVV caused by a known drug or infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=see_link&amp;anchor=H606309#H606309\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Terminology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364697\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSVV is characterized by the presence of cutaneous lesions in conjunction with histopathologic evidence for a leukocytoclastic vasculitis involving the capillaries, venules, and arterioles in the skin. Although palpable purpura are the most common associated skin manifestations, other lesions such as petechiae, hemorrhagic bullae, ulcers, and urticaria may also develop (",
"    <a class=\"graphic graphic_picture graphicRef77522 graphicRef56272 graphicRef70300 graphicRef65932 graphicRef58626 graphicRef57440 graphicRef77723 \" href=\"UTD.htm?43/26/44458\">",
"     picture 1A-G",
"    </a>",
"    ). The skin lesions are often most prevalent on the lower legs and other dependent areas.",
"   </p>",
"   <p>",
"    A wide variety of factors can induce CSVV, including drugs, infections, systemic diseases, malignancy, and rarely dietary factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/1\">",
"     1",
"    </a>",
"    ]. Idiopathic CSVV, which accounts for 30 to 60 percent of cases, is a diagnosis of exclusion that can only be made when clinical and laboratory investigations fail to yield both an underlying cause and the presence of systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The performance of a conscientious search for an inciting factor is important because removal of the underlying cause may result in the resolution of CSVV [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In addition, systemic involvement should be excluded prior to making this diagnosis since a more aggressive approach to therapy is usually indicated in patients with internal disease.",
"   </p>",
"   <p>",
"    The clinical and pathological findings of cutaneous vasculitis, the evaluation for an etiologic agent, and the assessment of the extent of disease in patients with cutaneous lesions of vasculitis are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=see_link&amp;anchor=H16171984#H16171984\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the clinical features, diagnosis, and treatment of idiopathic urticarial vasculitis, a type of CSVV that presents with persistent urticarial skin lesions, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link&amp;anchor=H43#H43\">",
"     \"Urticarial vasculitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15696119\">",
"    <span class=\"h1\">",
"     DISEASE COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with CSVV, the condition is self-limited, and spontaneously resolves within two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/2\">",
"     2",
"    </a>",
"    ]. In patients with self-limited disease, new lesion formation usually continues to occur during the first one to two weeks of the disease process. Chronic or recurrent disease occurs in approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postinflammatory hyperpigmentation and red-brown hemosiderin deposits in the skin that are secondary to the breakdown of extravasated erythrocytes commonly remain after an episode of CSVV. These lesions tend to resolve slowly over time; several months or more may be required for resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368147\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of idiopathic CSVV influences the approach to treatment. The management of patients with acute disease differs from those with chronic or recurrent lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368515\">",
"    <span class=\"h2\">",
"     Acute and uncomplicated idiopathic CSVV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the high likelihood for spontaneous resolution, treatment to suppress the vasculitic process is not necessary in patients who present with only acute palpable purpura or petechiae. However, some of these patients experience bothersome pruritus, pain, or local edema, and may benefit from interventions that improve these symptoms.",
"   </p>",
"   <p>",
"    Clinical experience suggests that the following measures can be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rest, leg elevation, and compression stockings &ndash;",
"      </strong>",
"      Disease may be exacerbated by exercise or prolonged maintenance of affected areas in dependent positions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/1\">",
"       1",
"      </a>",
"      ]. Leg elevation and use of compression stockings may decrease immune complex deposition in the lower extremities, thereby decreasing the progression of vasculitic skin lesions.",
"     </li>",
"     <li>",
"      <strong>",
"       Nonsteroidal antiinflammatory drugs (NSAIDs) &ndash;",
"      </strong>",
"      NSAIDs may be useful for pain management.",
"     </li>",
"     <li>",
"      <strong>",
"       Oral antihistamines &ndash;",
"      </strong>",
"      Antihistamines may help to suppress pruritus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25558627\">",
"    <span class=\"h2\">",
"     Complicated or chronic idiopathic CSVV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although measures to improve symptoms can be beneficial for all patients, treatment aimed at arresting the disease process is indicated in patients with idiopathic CSVV complicated by the presence of hemorrhagic blisters, cutaneous necrosis, or ulceration, as these manifestations may lead to secondary infections, chronic wounds, and scarring. Patients with chronic CSVV (active disease that persists for more than four weeks) or recurring disease are also candidates for therapeutic intervention. When chronic or recurrent disease is asymptomatic and patients are not bothered by the appearance of skin lesions, deferring treatment is an additional option.",
"   </p>",
"   <p>",
"    Much of the data used to guide the approach to treatment of idiopathic CSVV are derived from case reports and small case series of patients with cutaneous leukocytoclastic vasculitis associated with a predisposing factor, with or without concomitant extracutaneous disease. The paucity of data on the efficacy of treatments precludes definitive conclusions on the efficacy of any specific therapy.",
"   </p>",
"   <p>",
"    Systemic immunomodulatory drugs are the mainstays of treatment for patients with complicated or chronic idiopathic CSVV. Our approach to these patients involves the initial use of a short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in an attempt to abruptly suppress the disease process, followed by the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in patients who continue to have active disease. If the response to this regimen is inadequate, we consider the use of more aggressive immunosuppressive agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1132405\">",
"    <span class=\"h3\">",
"     First-line therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58265601\">",
"    <span class=\"h4\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are the most commonly utilized agents for the management of acute, single episodes of CSVV [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/1\">",
"     1",
"    </a>",
"    ]. No randomized trials have evaluated the efficacy of systemic glucocorticoid therapy in CSVV, and the use of these agents is primarily based upon reports of efficacy from small series of patients with various forms of cutaneous leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]. In our experience, the vast majority of patients with idiopathic CSVV improve during therapy.",
"   </p>",
"   <p>",
"    We typically initiate treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of ideal body weight until new lesion formation ceases (usually one to two weeks). This is followed by a taper to treatment cessation over the course of three to six weeks. Improvement is often detectable within one week after starting therapy.",
"   </p>",
"   <p>",
"    For patients in whom disease recurs upon tapering or discontinuation of a course of systemic glucocorticoid therapy, continuation of long-term monotherapy with glucocorticoids is not recommended due to the risk for drug-related side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/10\">",
"     10",
"    </a>",
"    ]. Rather, such patients should be transitioned to glucocorticoid-sparing medications (see",
"    <a class=\"local\" href=\"#H1132420\">",
"     'Second-line therapy'",
"    </a>",
"    below). If significant morbidity is likely to result from a disease flare, we continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at the lowest effective dose until the onset of action of the glucocorticoid-sparing agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1132420\">",
"    <span class=\"h3\">",
"     Second-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients who relapse after an initial course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , both of which are inhibitors of neutrophil function. Although the data to support the efficacy of these therapies are limited, a trial of these agents is reasonable prior to the use of more aggressive immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1132622\">",
"     'Refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In our experience, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy are useful for decreasing the reliance on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in the majority of treated patients. We usually attempt treatment with colchicine first, due to the broader range of adverse effects associated with dapsone therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25558641\">",
"    <span class=\"h4\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data conflict on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in CSVV. An unblinded randomized trial in which 41 patients with histopathologically confirmed cutaneous leukocytoclastic vasculitis (either idiopathic or associated with a predisposing factor) were treated for at least one month with either colchicine alone (0.5 mg twice daily) or topical emollients found no significant difference in efficacy between the two treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/11\">",
"     11",
"    </a>",
"    ]. The study included 16 patients who had been treated with other agents with variable responses, suggesting that an unspecified proportion of patients may have had refractory disease.",
"   </p>",
"   <p>",
"    In contrast to the randomized trial, case series and case reports have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy can be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/2,8,12-15\">",
"     2,8,12-15",
"    </a>",
"    ]. In one series, seven out of nine patients with chronic biopsy-proven leukocytoclastic vasculitis who demonstrated improvement during treatment with colchicine had disease flares upon discontinuation of the drug and recurrent improvement with drug reinitiation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    for CSVV is usually given as a 0.6 mg dose twice daily. Initial signs of response are typically observed within one to two weeks. If no response is noted after one week, increasing the dose to 0.6 mg three times per day may be attempted. However, drug-related gastrointestinal adverse effects such as diarrhea, nausea, vomiting, and abdominal pain often limit dose escalation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25558648\">",
"    <span class=\"h4\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data in support of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    use are limited to case reports in patients with various forms of cutaneous leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/16-24\">",
"     16-24",
"    </a>",
"    ]. As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , there are reports in which disease improved during treatment and recurred upon the discontinuation of dapsone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Doses of 50 to 150 mg per day are typically utilized for CSVV, and signs of improvement are often noted as early as one week after the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians who prescribe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    must remain cognizant of the drug&rsquo;s potential adverse effects. Hemolytic anemia is a common consequence of treatment that occurs in all patients with varying severity, and close monitoring of hematologic status, especially early in the course of therapy, is essential. In particular, dapsone therapy should be avoided in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to a high risk for severe hemolytic anemia. Other potential adverse effects of dapsone include idiosyncratic agranulocytosis, a hypersensitivity syndrome, hepatitis, and peripheral motor neuropathy.",
"   </p>",
"   <p>",
"    If baseline laboratory studies, including a complete blood count, comprehensive metabolic panel to assess liver and renal function, and a G6PD assay are within normal limits, we typically begin treatment with 100 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    per day. Complete blood counts and liver function tests are obtained once weekly for the first month of therapy. Provided the drug dose remains stable, the frequency of these studies can then be reduced to once monthly for three to four months, followed by once every three to four months. &nbsp;",
"   </p>",
"   <p>",
"    For patients who fail to exhibit signs of improvement after two weeks at 100 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    per day, we increase the daily dose to 150 mg. If the response to dapsone 150 mg per day of dapsone is unsatisfactory, we initiate a trial of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    or switch to an alternative therapy. The addition of pentoxifylline (400 mg three times daily) to dapsone (100 mg per day) was associated with improvement of dapsone-resistant cutaneous leukocytoclastic vasculitis related to rheumatoid arthritis and urticarial vasculitis in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/25\">",
"     25",
"    </a>",
"    ]. However, additional studies are necessary to confirm the efficacy of the dapsone-pentoxifylline combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1132622\">",
"    <span class=\"h3\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When disease persists despite a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , we consider the initiation of more aggressive systemic immunosuppressive therapy. Because no high quality studies have evaluated the efficacy of these agents for cutaneous vasculitis, patient specific concerns for drug adverse effects and contraindications heavily influence treatment selection.",
"   </p>",
"   <p>",
"    The agents we most frequently prescribe for idiopathic CSVV are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Although a randomized trial in 19 patients with cutaneous leukocytoclastic vasculitis and rheumatoid arthritis failed to find significant benefit of treatment with azathioprine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      when this regimen was compared with the continuation of arthritis regimens containing NSAIDs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , aurothioglucose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/26\">",
"       26",
"      </a>",
"      ], small case series have documented improvement in cutaneous leukocytoclastic vasculitis during azathioprine therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/8,27,28\">",
"       8,27,28",
"      </a>",
"      ]. Azathioprine may be administered in doses of 0.5 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with appropriate dosing dependent upon the patient&rsquo;s TPMT enzyme activity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/29\">",
"       29",
"      </a>",
"      ]. Responses to therapy are typically evident within two months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link\">",
"       \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Methotrexate (10 to 20 mg per day) has been reported to be effective in individual patients with cutaneous vasculitis related to autoimmune disorders, with responses often detected within four to eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/30-33\">",
"       30-33",
"      </a>",
"      ]. However, treatment with methotrexate has also been associated with the induction of cutaneous vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      <strong>",
"       mofetil &ndash;",
"      </strong>",
"      Data on the efficacy of mycophenolate mofetil in CSVV are limited. Treatment with mycophenolate mofetil (1 to 1.5 mg twice daily) led to the resolution of idiopathic CSVV within two months in a patient who improved only partially on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/37\">",
"       37",
"      </a>",
"      ]. Mycophenolate mofetil has also been associated with beneficial effects in a few patients with cutaneous leukocytoclastic vasculitis related to Henoch-Sch&ouml;nlein purpura (IgA vasculitis) or urticarial vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link\">",
"       \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    also may be beneficial in some patients with cutaneous vasculitis; in a small open-label study of patients with severe or refractory cutaneous leukocytoclastic vasculitis, a regimen containing cyclosporine (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or cyclosporine followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy was linked to good responses in 5 out of 12 patients (follow-up period of 4 to 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the development of renal toxicity may limit the duration of treatment with cyclosporine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    , an aggressive immunosuppressive agent used in the management of systemic vasculitis, is not typically prescribed for CSVV due to the possibility for serious drug-related adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294453\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is a well-tolerated drug that has been reported to be effective in the treatment of urticarial vasculitis. The efficacy of hydroxychloroquine in other forms of idiopathic CSVV is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link&amp;anchor=H43#H43\">",
"     \"Urticarial vasculitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional agents reported to be useful in individual patients with cutaneous leukocytoclastic vasculitis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/41\">",
"     41",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/42\">",
"     42",
"    </a>",
"    ], and intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10904/abstract/43\">",
"     43",
"    </a>",
"    ]. Topical corticosteroids are commonly used for the management of inflammatory skin diseases, but these agents have not been formally evaluated in the treatment of CSVV. In our experience, treatment with topical corticosteroids has not been beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294543\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment in patients with chronic or complicated CSVV varies. We typically attempt to discontinue therapy once existing lesions have healed and no new lesions have developed for two to three months. If lesions recur, treatment is reinitiated. The optimal regimen for discontinuing therapy in idiopathic CSVV is unknown; we typically decrease the dose of medication over the course of a few weeks and monitor for disease flares prior to complete drug cessation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294555\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous small vessel vasculitis (CSVV) is a vasculitic disorder characterized by involvement limited to the skin. Idiopathic CSVV, which accounts for 30 to 60 percent of cases, is a diagnosis of exclusion. (See",
"      <a class=\"local\" href=\"#H25558599\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H364697\">",
"       'Clinical features and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients, idiopathic CSVV resolves spontaneously within a few weeks, negating the need for treatment to stop the disease process. Treatment in patients with acute, uncomplicated disease is directed towards the alleviation of symptoms. (See",
"      <a class=\"local\" href=\"#H368515\">",
"       'Acute and uncomplicated idiopathic CSVV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with idiopathic CSVV complicated by hemorrhagic blister or ulcer formation are candidates for therapeutic intervention to arrest disease activity. Such treatment is also appropriate in patients with chronic (lasting more than four weeks) or recurrent CSVV. (See",
"      <a class=\"local\" href=\"#H25558627\">",
"       'Complicated or chronic idiopathic CSVV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic immunomodulatory therapies are utilized for the treatment of patients with symptomatic complicated, chronic, or recurrent CSVV. We suggest a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      taper given over the course of three to six weeks as the initial course of therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25558627\">",
"       'Complicated or chronic idiopathic CSVV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who experience relapses upon tapering or discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , we suggest the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      to reduce the risk for glucocorticoid-related adverse effects (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). More aggressive immunosuppressive therapy may be beneficial in patients who fail to respond to these agents. (See",
"      <a class=\"local\" href=\"#H25558627\">",
"       'Complicated or chronic idiopathic CSVV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/1\">",
"      Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol 2006; 45:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/2\">",
"      Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/3\">",
"      Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006; 24:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/4\">",
"      Lotti T, Ghersetich I, Comacchi C, Jorizzo JL. Cutaneous small-vessel vasculitis. J Am Acad Dermatol 1998; 39:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/5\">",
"      Lunardi C, Bambara LM, Biasi D, et al. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol 1992; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/6\">",
"      Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/7\">",
"      Sanchez NP, Winkelmann RK, Schroeter AL, Dicken CH. The clinical and histopathologic spectrums of urticarial vasculitis: study of forty cases. J Am Acad Dermatol 1982; 7:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/8\">",
"      Callen JP, af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J 1987; 80:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/9\">",
"      O'Loughlin S, Schroeter AL, Jordon RE. Chronic urticaria-like lesions in systemic lupus erythematosus. A review of 12 cases. Arch Dermatol 1978; 114:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/10\">",
"      Cupps TR, Springer RM, Fauci AS. Chronic, recurrent small-vessel cutaneous vasculitis. Clinical experience in 13 patients. JAMA 1982; 247:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/11\">",
"      Sais G, Vidaller A, Jucgl&agrave; A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 1995; 131:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/12\">",
"      Hazen PG, Michel B. Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behcet's syndrome. Arch Dermatol 1979; 115:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/13\">",
"      Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol 1985; 13:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/14\">",
"      Plotnick S, Huppert AS, Kantor G. Colchicine and leukocytoclastic vasculitis. Arthritis Rheum 1989; 32:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/15\">",
"      Wiles JC, Hansen RC, Lynch PJ. Urticarial vasculitis treated with colchicine. Arch Dermatol 1985; 121:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/16\">",
"      Cribier B, Cuny JF, Schubert B, et al. Recurrent annular erythema with purpura: a new variant of leucocytoclastic vasculitis responsive to dapsone. Br J Dermatol 1996; 135:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/17\">",
"      Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987; 16:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/18\">",
"      Seybold H, Simon M, Schuler G, L&uuml;ftl M. [Refractory cutaneous necrotizing vasculitis. Successful sulfone therapy]. Hautarzt 2006; 57:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/19\">",
"      Wells GC. Allergic vasculitis(tri-symptom of Gougerot) treated with dapsone. Proc R Soc Med 1969; 62:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/20\">",
"      Fortson JS, Zone JJ, Hammond ME, Groggel GC. Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone. J Am Acad Dermatol 1986; 15:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/21\">",
"      N&uuml;rnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol 1995; 75:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/22\">",
"      Eiser AR, Singh P, Shanies HM. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report. Angiology 1997; 48:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/23\">",
"      Muramatsu C, Tanabe E. Urticarial vasculitis: response to dapsone and colchicine. J Am Acad Dermatol 1985; 13:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/24\">",
"      Ruiz Villaverde R, Blasco Melguizo J, Martin Sanchez MC, Naranjo Sintes R. Annular leucocytoclastic vasculitis: response to dapsone. J Eur Acad Dermatol Venereol 2002; 16:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/25\">",
"      N&uuml;rnberg W, Grabbe J, Czarnetzki BM. Synergistic effects of pentoxifylline and dapsone in leucocytoclastic vasculitis. Lancet 1994; 343:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/26\">",
"      Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991; 151:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/27\">",
"      Callen JP, Kalbfleisch S. Urticarial vasculitis: a report of nine cases and review of the literature. Br J Dermatol 1982; 107:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/28\">",
"      Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/29\">",
"      Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/30\">",
"      Upchurch KS, Heller K, Bress NM. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol 1987; 17:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/31\">",
"      Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997; 56:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/32\">",
"      Williams HC, Pembroke AC. Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. J R Soc Med 1989; 82:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/33\">",
"      Espinoza LR, Espinoza CG, Vasey FB, Germain BF. Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol 1986; 15:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/34\">",
"      Halevy S, Giryes H, Avinoach I, et al. Leukocytoclastic vasculitis induced by low-dose methotrexate: in vitro evidence for an immunologic mechanism. J Eur Acad Dermatol Venereol 1998; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/35\">",
"      Torner O, Ruber C, Olive A, Tena X. Methotrexate related cutaneous vasculitis. Clin Rheumatol 1997; 16:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/36\">",
"      Simonart T, Durez P, Margaux J, et al. Cutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: a possible manifestation of methotrexate hypersensitivity. Clin Rheumatol 1997; 16:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/37\">",
"      Haeberle MT, Adams WB, Callen JP. Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil. Arch Dermatol 2012; 148:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/38\">",
"      Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, et al. Treatment of complicated henoch-sch&ouml;nlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol 2010; 2010:254316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/39\">",
"      Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 2000; 143:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/40\">",
"      Tosca A, Ioannidou DJ, Katsantonis JC, Kyriakis KP. Cyclosporin A in the treatment of cutaneous vasculitis.  Clinical and cellular effects. J Eur Acad Dermatol Venerol 1996; 6:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/41\">",
"      Houck HE, Kauffman CL, Casey DL. Minocycline treatment for leukocytoclastic vasculitis associated with rheumatoid arthritis. Arch Dermatol 1997; 133:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/42\">",
"      Swaminath A, Magro CM, Dwyer E. Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab. J Clin Rheumatol 2011; 17:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10904/abstract/43\">",
"      Ong CS, Benson EM. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol 2000; 143:447.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13785 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10904=[""].join("\n");
var outline_f10_41_10904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H294555\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25558599\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368130\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364697\">",
"      CLINICAL FEATURES AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15696119\">",
"      DISEASE COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368147\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368515\">",
"      Acute and uncomplicated idiopathic CSVV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25558627\">",
"      Complicated or chronic idiopathic CSVV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1132405\">",
"      - First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H58265601\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1132420\">",
"      - Second-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25558641\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25558648\">",
"      Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1132622\">",
"      - Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294453\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294543\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294555\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13785\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13785|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/55/1907\" title=\"picture 1A\">",
"      Palpable purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/5/16467\" title=\"picture 1B\">",
"      Palpable purpura on legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/37/11862\" title=\"picture 1C\">",
"      Leukocytoclastic vasculitits - palpable purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/33/40467\" title=\"picture 1D\">",
"      Palpable purpura legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/16/22786\" title=\"picture 1E\">",
"      Leukocytoclastic vasculitis - lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/26/18850\" title=\"picture 1F\">",
"      Leukocytoclastic vasculitis - bullous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/55/16242\" title=\"picture 1G\">",
"      Leukocytoclastic vasculitis with ulcer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=related_link\">",
"      Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=related_link\">",
"      Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=related_link\">",
"      Treatment of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_41_10905="Evaluation of hibernating myocardium";
var content_f10_41_10905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of hibernating myocardium",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/41/10905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/41/10905/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/41/10905/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/41/10905/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/41/10905/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/41/10905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/41/10905/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/41/10905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has become apparent that impaired left ventricular (LV) function in patients with coronary heart disease (CHD) is not always an irreversible process, but may be stunned or hibernating:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient postischemic dysfunction is called \"stunned\" myocardium",
"     </li>",
"     <li>",
"      Chronic but potentially reversible ischemic dysfunction due to a stenosed coronary artery is called \"hibernating\" myocardium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From 20 to more than 50 percent of patients with chronic ischemic LV dysfunction have a significant amount of viable hibernating myocardium and therefore the potential for clinically important improvement in LV function after revascularization (",
"    <a class=\"graphic graphic_figure graphicRef55621 \" href=\"UTD.htm?10/24/10638\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the detection of hibernating myocardium will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef59009 \" href=\"UTD.htm?34/0/34827\">",
"     table 1",
"    </a>",
"    ). The pathophysiology of and clinical syndromes associated with hibernation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hibernating myocardium is defined as a region of depressed myocardial contractility at rest due to persistently impaired coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. It can occur in chronic stable or unstable angina, acute myocardial infarction, heart failure with and without severe LV dysfunction, and an anomalous coronary artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the ischemic myocardium remains viable, the LV dysfunction can be partially or completely restored to normal by improving blood flow or by reducing oxygen demand. Both the reduction in resting coronary blood flow in hibernating segments and the improvement following percutaneous coronary intervention have been directly demonstrated by cardiovascular magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) has shown that regions with abnormal wall motion may still be metabolically active; these are the regions that can improve after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/10\">",
"     10",
"    </a>",
"    ]. In an autopsy series, 52 percent of myocardial segments that were hypokinetic had normal myocardium when examined histologically compared to only 7 percent of akinetic or dyskinetic segments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hibernating myocardium has been thought to be different from stunned myocardium in which myocardial dysfunction persists for a variable period after transient myocardial ischemia (",
"    <a class=\"graphic graphic_table graphicRef52865 \" href=\"UTD.htm?27/52/28491\">",
"     table 2",
"    </a>",
"    ). However, several observations suggest that the difference between hibernation and stunning may be one of degree: in hibernation, resting blood flow is low, whereas in stunning resting flow is normal but maximal blood flow is reduced, leading to the hypothesis that hibernation may result in some cases from repetitive stunning, secondary to repeated episodes of ischemia, or from chronic stunning (",
"    <a class=\"graphic graphic_figure graphicRef62157 \" href=\"UTD.htm?27/21/27997\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/12\">",
"     12",
"    </a>",
"    ]. Hibernation has more damage than stunned myocardium; recovery may thus also take longer after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology of stunned or hibernating myocardium\", section on 'Relation between hibernation and stunning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY OF IMAGING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tests can assist in the evaluation of myocardial viability and contractile reserve and identification of patients in whom there is the potential for recovery of LV function with revascularization. These tests include radionuclide myocardial perfusion imaging,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography, positron emission tomography (PET) scanning, and an increase in segmental contraction with pharmacologic or nonpharmacologic stimulation (postextrasystolic potentiation) during left ventriculography.",
"   </p>",
"   <p>",
"    Computed tomography (CT) and cardiovascular magnetic resonance imaging (CMR) also can detect hibernating myocardium, but their roles have not been systematically evaluated and comparisons with radionuclide myocardial perfusion imaging are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ventriculography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventriculography is the oldest imaging technique and is rarely used clinically today.",
"   </p>",
"   <p>",
"    Assessment of regional wall motion by ventriculography, and its improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or positive inotropic stimulation has at least two limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Subjective evaluation may not be accurate [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The technique used to superimpose the end-systolic silhouette on the end-diastolic silhouette may influence the assessment of regional wall motion function [",
"      <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, some assessments that regional wall motion function has improved or deteriorated could be erroneous. The finding of improved wall motion function would be accepted more confidently if it were reflected in improved global LV systolic function or left ventricular ejection fraction (LVEF). However, for LVEF to improve, it appears that wall motion function must improve in at least two to three myocardial regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Use of nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the hibernating myocardium is a result of reduced myocardial blood flow, one way to demonstrate its presence would be to show an improvement in function after reducing the myocardial oxygen requirement with nitrates&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    with contrast medium, two dimensional echocardiography, or radionuclide ventriculography can be utilized for this purpose. The sensitivity, specificity, and predictive accuracy of nitroglycerin contrast ventriculography for the detection of hibernating myocardium is only 76 percent, 65 percent, and 70 percent, respectively. However, if left ventricular wall segments improve with nitroglycerin preoperatively, there is an 85 percent chance of their improving with CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Inotropic stimulation/postextrasystolic potentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With inotropic stimulation caused by low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    or postextrasystolic potentiation, the ventriculogram may appear to show an improvement in akinetic wall motion segments by increasing the force of contraction of the normal myocardium leading to a tethering effect on the akinetic segment.",
"   </p>",
"   <p>",
"    Despite this limitation, inotropic stimuli may demonstrate reversible abnormal wall motion, a response that appears to be similar to that seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, one study found that low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    left ventriculography is a useful technique for identifying myocardial viability, especially in patients with a suboptimal dobutamine echocardiographic study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/19\">",
"     19",
"    </a>",
"    ]. A positive response to inotropic stimuli predicts a better short-and long-term survival with CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with global LV dysfunction due to an ischemic cardiomyopathy, improvement in global LV function or LVEF with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    may be of greater importance than reversibility of a regional wall motion abnormality. In one study of 56 patients with an ischemic cardiomyopathy and multivessel coronary disease, a dobutamine radionuclide ventriculogram, which provides an objective quantification of LV function, was performed to assess viability; a 10 percent increase in global LVEF with low dose dobutamine had a sensitivity, specificity, and positive and negative predictive values of 67, 93, 91, and 72 percent, respectively, for improvement in LV function after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concern about the augmentation of myocardial oxygen demand with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    infusion has led to the evaluation of inamrinone (formerly known as amrinone), an inotropic agent which does not significantly increase oxygen demand because it also induces coronary vasodilation. One study evaluated 44 patients with coronary disease and an LVEF below 40 percent; inamrinone was infused at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight and LVEF measured with radionuclide ventriculography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/24\">",
"     24",
"    </a>",
"    ]. An increase in LVEF of &ge;10 percent with inamrinone predicted the same increase in LVEF after CABG, while those with a lesser change with inamrinone had little, if any, improvement after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased inotropy can also be observed on ventriculography or echocardiography by measuring the change in LVEF following an induced or spontaneous premature beat (ie, the degree of postextrasystolic potentiation) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radionuclide myocardial perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive testing with thallium or technetium sestamibi radionuclide myocardial perfusion imaging (rMPI) or positron emission tomography (PET) is often performed to identify the presence of dysfunctional segments that are viable. The major rMPI techniques are thallium stress-redistribution-reinjection SPECT, thallium rest-redistribution SPECT, and technetium-sestamibi SPECT. PET with the use of tracers to detect myocardial metabolism is an alternative method. The role of myocardial imaging in the detection of myocardial viability is discussed in detail elsewhere and the relative efficacy of the different tests is reviewed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pooled analysis of rMPI and DE studies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     End-diastolic wall thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since myocardial necrosis is associated with thinning of the myocardial wall, preserved end-diastolic wall thickness may provide a simple method for determining myocardial viability. This was investigated in a study that compared the end-diastolic wall thickness, obtained on a resting two-dimensional echocardiography, with the results of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography (DSE) and rest-distribution thallium-201 scan [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/26\">",
"     26",
"    </a>",
"    ]. An end-diastolic wall thickness &le;0.6 cm excluded the potential for functional recovery with a sensitivity and specificity of 94 and 48 percent, respectively, which was similar to the results with thallium scanning. Combination of the end-diastolic wall thickness with the results of DSE had a sensitivity and specificity of 88 and 77 percent.",
"   </p>",
"   <p>",
"    However, the presence of a thinned wall does not exclude the possibility of myocardial viability. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dobutamine echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography (DSE) is an important noninvasive clinical tool for the detection of hibernating myocardium (",
"    <a class=\"graphic graphic_figure graphicRef61817 \" href=\"UTD.htm?26/42/27309\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55003 \" href=\"UTD.htm?18/10/18606\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    echocardiography examines the \"inotropic reserve\" of dysfunctional but viable myocardium.",
"   </p>",
"   <p>",
"    Viable myocardium shows improved regional contractile function (inotropic reserve), as assessed by simultaneous transthoracic echocardiography, in response to these agents. The prevalence of contractile reserve in patients with CHD and LV dysfunction is independent of the angiographic extent and severity of coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/29\">",
"     29",
"    </a>",
"    ] and the improvement in contractility in hypoperfused viable myocardium does not require an increase in regional myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/30\">",
"     30",
"    </a>",
"    ] although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    may also increase myocardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A contractile response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    appears to require at least 50 percent viable myocytes in a given segment and correlates inversely with the extent of interstitial fibrosis on myocardial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/32\">",
"     32",
"    </a>",
"    ]. In comparison, radionuclide myocardial perfusion imaging can identify segments with fewer viable myocytes. In one series, for example, dobutamine echocardiography and thallium imaging showed equivalent sensitivity among segments with more than 75 percent viable myocytes (78 versus 87 percent) but dobutamine was much less sensitive among segments with 25 to 50 percent viable myocytes (15 versus 82 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    may be given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    to enhance the diagnostic value of the technique by increasing myocardial blood flow; in one series, atropine was necessary in 36 percent of patients to evaluate myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition to atropine therapy, other methods to improve the predictive value are to combine DE with myocardial contrast echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/35\">",
"     35",
"    </a>",
"    ], Doppler assessment of mitral inflow pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/36\">",
"     36",
"    </a>",
"    ], and strain rate imaging with tissue Doppler [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible approach is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . Potential efficacy was illustrated in a report of 32 patients in whom 309 of 512 myocardial segments were akinetic or dyskinetic. In terms of improved contractility after revascularization, nitroglycerin-dobutamine echocardiography had a lower sensitivity than rest-redistribution thallium and myocardial contrast echocardiography (63 versus 95 and 87 percent, respectively), but was the most specific (83 versus 37 and 48 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/39\">",
"     39",
"    </a>",
"    ]. Nitroglycerin alone increased regional thickening in 20 percent of viable akinetic segments, suggesting that it may be a useful addition to dobutamine stimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     TDE/strain rate imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;An refinement in the assessment of regional left ventricular function has been strain rate imaging from tissue Doppler echocardiography (TDE). Strain rate imaging (SRI) involves mathematical subtraction of the whole heart or translational motion from regional thickening velocity using a transmural data set from color-coded TDE. The results are less subjective than with wall motion scoring with traditional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link&amp;anchor=H7#H7\">",
"     \"Tissue Doppler echocardiography\", section on 'Strain and strain rate imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , TDE is a useful method for assessing the degree of myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The possible incremental value SRI to wall motion scoring was illustrated in review of 55 stable patients with a prior MI and mean LVEF of 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/38\">",
"     38",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Global functional recovery was seen after CABG in 21 patients (mean LVEF 35 percent at baseline to 47 percent at follow-up). There remaining patients had no increase in LVEF after CABG (38 to 39 percent).",
"     </li>",
"     <li>",
"      The combination of SRI and wall motion scoring significantly increased the sensitivity for predicting recovery of function after CABG compared to wall motion scoring alone (82 versus 73 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mitral inflow pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data indicate that the early diastolic deceleration time may correlate with the extent of myocardial viability. The value of measuring the early diastolic deceleration time (DT) on Doppler was assessed in 40 patients with ischemic cardiomyopathy who also underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography and rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a linear relationship between DT and both the number of viable segments on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography and the increase in LVEF after coronary artery bypass graft surgery (CABG).",
"     </li>",
"     <li>",
"      A DT &gt;150 msec predicted an increase in LVEF after CABG of &ge;5 percent (mean 29 percent at baseline to 40 percent after surgery) with a sensitivity and specificity of about 80 percent. In comparison, a DT &le;150 msec predicted an increase in LVEF &lt;5 percent (mean 27 percent before and after CABG).",
"     </li>",
"     <li>",
"      At one year, the rate of death or heart transplantation was much lower in the patients with a DT &gt;150 msec (5 versus 37 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pooled analysis of rMPI and DE studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative predictive value of the different forms of radionuclide myocardial perfusion imaging and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography for detecting hibernating myocardium was evaluated in an analysis from 52 published studies that utilized thallium stress-redistribution-reinjection SPECT, thallium rest-redistribution SPECT, FDG-PET scanning, technetium-sestamibi SPECT, or low dose dobutamine echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The following findings were noted (",
"    <a class=\"graphic graphic_figure graphicRef50864 \" href=\"UTD.htm?43/30/44526\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For each technique, the negative predictive value was higher than the positive predictive value. The highest negative predictive values were seen with FDG-PET, reinjection thallium SPECT, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography, while lower values were noted for rest-redistribution thallium SPECT and technetium-sestamibi SPECT.",
"     </li>",
"     <li>",
"      The highest positive predictive value was seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography, with intermediate values for FDG-PET, rest-redistribution thallium SPECT, and technetium-sestamibi SPECT, and the lowest value for reinjection thallium SPECT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these studies did not compare imaging techniques in the same patients. In a subset of studies in which two techniques were compared to detect viability, the pooled results showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography had significantly higher positive predictive value than nuclear imaging (84 versus 75 percent) and a significantly lower negative predictive value (69 versus 80 percent).",
"   </p>",
"   <p>",
"    Data were also available on the relationship between the change in LVEF after revascularization and the presence or absence of hibernating myocardium on imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. There was a mean increase in LVEF of about 8 percent after revascularization when hibernating myocardium was present (37 versus 45 percent) compared to no change in the absence of hibernation (36 versus 37 percent). The pooled results suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography had a slightly higher positive and negative predictive values than nuclear imaging (77 versus 70 percent and 85 versus 78 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\", section on 'Revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Wall thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with echocardiography, cardiovascular magnetic resonance (CMR) evidence of reduced end-diastolic wall thickness (thinned wall) has been proposed as an indicator of lack of viability. In a study of 35 patients with prior myocardial infarction and regional akinesia or dyskinesia, resting end-diastolic wall thickness and low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    -induced systolic wall thickening were assessed by CMR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/42\">",
"     42",
"    </a>",
"    ]. Dobutamine-induced wall thickening was a better predictor of residual metabolic activity on positron emission tomography (PET) (sensitivity 81 percent specificity 95 percent) than end-diastolic wall thickness (sensitivity 72 percent and specificity 89 percent). If at least one CMR parameter was used to identify viability, the sensitivity was 88 percent and specificity was 87 percent.",
"   </p>",
"   <p>",
"    However, a region of thinned myocardium may be viable with potential for structural and functional recovery following revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/43\">",
"     43",
"    </a>",
"    ]. Also, normal ventricles have significant regional variation in viable myocardial thickness. Therefore, identification of the extent of scar (eg, through contrast enhancement) along with the extent of viable tissue may provide a more accurate means of evaluating viability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Contrast-enhanced imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced cardiovascular magnetic resonance (CMR) imaging can be used to identify the extent of myocardial viability. Regions of myocardium exhibiting late (or delayed) gadolinium enhancement (LGE) coincide with regions of myocardial necrosis and irreversible injury; regions that fail to hyperenhance are viable. In addition, quantitative perfusion assessment can document the reduction in resting coronary blood flow in hibernating segments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H36992887#H36992887\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Myocardial viability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of 24 patients with stable coronary artery disease and left ventricular dysfunction, delayed (three to 15 minute) enhancement of contrast-enhanced CMR images were associated with nonviability as established with rest-distribution thallium imaging and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/44\">",
"     44",
"    </a>",
"    ]. The absence of enhancement correlated with radionuclide and echocardiographic viability, regardless of the status of resting contractile function.",
"   </p>",
"   <p>",
"    The degree of enhancement with contrast-enhanced CMR can predict recovery of left ventricular function after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This was illustrated in a study of 50 patients with coronary artery disease who had left ventricular dysfunction prior to surgical or percutaneous revascularization; 33 percent of myocardial segments in 80 percent of patients had late myocardial enhancement; 38 percent of segments had abnormal contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/45\">",
"     45",
"    </a>",
"    ]. After revascularization, more dysfunctional segments without enhancement improved (78 versus 17 percent with enhancement of &gt;75 percent of the tissue).",
"   </p>",
"   <p>",
"    The likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of hyperenhancement increased. The percentage of the left ventricle that was dysfunctional and not enhanced was significantly related to the degree of improvement in left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    A similar relationship was noted in another series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/46\">",
"     46",
"    </a>",
"    ]. An additional finding was that, among the nonenhancing or minimal enhancing segments that did not improve after revascularization, 36 percent showed new late enhancement on the early postoperative CMR scan.",
"   </p>",
"   <p>",
"    Magnetic resonance myocardial tagging is another CMR method that quantifies local myocardial segment shortening throughout the LV myocardium at sites across the LV wall thickness. When combined with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , this method can quantify the amount of myocardial viability, based upon myocardial shortening and thickening, after an acute MI and may provide prognostic information. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H36992887#H36992887\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Myocardial viability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gadolinium administration during MR imaging to patients with moderate to severe kidney disease (particularly dialysis patients) has been associated with the often severe syndrome of nephrogenic systemic fibrosis. It is recommended that gadolinium-based imaging be avoided in such patients. This issue, including the definition of patients at risk, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Newer methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several newer methods may be useful in the evaluation of hibernating myocardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Electroanatomic mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroanatomic mapping, which uses low-intensity magnetic field energy to determine the location of sensor-tipped catheter electrodes in the left ventricle, has been widely applied for mapping of arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By simultaneously measuring the electrical data (amplitude of endocardial electrical signals) and mechanical data (regional wall motion reflecting average local shortening) from the myocardium, which correlate inversely with the extent of myocardial ischemia, this technique may also have a role in distinguishing between infarcted and ischemic, but still viable, myocardium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81609 graphicRef57238 graphicRef81092 \" href=\"UTD.htm?31/59/32698\">",
"     image 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/47-51\">",
"     47-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and specificity for viable myocardium compared to other imaging studies has ranged from 70 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/47,49,50\">",
"     47,49,50",
"    </a>",
"    ]. In one report of 20 patients in whom testing for viability was directly compared to the results of revascularization, the diagnostic performance of electroanatomic mapping was not as good as that of radionuclide myocardial perfusion imaging with PET or single photon emission computed tomography (SPECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Myocardial contrast echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial contrast echocardiography (MCE) utilizes intravenous infusion of microbubbles, which have a distinct ultrasonic density from blood or tissue and which can traverse the microvasculature, permitting visualization of myocardial perfusion. This technique compares favorably with other modalities in the detection of hibernating myocardium, although contrast agents have not yet been FDA approved for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link&amp;anchor=H14#H14\">",
"     \"Contrast echocardiography: Clinical applications\", section on 'Myocardial viability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential value of MCE was illustrated in a study in which 20 patients with coronary disease and ventricular dysfunction underwent MCE,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography, and rest-redistribution thallium scintigraphy prior to coronary artery bypass grafting (CABG) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/52\">",
"     52",
"    </a>",
"    ]. Echocardiography was repeated three to four months after surgery. The sensitivity of MCE in detecting segments with recovery of function after surgery was comparable to that of dobutamine echocardiography or thallium scintigraphy (90, 80, and 92 percent, respectively), and the specificity was significantly greater (63, 54, and 45 percent, respectively).",
"   </p>",
"   <p>",
"    A second report compared these three approaches in 32 patients in whom 309 of 512 myocardial segments were akinetic or dyskinetic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/39\">",
"     39",
"    </a>",
"    ]. In terms of predicting functional recovery after revascularization, MCE had the intermediate sensitivity (87 versus 95 and 63 percent with rest-redistribution thallium and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography) and specificity (48 versus 37 and 83 percent with rest-redistribution thallium and nitroglycerin-dobutamine echocardiography).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RECOMMENDED APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major imaging tests used to detect hibernating myocardium include thallium stress-redistribution-reinjection, thallium rest-redistribution, PET scanning, technetium sestamibi imaging, and low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography. All of these tests are highly sensitive and can predict the benefit from revascularization, although there are some differences (",
"    <a class=\"graphic graphic_figure graphicRef50864 \" href=\"UTD.htm?43/30/44526\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/1,40,41,53\">",
"     1,40,41,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pooled analysis of rMPI and DE studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We agree with the following conclusions from a Study Group of the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment for hibernation is most relevant in patients with dyspnea rather than angina.",
"     </li>",
"     <li>",
"      Radionuclide myocardial perfusion imaging and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography have similar test performance for the detection of viable myocardium. Thus, the choice may depend upon availability, local expertise, and whether a more sensitive (radionuclide myocardial perfusion imaging) or a more specific technique (dobutamine echocardiography) is required for predicting recovery of left ventricular function.",
"     </li>",
"     <li>",
"      Positron emission tomography (PET) scanning or cardiac magnetic resonance (CMR) imaging is usually performed if clarification is required after echocardiography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radionuclide myocardial perfusion imaging. However, if readily available, PET scanning is an alternative initial test and CMR is an acceptable alternative to echocardiography when assessment of left ventricular function at rest and during stress is also desired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on chronic heart failure reached the following conclusions on noninvasive imaging, unless the patient is not eligible for revascularization of any kind [",
"    <a class=\"abstract\" href=\"UTD.htm?10/41/10905/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients with known coronary artery disease and no angina.",
"     </li>",
"     <li>",
"      Noninvasive imaging may be considered (evidence less well established) to define the likelihood of coronary artery disease in patients with HF and left ventricular dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of viable myocardium is of importance because the restoration of blood flow with revascularization can reverse depressed LV contractility, improve LV function, and reduce long-term mortality. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H500617\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hibernating myocardium, defined as a region of depressed myocardial contractility at rest due to persistently impaired coronary blood flow, can occur in a variety of clinical scenarios (eg, chronic stable or unstable angina, acute myocardial infarction, heart failure). Since the ischemic myocardium remains viable, the LV dysfunction can be partially or completely restored to normal by improving blood flow or by reducing oxygen demand. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several tests, including radionuclide myocardial perfusion imaging,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography, positron emission tomography (PET) scanning, and cardiac magnetic resonance (CMR) imaging, can assist in the evaluation of myocardial viability and contractile reserve and identification of patients in whom there is the potential for recovery of LV function with revascularization. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy of imaging tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our recommended approach to the evaluation of hibernating myocardium is to begin with either radionuclide myocardial perfusion imaging or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography depending upon availability and local expertise. Positron emission tomography (PET) scanning or cardiac magnetic resonance (CMR) imaging are acceptable alternatives which may have greater sensitivity but are more challenging to perform and not as widely available. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Recommended approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/1\">",
"      Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/2\">",
"      Bonow RO. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol 1995; 75:17A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/3\">",
"      Ragosta M, Beller GA, Watson DD, et al. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/4\">",
"      Auerbach MA, Sch&ouml;der H, Hoh C, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/5\">",
"      Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the \"hibernating myocardium\". J Am Coll Cardiol 1986; 8:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/6\">",
"      Rahimtoola SH. From coronary artery disease to heart failure: role of the hibernating myocardium. Am J Cardiol 1995; 75:16E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/7\">",
"      Kloner RA, Przyklenk K. Hibernation and stunning of the myocardium. N Engl J Med 1991; 325:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/8\">",
"      Marban E. Myocardial stunning and hibernation. The physiology behind the colloquialisms. Circulation 1991; 83:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/9\">",
"      Selvanayagam JB, Jerosch-Herold M, Porto I, et al. Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment. Circulation 2005; 112:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/10\">",
"      Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/11\">",
"      Cabin HS, Clubb KS, Vita N, Zaret BL. Regional dysfunction by equilibrium radionuclide angiocardiography: a clinicopathologic study evaluating the relation of degree of dysfunction to the presence and extent of myocardial infarction. J Am Coll Cardiol 1987; 10:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/12\">",
"      Vanoverschelde JL, Wijns W, Borgers M, et al. Chronic myocardial hibernation in humans. From bedside to bench. Circulation 1997; 95:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/13\">",
"      Bax JJ, Visser FC, Poldermans D, et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 2001; 104:I314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/14\">",
"      Chaitman BR, DeMots H, Bristow JD, et al. Objective and subjective analysis of left ventricular angiograms. Circulation 1975; 52:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/15\">",
"      Chaitman BR, Bristow JD, Rahimtoola SH. Left ventricular wall motion assessed by using fixed external reference systems. Circulation 1973; 48:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/16\">",
"      Helfant RH, Pine R, Meister SG, et al. Nitroglycerin to unmask reversible asynergy. Correlation with post coronary bypass ventriculography. Circulation 1974; 50:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/17\">",
"      Banka VS, Bodenheimer MM, Shah R, Helfant RH. Intervention ventriculography. Comparative value of nitroglycerin, post-extrasystolic potentiation and nitroglycerin plus post-extrasystolic potentiation. Circulation 1976; 53:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/18\">",
"      Rahimtoola SH. Postoperative exercise response in the evaluation of the physiologic status after coronary bypass surgery. Circulation 1982; 65:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/19\">",
"      Dalla Vecchia L, Storti T, Cogliati C, et al. Comparison of low-dose dobutamine ventriculography with low-dose dobutamine echocardiography for predicting regional improvement in left ventricular function after coronary artery bypass grafting. Am J Cardiol 2000; 86:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/20\">",
"      Popio KA, Gorlin R, Bechtel D, Levine JA. Postextrasystolic potentiation as a predictor of potential myocardial viability: preoperative analyses compared with studies after coronary bypass surgery. Am J Cardiol 1977; 39:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/21\">",
"      Cohn PF, Gorlin R, Herman MV, et al. Relation between contractile reserve and prognosis in patients with coronary artery disease and a depressed ejection fraction. Circulation 1975; 51:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/22\">",
"      Nesto RW, Cohn LH, Collins JJ Jr, et al. Inotropic contractile reserve: a useful predictor of increased 5 year survival and improved postoperative left ventricular function in patients with coronary artery disease and reduced ejection fraction. Am J Cardiol 1982; 50:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/23\">",
"      Zafrir N, Vidne B, Sulkes J, Sclarovsky S. Usefulness of dobutamine radionuclide ventriculography for prediction of left ventricular function improvement after coronary artery bypass grafting for ischemic cardiomyopathy. Am J Cardiol 1999; 83:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/24\">",
"      Perez-Bali&ntilde;o NA, Masoli OH, Meretta AH, et al. Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function. J Am Coll Cardiol 1996; 28:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/25\">",
"      Scognamiglio R, Fasoli G, Casarotto D, et al. Postextrasystolic potentiation and dobutamine echocardiography in predicting recovery of myocardial function after coronary bypass revascularization. Circulation 1997; 96:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/26\">",
"      Cwajg JM, Cwajg E, Nagueh SF, et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation: relation to rest-redistribution T1-201 tomography and dobutamine stress echocardiography. J Am Coll Cardiol 2000; 35:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/27\">",
"      Beckmann S, Schartl M, Bocksch W, Fleck E. Diagnosis of coronary artery disease and viable myocardium by stress echocardiography. Diagnostic accuracy of different stress modalities. Eur Heart J 1995; 16 Suppl J:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/28\">",
"      Cheirif J, Murgo JP. Assessment of myocardial viability by dobutamine echocardiography. Coron Artery Dis 1995; 6:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/29\">",
"      Main ML, Grayburn PA, Landau C, Afridi I. Relation of contractile reserve during low-dose dobutamine echocardiography and angiographic extent and severity of coronary artery disease in the presence of left ventricular dysfunction. Am J Cardiol 1997; 79:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/30\">",
"      Barill&agrave; F, De Vincentis G, Mangieri E, et al. Recovery of contractility of viable myocardium during inotropic stimulation is not dependent on an increase of myocardial blood flow in the absence of collateral filling. J Am Coll Cardiol 1999; 33:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/31\">",
"      Krivokapich J, Czernin J, Schelbert HR. Dobutamine positron emission tomography: absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease. J Am Coll Cardiol 1996; 28:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/32\">",
"      Nagueh SF, Mikati I, Weilbaecher D, et al. Relation of the contractile reserve of hibernating myocardium to myocardial structure in humans. Circulation 1999; 100:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/33\">",
"      Baumgartner H, Porenta G, Lau YK, et al. Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts. J Am Coll Cardiol 1998; 32:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/34\">",
"      Poldermans D, Rambaldi R, Bax JJ, et al. Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction. Eur Heart J 1998; 19:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/35\">",
"      Meza MF, Ramee S, Collins T, et al. Knowledge of perfusion and contractile reserve improves the predictive value of recovery of regional myocardial function postrevascularization: a study using the combination of myocardial contrast echocardiography and dobutamine echocardiography. Circulation 1997; 96:3459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/36\">",
"      Yong Y, Nagueh SF, Shimoni S, et al. Deceleration time in ischemic cardiomyopathy: relation to echocardiographic and scintigraphic indices of myocardial viability and functional recovery after revascularization. Circulation 2001; 103:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/37\">",
"      Hoffmann R, Altiok E, Nowak B, et al. Strain rate measurement by doppler echocardiography allows improved assessment of myocardial viability inpatients with depressed left ventricular function. J Am Coll Cardiol 2002; 39:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/38\">",
"      Hanekom L, Jenkins C, Jeffries L, et al. Incremental value of strain rate analysis as an adjunct to wall-motion scoring for assessment of myocardial viability by dobutamine echocardiography: a follow-up study after revascularization. Circulation 2005; 112:3892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/39\">",
"      Ling LH, Christian TF, Mulvagh SL, et al. Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography. Am Heart J 2006; 151:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/40\">",
"      Bax JJ, Poldermans D, Elhendy A, et al. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001; 26:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/41\">",
"      Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     Circulation 1995;91:1006.",
"    </li>",
"    <li>",
"     Heart 2004;90:137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/44\">",
"      Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998; 98:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/45\">",
"      Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/46\">",
"      Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 2004; 110:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/47\">",
"      B&oslash;tker HE, Lassen JF, Hermansen F, et al. Electromechanical mapping for detection of myocardial viability in patients with ischemic cardiomyopathy. Circulation 2001; 103:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/48\">",
"      Fuchs S, Hendel RC, Baim DS, et al. Comparison of endocardial electromechanical mapping with radionuclide perfusion imaging to assess myocardial viability and severity of myocardial ischemia in angina pectoris. Am J Cardiol 2001; 87:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/49\">",
"      Koch KC, vom Dahl J, Wenderdel M, et al. Myocardial viability assessment by endocardial electroanatomic mapping: comparison with metabolic imaging and functional recovery after coronary revascularization. J Am Coll Cardiol 2001; 38:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/50\">",
"      Gy&ouml;ngy&ouml;si M, Sochor H, Khorsand A, et al. Online myocardial viability assessment in the catheterization laboratory via NOGA electroanatomic mapping: Quantitative comparison with thallium-201 uptake. Circulation 2001; 104:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/51\">",
"      Wiggers H, B&oslash;tker HE, S&oslash;gaard P, et al. Electromechanical mapping versus positron emission tomography and single photon emission computed tomography for the detection of myocardial viability in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2003; 41:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/52\">",
"      Shimoni S, Frangogiannis NG, Aggeli CJ, et al. Identification of hibernating myocardium with quantitative intravenous myocardial contrast echocardiography: comparison with dobutamine echocardiography and thallium-201 scintigraphy. Circulation 2003; 107:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/53\">",
"      Bax JJ, Wijns W, Cornel JH, et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997; 30:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/41/10905/abstract/54\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1474 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10905=[""].join("\n");
var outline_f10_41_10905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H500617\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY OF IMAGING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ventriculography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Use of nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Inotropic stimulation/postextrasystolic potentiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - End-diastolic wall thickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dobutamine echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - TDE/strain rate imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mitral inflow pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pooled analysis of rMPI and DE studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Wall thickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Contrast-enhanced imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Newer methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Electroanatomic mapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Myocardial contrast echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RECOMMENDED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H500617\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1474|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/62/22501\" title=\"diagnostic image 1A\">",
"      Pathology electroanatomic map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/20/15683\" title=\"diagnostic image 1B\">",
"      Electroanatomic map MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/36/44613\" title=\"diagnostic image 1C\">",
"      Electroanatomic map LV ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1474|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/24/10638\" title=\"figure 1\">",
"      Revasc hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/21/27997\" title=\"figure 2\">",
"      Flow function relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/42/27309\" title=\"figure 3\">",
"      Dobut response outcome CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/10/18606\" title=\"figure 4\">",
"      Dobutamine echo outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/30/44526\" title=\"figure 5\">",
"      Techniques myocardial viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1474|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/0/34827\" title=\"table 1\">",
"      Noninvasive methods hibernation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/52/28491\" title=\"table 2\">",
"      Myocardial states LV dysfunct",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_41_10906="Lymphomatoid papulosis 2";
var content_f10_41_10906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74972%7EDERM%2F54022%7EDERM%2F82762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74972%7EDERM%2F54022%7EDERM%2F82762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lymphomatoid papulosis nodule showing initial central necrosis (whitish area).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphomatoid papulosis nodule with central ulceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions in various states of development and regression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10906=[""].join("\n");
var outline_f10_41_10906=null;
var title_f10_41_10907="Survival appendix tumors SEER";
var content_f10_41_10907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognosis of primary malignant neoplasms of the appendix from SEER data, 1973-1998",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goblet cell carcinoma (adenocarcinoid)",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonic-type adenocarcinoma",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous adenocarcinoma",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signet ring cell carcinoma",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SEER: Surveillance, Epidemiology and End Results.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: A population based study from the Surveillance, Epidemiology and End-Results program, 1973-1998. Cancer 2002; 94:3307.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10907=[""].join("\n");
var outline_f10_41_10907=null;
var title_f10_41_10908="AAT deficiency and ANCA";
var content_f10_41_10908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alpha-1 antitrypsin phenotypes in anti-PR3 (C-ANCA) positive vasculitic disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        France",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sweden",
"       </td>",
"       <td class=\"subtitle1\">",
"        Austria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Australia",
"       </td>",
"       <td class=\"subtitle1\">",
"        UK",
"       </td>",
"       <td class=\"subtitle1\">",
"        Denmark",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number&nbsp;of patients",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PI*ZZ",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Z allele frequency",
"       </td>",
"       <td>",
"        17.6",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        10.9",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        9.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Z allele in controls",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     anti-PR3: antibody to proteinase 3; C-ANCA: cytoplasmic staining pattern of antineutrophil cytoplasmic antibodies; PI: protease inhibitor; PI*ZZ: homozygosity of protease inhibitor allele (Z) that is most commonly associated with alpha-1 antitrypsin deficiency.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Esnault VL, Testa A, Audrain M, et al. Alpha-1 antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43:1329.",
"     <br>",
"      Reproduced with permission from: American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818. Official Journal of the American Thoracic Society. Copyright &copy; 2003 American Thoracic Society.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10908=[""].join("\n");
var outline_f10_41_10908=null;
var title_f10_41_10909="Cross sectional area of airways";
var content_f10_41_10909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The total cross-sectional area of the air passages at different generations of the airways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 309px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the minimum cross-sectional area is at generation 3 (lobar to segment bronchi). The total cross-sectional area becomes very large in the smaller air passeges, approaching a square meter in the alveolar ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10909=[""].join("\n");
var outline_f10_41_10909=null;
var title_f10_41_10910="Heliox ventilator calibration";
var content_f10_41_10910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Correction factors for inspiratory and expiratory volumes during use of Heliox",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        FiO",
"        <sub>",
"         2",
"        </sub>",
"        set",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Veolar FT",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Galileo",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Servo 900C",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Servo 300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.21",
"       </td>",
"       <td>",
"        1.68",
"       </td>",
"       <td>",
"        1.70",
"       </td>",
"       <td>",
"        1.68",
"       </td>",
"       <td>",
"        1.70",
"       </td>",
"       <td>",
"        1.38",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.36",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.30",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        1.50",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        1.50",
"       </td>",
"       <td>",
"        1.35",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        1.44",
"       </td>",
"       <td>",
"        1.47",
"       </td>",
"       <td>",
"        1.44",
"       </td>",
"       <td>",
"        1.47",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.23",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.45",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.29",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        1.17",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.60",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        1.24",
"       </td>",
"       <td>",
"        1.13",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        1.01",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        1.01",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        1.09",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        1.09",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        FiO",
"        <sub>",
"         2",
"        </sub>",
"        set",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Evita 2",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Evita 4",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        7200 series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        VFe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.21",
"       </td>",
"       <td>",
"        1.83",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.10",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1.75",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.14",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.30",
"       </td>",
"       <td>",
"        1.73",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.19",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        1.66",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.25",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.30",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.45",
"       </td>",
"       <td>",
"        1.55",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.35",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        1.48",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.40",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.60",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.50",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        0.986",
"       </td>",
"       <td>",
"        1.093",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        1.093",
"       </td>",
"       <td colspan=\"2\">",
"        1.05",
"       </td>",
"       <td colspan=\"2\">",
"        1.05",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Inop: inoperative; NL: nonlinear relationship; VFe: expiratory volume correction factor (VTe = VTe meas x VFe); VFi: inspiratory volume correction factor (VTdel = VTset x VFi).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tassaux D, Jolliet P, Thouret J, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22. Copyright &copy;1999 American Lung Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10910=[""].join("\n");
var outline_f10_41_10910=null;
var title_f10_41_10911="Neonate with omphalocele";
var content_f10_41_10911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neonate with an omphalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_41_10911=[""].join("\n");
var outline_f10_41_10911=null;
